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Results presented in the thesis demonstrate that rats after 14 weeks of 
administration of a single dose (60 mg/Kg) of STZ became substantially hyperglycemic 
as well as hyperlipidemic. In addition, long-term diabetes was associated with fully 
developed nephropathy and retinopathy. Daily treatment of these diabetic-hyperlipidemic 
rats with 6 mg Tocomin (tocotrienols) or 0.50 mg Lovastatin for 14 weeks significantly 
lowered the elevated blood glucose levels to near normal values. Since the extent of 
hemoglobin glycation is currently used as a cumulative index of glycemia over the 
previous few weeks in the clinical management of diabetes, our results demonstrate a 
significant increase in HbAi levels in diabetic rats, which were restored close to normal 
control values after 14 weeks of Tocomin or Lovastatin treatment. After 14 weeks of 
STZ-induced diabetes, histology of kidney resulted in the progression of diffused nodular 
glomerulosclerosis along with thickening of basement membrane in capillaries. An 
increase in the number of mesangial cells and enlarged Bowman space was also seen. 
Similarly, after 14 weeks of sustained hyperglycemia and increased oxidative stress, 
retina from diabetic rats exhibited proliferative retinopathy, characterized by complete 
retinal detachment. Consistent with the Tocomin and Lovastatin mediated decline in 
blood glucose and HbAi levels, and normalization of glycemic state, histologically, all 
the untoward features of nephropathy and retinopathy were regressed and normalized in 
Tocomin or Lovastatin treated diabetic rats. However, treatment of chronic diabetic rats 
with Lovastatin, which is known to have host of side effects, induced interstitial 
inflammation of kidney lymphocytes as well as separation of retinal membrane from the 
lens, resulting in an open space. In contrast, dietary tocotrienols (Tocomin), are vitamin E 
and have no toxicity, therefore, did not exhibit any side effect. These results represent an 
initial demonstration of strong hypoglycemic and antidiabetic action of Tocomin and 
Lovastatin in rats induced with chronic diabetes coupled with hyperlipidemia. 
Since long-term STZ-induced diabetes in rats is associated with a substantial 
hyperlipidemia, feeding of Tocomin or Lovastatin significantly prevented the increase in 
plasma TG, TC, atherogenic non-HDL-C, VLD-C, LDL-C, HDL-C and its subfractions, 
HDL2-C and HDL3-C levels. The cholesterol content of HDL2, which is considered to be 
a strong predictor of presence and extent of CAD, was significantly and equally reduced 
in both Tocomin and Lovastatin treated diabetic rats. However, Lovastatin, in comparison 
to Tocomin, was more effective in selectively reducing the atherogenic non-HDL-C, 
whereas, levels of plasma antiatherogenic HDL-C and HDL3-C in Lovastatin treated 
diabetic rats were significantly higher than Tocomin treated group. 
Consistent with published reports that relative to Ib-LDL, the concentration of 
more atherogenic sd-LDL was substantially increased in patients with diabetes, CHD 
alone or diabetes with CHD, sd-LDL-C and sd-LDL-apoB levels of diabetic-
hyperlipidemic rats were increased by 245 % and 154 %, respectively, in comparison to 
corresponding values in N-C. Thus, > 60 % of total LDL-C and LDL-apo B were 
recognized in sd-LDL fraction, isolated from LDL of diabetic rats. Treatment of diabetic 
rats with Tocomin or Lovastatin significantly reduced both the cholesterol and apoB 
content of sd-LDL, as well as their percent share of total LDL, close to normal control 
values. In addition, sd-LDL-C/HDL-C ratio was increased (80 %), HDL-C/sd-LDL-C 
ratio was reduced (44 %) in diabetic-hyperlipidemic rats. Treatment with Tocomin or 
Lovastatin during diabetes resulted in significant improvement in these ratios, indicating 
normalization of sd-LDL levels and strong antiatherogenic property of Tocomin and 
Lovastatin. The therapeutic intervention of dietary tocotrienols (Tocomin) and Lovastatin 
in diabetic-hyperlipidemic rats, indicating a significant decline in the levels of sd-LDL-C, 
represents an initial demonstration. 
Both tocotrienols (Tocomin) and Lovastatin are known to exert their 
hypolipidemic effects in hyperlipidemic animals by reducing hepatic HMG-CoA 
reductase activity. However, results in the present study show a decrease of 57 % in liver 
HMG-CoA reductase activity along with a substantial increase in plasma and tissue lipid 
levels after 14 weeks of chronic diabetes. This decrease in hepatic HMG-CoA reducatse 
activity in diabetic animals may be due to a sustained insulin deficiency/hyperglycemia 
and hyperlipidemia. Treatment of these rats with Tocomin or Lovastatin for 14 weeks 
was associated with a significant reduction in glucose and lipid levels as well as 
restoration of HMG-CoA reducatse activity to near normal levels. This increase in 
enzyme activity in treated diabetic rats may be due to an increase in insulin activity as a 
result of normalization of both glucose and lipid levels. Recently, it has been shown that 
RBO containing 7-T3 or y-oryzanol exert their hypolipidemic effects in diabetic rats by 
increasing fecal neutral sterPl and bile acid excretion, via up regulating cholesterol 
synthesis and catabolism. In the present study involving diabetic-hyperlipidemic rats, 
dietary tocotrienols and Lov^tatin may exert their hypolipidemic effects in a similar 
fashion. 
In response to oxidative stress, evoked in experimental diabetes/hyperlipidemia, 
as reflected by increased formation of plasma and liver lipid peroxidation products, 
conjugated dienes, lipid hydroperoxides and TBARS, and increased release of MDA 
from intact erythrocytes subjt*cted to hydrogen peroxide-induced lipid peroxidation was 
substantially and significantly blocked by Tocomin and Lovastatin. In addition, the 
enhanced oxidative damage of membranes during long-term diabetes is also associated 
with a decrease in membrane bound Na^, K^-ATPase activity, which is implicated in the 
pathogenesis of several diabetic complications. Consistent with these reports, our results 
show a significant reduction in total and Na"^ , K" -^ATPase activities m erythrocyte 
membranes of diabetic rats. Consistent with hypoglycemic, hypolipidemic and 
antioxidant properties, Tocorpin or Lovastatin feeding during diabetes prevented the 
decline in total and Na^, K^-ATPase activities and restored to a level close to normal 
values, apparently by blocking and protecting the ROS-mediated membrane damage. 
Similarly, due to enhanced oxidative stress and increased consumption of antioxidants in 
chronic diabetic rats, total antioxidant concentrations in plasma was significantly 
reduced, which was substantially increased to a level higher than normal control value in 
both the treated groups. 
Our results show that due to substantial oxidative stress in diabetic-
hyhyperlipidemic rats, the ex vivo base line diene cojugation (BDC) levels of sd-LDL and 
Ib-LDL including LDL were increased. However, in comparison to Ib-LDL BDC level, 
sd-LDL BDC value was higher by more than 3-fold indicating a markedly enhanced 
susceptibility of sd-LDL to in vivo oxidation. Similarly, treatment of diabetic rats with 
Tocomin or Lovastatin reduced the ex vivo BDC levels of sd-LDL, Ib-LDL and LDL, 
with a maximum effect on sd-LDL. Consistent with ex vivo BDC levels of LDL, sd-LDL. 
and Ib-LDL, susceptibility of these particles to Cu^-induced oxidation, as measured by 
their lag time, was decreased in diabetic rats. It is important to mention that in 
comparison to a lag phase value of 98 min and 50 min for LDL and Ib-LDL, respectively. 
in N-C, the lag phase of sd-LDL was only 17.0 min, indicating a substantially increased 
in vitro oxidative susceptibility to oxidation. In treated groups, both Tocomin and 
Lovastatin increased the resistance of sd-LDL to oxidative modification, as shown by an 
increase in lag time from a value of 8.5 min in D-C to 12.5 min. In contrast to sd-LDL, 
the lag time of Ib-LDL was reduced from 50 min in N-C to 40 min in D-C, which was 
fiilly restored to 50 min in Tocomin or Lovastatin treated groups. Consistent with known 
property of glucose that it may act either as LDL antioxidant or prooxidant depending on 
the vitamin E/antioxidant content of LDL, presence of glucose during Cu^-induced 
oxidation of LDL, sd-LDL and Ib-LDL from normal rats, ftirther reduced their lag 
phases. However, in diabetic rats, which were deficient in antioxidants, and had a high 
plasma glucose level, addition of glucose in the incubation medium further mediated a 
prooxidant effect on sd-LDL lag phase with no effect on Ib-LDL and LDL. The 
substantial prooxidant effect of glucose on lag phase of sd-LDL from normal and diabetic 
rats is consistent with its enhanced susceptibility to oxidation and reduced content of 
antioxidants, relative to Ib-LDL. In Tocomin or Lovastatin treated rats due to the 
presence of high plasma concentrations of antioxidants, tocotrienols 
(Tocomin)/Lovastatin, prooxidant effect of glucose was blocked and lag phase value of 
sd-LDL was increased. 
Based on the ex vivo results, proooxidant/antioxidant effect of glucose was 
investigated on Cu^-induced oxidative modification of LDL, sd-LDL and Ib-LDL, 
isolated from normal rat plasma prefreated with no antioxidant, Tocomin, a-tocopherol or 
Lovastatin. Similar to ex vivo studies, BDC level of untreated sd-LDL represented a 3-
fold increase in comparison to BDC value of Ib-LDL. As expected, glucose mediated a 
maximum prooxidant effect by decreasing the lag pahse of sd-LDL, which was isolated 
from untreated confrol plasma and apparently had a least amount of associated 
antioxidants. When Tocomin, a-tocopherol or Lovastatin enriched LDL, sd-LDL and Ib-
LDL were subjected to oxidation with copper, a marked increase in the lag phase of LDL 
was observed. However, apparently due to low retention of antioxidants in sd-LDL and 
Ib-LDL particles, after their fractionation from LDL, the increase in lag phase values of 
sd-LDL and Ib-LDL was less pronounced. Addition of glucose to the media delayed the 
oxidation of antioxidant-enriched LDL, sd-LDL and Ib-LDL, and markedly increased the 
lag phase values similar to their corresponding values in untreated control samples 
obtained in the absence of glucose. These results represent an initial demonstration of ex 
vivo and in vitro oxidative modification of sd-LDL and Ib-LDL, isolated from LDL. In 
addition, in response to substantial increase in oxidative stress, evoked in experimental 
diabetes coupled with hyperlipidemia as reflected by higher ex vivo BDC levels of sd-
LDL and Ib-LDL including LDL, as modified in vivo, and a decrease in lag phase time of 
their oxidation, was substantially and effectively blocked by Tocomin or Lovastatin, also 
represents an initial investigation. 
Xanthine oxidase is known to be an important biological source of superoxide 
radical generating enzyme. In diabetic animals, xanthine oxidase is released by the 
vascular endothelial cells. Serum xanthine oxidase activity is known to be increased in 
various pathological disorders, such as carcinogenesis, hepatitis, inflammatory diseases, 
aging, hyperlipidemia and diabetes and that fi'ee radicals generated in the enzymatic 
processes are involved in the oxidative damage. Thus, it is possible that the inhibition of 
this enzymatic pathway by compounds, such as tocotrienols (Tocomin) and Lovastatin, 
that have both antiradical and xanthine oxidase inhibitory properties may have additional 
therapeutic importance in the treatment of diabetes with hyperlipidemia and other 
pathological disorders. Consistent with this hypothesis, our results show a significant 
increase in plasma and liver xanthine oxidase activity of diabetic-hyperlipidemic rats. 
Feeding of Tocomin or Lovastatin to diabetic rats was associated with a significant 
inhibition of the elevated levels of plasma and hepatic xanthine oxidase activity. These 
results show that both Tocomin and Lovastatin, in addition to their potent antioxidant 
activity, also exhibit xanthine oxidase inhibitory property, indicating an additional 
therapeutic benefit in the treatment of diabetes with and with out CHD. 
It is well known that diabetes may enhance oxidative stress not only through the 
increased production of ROS but also through weakening the antioxidant defense system. 
In this context the antioxidant role of serum HDL-complexed paraoxonase 
(PON)/arylesterase enzyme in the protection of LDL as well as HDL from oxidative 
modification is important. In diabetics, a lower PON/arylesterase activity and 
concentration, higher LDL: PON concentration ratio and a reduced capacity to prevent 
LDL oxidation have been reported. In addition, antioxidant supplementation may be 
expected to influence PON/arylesterase activity by altering oxidative stress. Consistent 
with these reports, our results show a significant decrease in plasma arylesterase activity 
and increase in the LDL-C: arylesterase activity ratio in diabetic-hyperlipidemic rats, 
indicating a reduced capacity to protect LDL from oxidation. Both Tocomin and 
Lovastatin treatment significantly blocked the reduction in arylesterase activity and 
increase in LDLC: arylesterase activity ratio, indicating an increased capacity to protect 
LDL from oxidation. However, Lovastatin not only prevented the decline in arylesterase 
activity but significantly increased its level above normal control value. Similarly, in D-
LT, LDL-C: arylesterase activity ratio was reduced to a level lower than N-C value. 
As indicated above, increased oxidative stress, which contributes substantially to 
the pathogenesis of long-term diabetic complications, is the consequences of either 
enhanced ROS production or attenuated ROS scavenging capacity. Several tissues, 
including erythrocytes and liver, have an effective mechanism to neutralize and prevent 
the free radical induced damage, which is accomplished by a set of endogenous enzymes 
such as catalase, SOD, Gpx and Gred, as well as nonenzymatic antioxidant, GSH. As the 
balance between ROS production and combined antioxidant defenses is lost, the resultant 
oxidative stress through a series of events deregulates the cellular fiinctions leading to 
various pathological conditions. An antioxidant compound might contribute partial or 
total alleviation of such damage. Our results demonstrate that feeding of 6 mg Tocomin 
or 0.50 mg Lovastatin/rat/day for 14 weeks were found to be therapeutically quiet 
effective in restoring/normalizing the altered enzymatic and nonenzymatic antioxidant 
defense system in erythrocytes and liver. 
Based on the above combined results, dietary tocotrienols (Tocomin) or 
Lovastatin can be used in the prevention and treatment of both type 1 and type 2 diabetes, 
including long-term complications, such as nephropathy and retinopathy, diabetes 
associated hyperlipidemia with and without CHD and atherosclerosis. However, 
considering the host of side effects exhibited by Lovastatin, use of dietary Tocomin as a 
multitherapeutic agent should be preferred. In addition, daily use of Tocomin as a dietary 
supplement will be highly cost effective as well as a good source of vitamin E. 
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Introduction/ 
^gview of Literature 
The prevalence of diabetes for all age groups worldwide was estimated to be 
2.8 % in 2000 and 4.4 % in 2030.The total number of subjects with diabetes is 
projected to increase from 171 million in 2000 to 366 million in 2030 (WHO, 2006). 
The prevalence of diabetes is higher in men than women. The most important 
demographic change to diabetes prevalence across the world appears to be the 
increase in the proportion of people greater than 65 years of age (Wild et al, 2004). 
According to recent estimates, close to 77 % of the global burden of disease is 
projected to occur in the developing countries. The increasing prevalence of diabetes 
in developing countries is closely associated with industrialization and socio-
economic development. The major determinants for projected increase in the number 
of diabetics in these countries are: population growth; age structure, and urbanization. 
The urban population in developing countries is projected to double between 2000 
and 2030. With the rise in the urban/rural population ratio in all regions, and growing 
prevalence of obesity among urban dwellers, diabetes will increasingly concentrate in 
the urban areas. Important differences are observed in age structure of diabetic 
population between developed and developing countries. In the developed countries, 
the majority of diabetics are aged 65 years and above, whereas it was 45-64 years in 
the developing countries. This means that in developing countries, the majority of 
diabetic patients acquire the condition during the most productive period of their 
lives. This will have major implications with respect to health care needs. 
Diabetes mellitus, once thought to be uncommon in the developing world, has 
now emerged as an important public health problem in Asia. An estimated 47 million 
individuals in the South-East Asia Region (SEAR) are affected at present. It is 
estimated that by the year 2030 there will be 119.5 million diabetics in the Region-
the highest among all WHO regions. Thus the SEAR will bare the maximum global 
burden of the disease (WHO, 2006). A bulk of evidence from studies on migrants 
indicates that the ethnic, presumably genetic vulnerability of Asians manifests in to 
diabetes when subjected to unfavorable life styles. The population in India has an 
increased susceptibility to diabetes mellitus. This propensity was demonstrated by 
multiple surveys of migrant Indians residing in Fiji, Singapore, South Africa, UK, and 
USA. The occurrence of diabetes in migrants from the Indian subcontinent has 
consistently shown to exceed those of the local population. The results of prevalence 
studies of diabetes mellitus in India were systematically reviewed with emphasis on 
those utilizing the standard WHO criteria for diabetes diagnosis. In the year 2000 an 
estimated 31.7 million individuals in India were reported to be diabetics and it is 
projected that by the year 2030 this number will be increased to 79.4 million. Since 
1995, India has been ranked number one with the highest number of cases of diabetes, 
followed by China, and USA (Wild et al., 2004). The American Heart Association has 
identified diabetes mellitus as an independent major risk factor for cardiovascular 
disease (CVD) in both men and women, which is the most costly complication 
(Grundy et al, 1999; Brown et al, 1999). The cardiovascular complications of 
diabetes mellitus include coronary heart disease (CHD), stroke, peripheral arterial 
disease, nephropathy, retinopathy, and possibly neuropathy including 
cardiomyopathy. Because of the aging of the population and an increasing prevalence 
of obesity and sedentary life style in the developed as well as developing coimtries, 
the prevalence of diabetes is increasing. In fact, from the point of view of 
cardiovascular medicine, diabetes may be termed as a cardiovascular disease (Grundy 
et al, 1999). According to a WHO report (2006), it was estimated that during 2000 
about 171 million persons worldwide were affected by diabetes mellitus. Out of 
which, 5 to 10 % were designated as type 1 (formerly known as insulin-dependent) 
and 90 to 95 % were type 2 (non-insulin-dependent) diabetes mellitus. Type 1 
diabetes is characterized by an absolute deficiency of insulin caused by immunologic 
destruction of pancreatic p-cells (Unger and Foster, 1998). Type 1 diabetes usually 
begins early in life and is often called juvenile diabetes. This form of diabetes 
frequently produces microvascular complications, nephropathy and retinopathy 
(Unger and Foster, 1998), but it also predisposes to CHD (Lloyd et al, 1996). The 
metabolic abnormalities of diabetes mellitus result from a deficiency of insulin and a 
relative excess of glucagon. These imbalances in hormonal levels most profoundly 
affect various metabolic pathways in liver, muscle, adipose tissue (Fig. 1.1, Champe, 
et al, 2005). Elevated levels of blood glucose and ketone bodies are the hallmarks of 
untreated diabetes mellitus. 
Hyperglycemia is caused by increased hepatic production of glucose in 
conjunction with diminished peripheral use due to an inability of glucose uptake by 
muscle and adipose cells. Ketosis results from substantial mobilization of fatty acids 
Amino acids 
from muscle and otiier 
peripheral tissues 
Fig. 1.1. Intertissue relationship in type 2 diabetes. 
(Adapted from Lippincott's Illustrated Reviews: Biochemistry, 3'** Edition 
by Pamela, C. C and Richard, A. H. Lippincott Williams and Wilkins 
Baltimore, MD, 2005, p. 337). 
from adipose tissue, combined with accelerated hepatic ketogenesis. Diabetic 
ketoacidosis occurs in 25 to 40 % of newly diagnosed type 1 diabetes, and may recur 
if the patient becomes ill (most commonly with an infection) or does not comply with 
therapy. Ketoacidosis is treated by replacing fluids and electrolytes, followed by low-
dose insulin administration to gradually correct hyperglycemia. The excess liver fatty 
acids left behind, after their oxidation or conversion to ketone bodies, are converted to 
triglyceride (TG), which is packaged and secreted in very low density lipoprotein 
(VLDL). Since in diabetes due to low lipoprotein lipase activity in adipose tissue, 
degradation of chylomicrons is reduced, the plasma chylomicrons and VLDL levels 
are increased resulting in hypertriglyceridemia. Patients with type 1 diabetes have 
virtually no functional P-cells, and can neither respond to variations in circulating 
ftaels nor maintain a basal secretion of insulin. Therefore, this type of diabetic must 
rely on exogenous insulin administered subcutaneously to control the hyperglycemia 
and ketoacidosis. The most prevalent form of diabetes mellitus is type 2 diabetes, 
which is heterogeneous disorder. This disorder typically makes its appearance latter in 
life and its clinical expression requires both genetic and environmental factors. The 
underlying metabolic causes of type 2 diabetes are the combination of impairment in 
insulin-mediated glucose disposal (insulin resistance) and defective secretion of 
insulin by pancreatic P-cells. Insulin resistance develops from obesity and physical 
inactivity, acting on a substrate of genetic susceptibility (Gerick, 1998; Chisholm et 
al., 1997). Insulin secretion declines with advancing age (MuUer et ai, 1996; 
Dechenes et a!., 1998), and this decline may be accelerated by genetic factors 
(Pimenta et a/. 1995; Humphriss et al, 1997). Insulin resistance typically precedes the 
onset of type 2 diabetes and is commonly accompanied by other cardiovascular risk 
factors, such as, dyslipidemia, hypertension and prothrombotic factors (Hopkins et al., 
1996; Gray et al., 1998). The common clustering of these risk factors in an individual 
has been called the metabolic syndrome. Many patients with the metabolic syndrome 
manifest impaired fasting glucose (Unger and Foster, 1998) even when they do not 
have overt diabetes mellitus (Stem, 1996). The metabolic syndrome commonly 
precedes the development of type 2 diabetes by many years (Haffiier et al., 1990). It is 
important to mention that the risk factors that constitute this syndrome, contribute 
independently to CVD risk. 
Recently, new criteria have been accepted for the diagnosis of diabetes 
(ECDCDM, 1997). The upper threshold of fasting plasma glucose for the diagnosis of 
diabetes has been lowered from > 140 mg/dl to > 126 mg/dl. The upper threshold for 
normoglycemia has been reduced from < 115 to 125 mg/dl is now designated as 
impaired fasting glucose. Patients with type 2 diabetes have a combination of insulin 
resistance and dysfunctional (3-cells, but do not require insulin to sustain life, although 
insulin may be required to control hyperglycemia in some patients. The occurrence of 
the type 2 diabetes is almost completely determined by genetic factor. Diagnosis is 
based on the presence of hyperglycemia-that is, a blood glucose concentration of 
greater than 126 mg/dl. Insulin resistance is the decrease ability of target tissues, such 
as liver, adipose, and muscle, to respond properly to normal circulating concentrations 
of insulin. For example, insulin resistance is characterized by unconfrolled hepatic 
glucose production, and decreased glucose uptake by muscle and adipose tissue. 
Obesity is the most common cause of insulin resistance. Most people with obesity and 
insuh'n resistance do not become diabetic. In the absence of a defect in (3-ce/l function, 
nondiabetic, obese individuals can compensate for insulin resistance with elevated 
levels of insulin. For example, insulin secretion is 2 to 3 times higher in obese 
subjects in comparison to lean individuals. This higher insulin level compensates for 
the diminished effect of the hormone (as a result of insulin resistance), and produces 
blood glucose levels similar to those observed in lean individuals. Insulin resistance 
alone will not lead to type 2 diabetes. Rather, type 2 diabetes develops in insulin-
resistant individuals who also exhibit impaired P-cell fimction. Insulin resistance and 
subsequent development of type 2 diabetes is commonly observed in the elderly, and 
in individuals who are obese, physically inactive, or in women who are pregnant. 
These patients are unable to sufficiently compensates for insulin resistance with 
increased insulin release. Insulin resistance increases with body weight gain^ and 
conversely, diminishes with weight loss. This suggests that fat accumulation is 
important in the development of insulin resistance. Regulatory substances, such as 
leptin, resistin and adiponectin produced by adipocytes may contribute to the 
development of insulin resistance. In addition, the elevated levels of free fatty acids in 
obesity have also been implicated in the development of insulin resistance. In type 2 
diabetes, the |3-cell is dysfimctional because it fails to secrete enough insulin to correct 
the prevailing hyperglycemia. Thus, the natural progression of the disease results in a 
declining ability to control hyperglycemia with endogenous secretion of insulin. 
Deterioration of p-cell function may also be accelerated by the toxic effects of 
sustained hyperglycemia and elevated levels of free fatty acid. The metabolic 
abnormalities of type 2 diabetes mellitus are the result of insulin resistance expressed 
primarily in liver, muscle and adipose tissue, summarized in Fig. 1.2. Hyperglycemia 
is caused by increased production of glucose combined with decreased peripheral use. 
Ketosis is usually minimal or absent in type 2 diabetic patients because the presence 
of insulin. In the liver, fatty acids are converted to TGs, which are packaged and 
secreted in VLDLs. Chylomicrons are synthesized from dietary lipids by the intestinal 
mucosal cells following a meal. Because of low lipoprotein lipase activity in adipose 
tissue, lipoprotein degradation is diminished in diabetics. Therefore, in type 2 diabetic 
patients with the plasma chylomicron and VLDL levels remain elevated, resulting in 
hypertriglyceridemia. 
As already mentioned, clustering of metabolic risk factors, called the 
metabolic syndrome, occurs commonly in type 2 diabetes (ADA, 1989). The onset of 
hyperglycemia in patients with the metabolic syndrome appears to accelerate 
atherogenesis, possibly by enhanced formation of glycosylated proteins and advanced 
gycation products (Brownlee et al., 1988: Hammes and Brownlee, 1996) and/or by 
increasing endothelial dysfunction (Nadler and Winer, 1996). These direct 
consequences of hyperglycemia probably contribute to the microvascular disease, 
underlying, retinopathy, nephropathy, and neuropathy, and they may promote 
macrovascular disease as well. The individual with diabetes has a 25-foId increase in 
the risk of blindness a 20-fold increase in the risk of renal failure, and a 20-fold 
increase in the risk of amputation as a resuh of gangrene (Klein et al., 1985). How 
hyperglycemia causes the chronic complications of diabetes is imclear. In cells where 
entry of glucose is not dependent on insulin, elevated blood glucose leads to increased 
intracellular glucose and its metabolites. For example, increased intracellular sorbitol 
contributes the formation of cataract. In addition, hyperglycemia promotes the 
condensation of glucose with cellular proteins in a reaction analogous to the formation 
of HbAi. These glycated proteins mediate some of the early microvascular changes of 
diabetes. Glycosylation of retinal proteins and retinal microvascular abnormalities 
leads to retinopathy and eventually blindness (Kelvin and Moss, 1992). In addition, a 
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Fig. 1.2. Typical progression of type 2 diabetes. 
(Adapted from Lippincott's Illustrated Reviews: Biochemistry, 3™ Edition 
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sustained high level of blood and tissue glucose is also responsible for the 
development of diabetic nephropathy, which is characterized by thickening of the 
basement membranes in renal glomeruli and peripheral capillaries (nodular 
glomerulosclerosis) as observed in diabetic patients (Anderson et al., 1983), and in 
STZ-induced diabetic rats (Olgemoller and Schleicher, 1993). Diabetic nephropathy is 
the most common cause of chronic kidney failure and end-stage kidney disease in the 
USA. People with both type 1 and type 2 diabetes are at risk and the disease may 
cause death 2 or 3 years after the initial lesion formation (AHSMD, 1995). Most 
patients with type 2 diabetes have insulin resistance, which seems to predispose to 
both CVD and diabetes (Reaven, 1996). Several lines of research suggest that insulin 
resistance is a multisystem disorder that induces multiple metabolic alterations. 
Metabolic risk factors that commonly occur in patients with insulin resistance are 
glucose intolerance, hypertension, prothrombotic state, and atherogenic dyslipidemia 
(Reaven, 1996). Hypertension is a well-established major risk factor for CVD 
(Wilson, 1998). It increases the risk for both CHD and stroke and contributes to 
diabetic nephropathy (Nelson et al, 1993). Several investigators (Edelson and 
Sowers, 1993; Sowers, 1990) report a positive assodation between insulin resistance 
and hypertension, which suggests that elevated blood pressure, deserves to be listed 
among the components of the metabolic syndrome. Hypertension nonetheless is a 
multifactorial disorder, and the mechanistic connections between insulin resistance 
and hypertension are largely conjectural. However, evidence for a casual link is 
growing (Reaven et al, 1996). When hypertension coexists with overt diabetes the 
risk for CVD including nephropathy is doubly increased. The first abnormality in 
plasma glucose in padents with insulin resistance is impaired fasting glucose 
tolerance (IFG), (ECDCDM, 1997). The presence of IFG usually accompanies long-
standing insulin resistance. Many prospective studies (Haffiner, 1997; Laakso and 
Letho, 1998) show that IFG is a risk factor for CVD; the degree of independence as a 
risk factor, however, is uncertain, because IFG usually coexist with other components 
of the metabolic syndrome (Haffner et al, 1990). Nonetheless, a patient with IFG 
must be considered at risk for both CVD and type 2 diabetes. As indicated above, 
once categorical hyperglycemia develops, it is considered as an independent risk 
factor for CVD (Wilson, 1998). A newly recognized component of the metabolic 
syndrome is a prothrombotic state (Reaven et al, 1996). Patients with insulin 
resistance frequently manifest several alterations in coagulation mechanism that 
predispose them to arterial thrombosis. These alterations include increased fibrinogen 
levels (Imperatore et al., 1998), increased plasminogen activator inhibitor-1 (Byberg 
et al, 1998), and various platelet abnormalities (Trovati and Anfossi, 1998). Diabetes 
mellitus substantially increases the risk of developing coronary, cerebrovascular and 
peripheral arterial disease. The pathophysiology of vascular disease in diabetes 
involves abnormalities in endothelial, vascular smooth muscle cell, and platelet 
function. The metabolic abnormalities that characterized diabetes, such as 
hyperglycemia, increased free fatty acids, and insulin resistance, each provoke 
molecular mechanisms that contribute to vascular dysfunction. These include 
decreased bioavailability of nitric oxide (NO), increased oxidative stress, disturbances 
of intracellular signal transduction and activation of receptors of AGEs. In addition, 
platelet function is abnormal, and there is increased production of several 
prothrombotic factors. These abnormalities contribute to the cellular events that cause 
atherosclerosis and subsequently increase the risk of the adverse cardiovascular events 
that occur in patients with diabetes and atherosclerosis (Creager et al, 2003). A better 
understanding of the mechanisms leading to vascular dysfunction may unmask new 
strategies to reduce cardiovascular morbidity and mortality in patients with diabetes. 
1.1 Pathogenesis of Diabetic Complications 
The Diabetes Control and Complications Trial (DCCT) and the UKPDS (U. 
K. Prospective Diabetes Study), established that hyperglycemia, is the initiating cause 
of the diabetic tissue damage that we see clinically (DCCTRG, 1993; UKPDS, 1998). 
Although this process is modified by both genetic determinants of individual 
susceptibility and by independent accelerating factors such as hypertension and 
hyperlipidemia. The tissue damaging effects of hyperglycemia is restricted to a 
particular subset of cell types: capillary endothelial cells in the retina, mesangial cells 
in the renal glomerulus, and neurons as well as Schawan cells in peripheral nerves. It 
is well known that in diabetes, hyperglycemia is bathing all the cells of every tissue. 
However, most cells are able to reduce the transport of glucose inside the cell when 
they are exposed to hyperglycemia, so that their internal glucose concentration stays 
constant. In contrast, the cells damaged by hyperglycemia are those that can not do 
this efficiently (Kaiser et al., 1993; Heilig et al., 1995). Thus, diabetes selectively 
damages cells, like endothelial cells and mesangial cells, whose glucose transport rate 
does not decline rapidly as a result of hyperglycemia, leading to high glucose inside 
the cell. 
The first such mechanism that was discovered was the polyol pathway and 
increased polyol pathway flux, described in peripheral nerve (Gabbay et al, 1966). 
The polyol pathway, shown schematically in Fig. 1.3, focuses on the enzyme aldose 
reductase. Aldose reductase normally has the function of reducing toxic aldehydes in 
the cell to inactive alcohols, but when the glucose concentration in the cell becomes 
too high, aldose reductase also reduces that glucose to sorbitol, which is latter 
oxidized to fructose. In the process of reducing high intracellular glucose to sorbitol, 
the aldose reductase consumes the cofactor NADPH (Lee and Ch^ng, 1999). But as 
shown in Figure 1.3, NADPH is also the essential cofactor for regenerating a critical 
intracellular antioxidant, reduced glutathione. By reducing the amount of reduced 
glutathione, the polyol pathway increases susceptibility to intracellular oxidative 
stress. The second discovery is related to intracellular production of advanced 
glycation end products (AGEs) precursors, which appear to damage cells by three 
mechanisms. The first mechanism is the modification of intracellular proteins 
including, most importantly, proteins involved in the regulation of gene transcription 
(Giardino et al, 1994; Shinohara et al, 1998). The second mechanism involves 
diffusion of AGE precursors out of the cell and modifies extracellular matrix 
molecules nearby (McLellan et al, 1994), which changes signaling between the 
matrix and the cell and causes cellular dysfunction (Charonis et al, 1990). The third 
mechanism is that these AGE precursors diffiise out of the cell and modify circulating 
proteins in the blood such as albumin. These modified circulating proteins can then 
bind to AGE receptors and activate them, thereby causing the production of 
inflammatory cytokines and growth factors, which intern cause vascular pathology (Li 
et al, 1996; Neeper et al, 1992; Smedsrod et al, 1997; Vlassara et al, 1995; Abordo, 
and Thomalley, 1997; Doi et al, 1992; Kirstein et al, 1992; Schimidt et al, 1995; 
Skolnick et al, 1991 and Vlassara et al, 1988). Animal studies show that 
pharmacologic inhibition of AGEs prevents late structural changes of experimental 
diabetic retinopathy (Hammes et al, 1991). The third mechanism was the protein 
10 
> Inactive alcohols 
* Sorbitol - j '^1^>,Fructose 
NAD+ NADH ^ ' 
Glutathione 
reductase 
«R^ 
Oxidized Reduced 
Fig. 1.3. Hyperglycemia increases flux through the polyol pathway. 
(Adapted from Brownlee, M. 2001. Biochemistry and molecular biology of 
diabetic complications. Nature. 414: 813-820). 
kinase-C (PKC) pathway as shown schematically in Figure 1.4. In this pathway, 
hyperglycemia inside the cell increases the synthesis of diacylglycerol, which is 
critical activating cofactor for the classic isoforms of PKC -P, -6. and -a (Koya and 
King, 1998; DeRubertis and Craven, 1994; Xia et al, 1994; Koya et al, 1997) (Fig. 
1.4). The last mechanism was related to increased flux through the hexosamine 
pathway. When glucose is high inside a cell, most of that glucose is metabolized 
through glycolysis, going first to glucose-6-phosphate, then fructose-6-phosphate and 
then on through the rest of the glycolytic pathway. However, some of that fructose-6-
phosphate gets diverted into a signaling pathway in which an enzyme called 
glutamine; fhictose-6-phosphate amidotransferase (GFAT) converts the fructose-6-
phosphate to glucosamine-6-phosphate and finally to uridine diphospahte (UDP)-N-
acetyl glucosamine. Similar to process of phosphorylation, serine and threonine 
residues of transcription factors modify the N-acetyl glucosamine, and over 
modification by this glucosamine often result in pathologic changes in gene 
expression (Kolm-Litty et al, 1998; Sayeski and Kudlow, 1996; Wells and Hart, 
2003) (Fig. 1.4.). 
> 
1.2 Oxidant and Antioxidant Status in Diabetes 
Oxidative stress has been implicated to be an important etiological factor in 
the pathogenesis of diabetic complications. As discussed above, during diabetes 
mellitus, persistent hyperglycemia causes increased oxidative stress resulting in 
excessive production of free radicals (Aoki et al, 1992; Ono et al, 1998; Osterby, 
1992). Diabetes mellitus therefore, is associated with increased oxidative damage of 
various tissues and organs due to the accumulation of lipid peroxides and AGEs 
(Brownlee et al, 1984; Lyons, 1992), which may lead to disruption of cellular 
functions and oxidative damage to membranes (Oberley, 1988). Free radicals affect 
the cells components such as lipid, protein, DNA and carbohydrates, of which lipids 
are most sensitive part. ROS can be classified in to oxygen-centered radicals and 
oxygen-centered nonradicals. Oxygen-centered radicals are superoxide anion (-02-), 
hydroxyl radical (-OH), alkoxyl radical (R0-), and peroxyl radical (R00-). Oxygen-
centerd nonradicals are hydrogen peroxide (H2O2) and singlet oxygen ('O2). Other 
reactive species are nitrogen species such as nitric oxide (NO-), nitric dioxide (N02-), 
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and peroxynitrite (OONO) (Halliwell et al, 1995; Simon et al, 2000). ROS in 
biological systems are related to free radicals, even though there are nonradical 
compounds in ROS such as singlet oxygen and hydrogen peroxide. A free radical 
exists with one or more unpaired electron in atomic or molecular orbital. Free radicals 
are generally unstable, highly reactive and energized molecules. ROS or free radicals 
in biological systems can be formed by prooxidative enzyme systems, lipid oxidation, 
irradiation, inflammation, smoking, air pollutants, and glycoxidation (Halliwell, 1997; 
Stief, 2003). Several clinical studies reported that ROS are associated with many age-
related degenerative diseases, including atherosclerosis, vasopasms, cancers, trauma, 
stroke, asthma, hyperoxia, arthritis, heart attack, age pigments, dermatitis, 
cataractogenesis, retinal damage, hepatitis, liver injury, and periodontis (Cohen et ah, 
2000; Packer and Webber, 2001). ROS also have been known to induce apoptosis of 
cells (Simon et al, 2000). Benign fimctions of free radicals have been reported, 
including the activation of nuclear transcription factors, gene expression and a defense 
mechanism to target tumor cells and microbial infections (Simon et al., 2000). 
Superoxide anion may serve as a cell growth regulator (Halliwell, 1997). Singlet 
oxygen can attack various pathogens and induced physiological inflammatory 
response (Stief, 2003). Nitric oxide is one of the most widespread signaling molecules 
and participates in every cellular and organ function in the body. Nitric oxide acts as 
neurotransmitter and an important mediator of the immune response (Fang et al., 
2002). 
Superoxide anion is a reduce form of molecular oxygen created by receiving 
one electron. Superoxide anion is an initial free radical formed from mitochondrial 
electron transport systems (Fig. 1.4). The superoxide anion plays an important role in 
the formation of other ROS such as hydrogen peroxide, hydroxyl radical or singlet 
oxygen (2O2" + 2H'*^  - H2O2 +O2) in living systems (Stief, 2003). The superoxide 
anion can react with nitric oxide (NO) and form peroxynitrite (ONOO'), which can 
generate toxic compounds such as hydroxyl radical and nitric dioxide (ONOO' +H^ -
•OH + •NO2) (Halliwell, 1997). Hydroxyl radical is the most reactive free radical and 
can be formed from superoxide anion and hydrogen peroxide in the presence of metal 
ions such as copper or iron (-02' + H2O2 • -OH + OH" + O2). Hydroxyl radicals have 
the highest I-electron reduction potential (2310 mV) and can react with everything in 
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living organisms at the second-order rate constants of 10^-lO'^/M/S (Korycka-Dahl 
and Richardson, 1978). In general, aromatic compounds or compounds with carbon-
carbon multiple bonds undergo addition reactions with hydroxyl radicals, resulting in 
the hydroxylated free radicals. In saturated compounds, a hydroxyl radical abstracts a 
hydrogen atom from the weakest C-H bond to yield a free radical (Korycka-Dahl and 
Richardson, 1978), The resulting radicals can react with oxygen and generate other 
free radicals. Hydroxyl radicals react with lipids, polypeptides, proteins, and DNA, 
especially thymine and guanosine (Ashok and Ali, 1999). Hydroxyl radicals also add 
readily to double bonds. The barrier to the addition of hydroxyl radicals to double 
bonds is less than that of hydrogen abstraction, so that in competition addition is often 
favored. When a hydroxy] radical reacts with aromatic compounds, it can add on 
across a double bond, resulting in hydroxycyclohexadienyl radical (Padmaja and 
Madison, 1999). The resulting radical can undergo fiirther reactions, such as reaction 
with oxygen, to give peroxyl radical, or decomposed to phenoxyl-type radicals by 
water elimination. 
Hydrogen peroxide can be generated through a dismutation reaction from 
superoxide anion by superoxide dismutase. Enzymes such as amino acid oxidase and 
xanthine oxidase also produce hydrogen peroxide from superoxide anion. Hydrogen 
peroxide is highly diffusible and crosses the plasma membrane easily. Hydrogen 
peroxide is the least reactive molecule among ROS and is stable imder physiological 
pH and temperature in the absence of metal ions. Hydrogen peroxide is a weak 
oxidizing and reducing agent and is thus regarded as being poorly reactive. Hydrogen 
peroxide can generate the hydroxyl radical in the presence of metal ions and 
superoxide anion {-O^ + H2O2 • -OH + OH' + O2) (Halliwell, 1997). Hydrogen 
peroxide can produce singlet oxygen through reaction with superoxide anion or with 
HOCI or chloroamines in living systems (Steif, 2000; Steif, 2003). Hydrogen peroxide 
can degrade certain heme proteins, such as hemoglobin, to release iron ions. Singlet 
oxygen is a non-radical and excited' status. Takayama et al. (2001) reported that 
metastable phospatidylcholine hydroperoxides present in the living organism 
produced smglet oxygen during their breakdown in the presence of Cu"^ ^ in the dark. 
Singlet oxygen can be formed from hydrogen peroxide, which reacts with superoxide 
anion or with HOCI or chloroamines in cells and tissues (Steif, 2003). Compared with 
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other ROS, singlet oxygen is rather mild and nontoxic for mammalian tissue (Steif, 
2003). However, singlet oxygen has been known to be involved in cholesterol 
oxidation (Girotti and Korytowski, 2000). Oxidation and degradation of cholesterol 
by singlet oxygen was observed to be accelerated by the co-presence of fatty acid 
methyl ester. In the human organism, singlet oxygen is both a signal and a weapon, 
with therapeutic potency against various pathogens such as microbes, viruses, and 
cancer cells (Steif, 2003). Peroxyl radicals (R00-) are formed by a direct reaction of 
oxygen with alkyl radicals (R-), for example, the reaction between lipid radicals and 
oxygen. Decomposition of alkyl peroxide (ROOH) also results in peroxyl (R00-) and 
alkoxyl (R0-) radicals. Irradiation of UV light or the presence of transition metal ions 
can cause hemolysis of peroxides to produce peroxyl and alkoxyl radicals (ROOH — 
ROO- + H- ; ROOH + Fe^^ - ROO- + Fe^^ + i f ) . Peroxyl and alkoxyl radicals are 
good oxidizing agents, having more than 1000 mV of standard reduction potential 
(Decker, 1998). They can abstract hydrogen from other molecules with lower 
standard reduction potential. This reaction is frequently observed in the propagation 
stage of lipid peroxidation. Very often the alkyl radical formed from this reaction can 
react with oxygen to form another peroxyl radical, resulting in chain reaction. Some 
peroxyl radicals break down to liberate superoxide anions or can react with each other 
to generate singlet oxygen (Halliwell and Gutteridge, 1985). Aromatic alkoxyl and 
peroxyl radicals are less reactive than respective open chain radicals because of the 
delocalization of the electrons in the ring. Nitric oxide (NO-) is a free radical with a 
single unpaired electron. Nitric oxide is formed from L-arginine by NO synthase 
(Fang et ah, 2002). Nitric oxide itself is not a very reactive free radical, but the 
overproduction of NO is involved in ischemia reperftision, and neurodegenerative and 
chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel 
disease. Nitric oxide, exposed in human blood plasma, can deplete the concentration 
of ascorbic acid and uric acid and initiate lipid peroxidation (Halliwell, 1996a). Nitric 
dioxide (NO2) is formed from the reaction of peroxyl radical and NO, polluted air 
and smoking (Nogouchi and Niki, 1999). Nitric dioxide adds to double bonds and 
abstract labile hydrogen atoms initiating lipid peroxidation and production of free 
radicals. It also oxidizes ascorbic acid (Papas, 1999). Reaction of NO and superoxide 
anion can generate peroxynitrite (O2' + NO- -OONO'). Peroxynitrite is a cytotoxic 
species and causes tissue injury and oxidizes low density lipoprotein (Halliwell, 
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1997). Peroxynitrite appears to be an important tissue-damaging species generated at 
the sites of inflammation (Papas, 1999) and has been shown to be involved in various 
neurodegenerative disorders and several kidney diseases (Knight, 1999). Peroxynitrite 
can cause direct protein oxidation and DNA base oxidation and modification acting as 
a "hydroxy! radical-like" oxidant (McVean et al, 1999). The significance of 
peroxynitrite as a biological oxidant comes from its high diffiisibility across cell 
membranes (Knight, 1999). Nitrotyrosine, which can be formed from peroxynitrite-
mediated reactions with amino acids, has been found in age-associated tissues 
(Knight, 1999). 
Prooxidative enzymes, including NADPH-oxidase (Babior, 1999), NO-
synthase (Stuehr et al, 1990) or the cytochrome P-450 chain (Stief, 2000), can 
generate ROS. Lipoxygenase generates free radicals. Lipoxygenase needs free 
polyunsaturated fatty acid (PUFA), which are not present in healthy tissue. 
Membrane-bound phospholipase produces PUFA and lysolecithins. Lysolecithins 
change the cell membrane structures, and free PUFA are oxidized to form lipid 
hydroperoxides. Lipoxygenase with Fe is inactivated status. Once Fe oxidized to 
Fe^ ,^ lipoxygenase can convert PUFA in to hydroperoxides (Spiteller, 2001). There 
are three major mammalian lipoxygenases: 5-, 12-, and 15-lipoxygenases (Hari et al, 
2000). These enzymes can oxidize arachidonic acid, a PUFA rich in the central 
nervous system, in to hydroperoxyeicosatetranoic acid. The primary localizations of 
5-, 12-, and 15- lipoxygenases are in leukocytes and lymphocytes, platelets and 
airway cells, respectively (Hari et al, 2000). 15-lipoxygenase has been identified with 
in atherosclerotic lesions, which suggests that this enzyme may be involved in the in 
vivo formation of oxidized lipids (Knight, 1999). A serious imbalance between ROS 
and antioxidants causes oxidative stress. Oxidative stress is caused by antioxidant 
deficient diets or by increased production of ROS by environmental toxins such as 
those caused by smoking or by inappropriate activation of phagocytes such as with 
chronic inflammatory disease (Halliwell et al, 1995). Clinical studies reported that 
ROS are associated with many degenerative diseases, which are associated with aging 
(Packer and Webber, 2001). Lipid oxidation is a free radical chain reaction, and ROS 
can accelerate lipid oxidation (Boff and Min, 2002). Cell membranes are phospholipid 
bilayers with extrinsic proteins and are the direct targets of lipid oxidation (Girotti, 
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1998). As lipid oxidation of cell membranes increases, the polarity of lipid-phase 
surface charge and formation of protein oligomers increase; and molecular mobility of 
lipids, number of SH groups, and resistance to thermodenaturation decrease. 
Malonaldehyde, one of the lipid oxidation products, can react with the free amino 
group of protein, phospholipids and nucleic acids leading to structural modification, 
which induce dysfunction of immune systems. A high level of lipid oxidation 
products can be detected in cell degradation after cell injury or disease. The increased 
lipid oxidation products are found in diabetes, atherosclerosis, liver disease, apoplexy, 
and inflammation. LDLs are complicated structures, and oxidative modification of 
LDLs has been reported to be involved with the development of atherosclerosis and 
CVD (Frei, 1995). Oxidized cholesterol or fatty acid moieties in the plasmafic LDL 
can develop atherosclerosis (Rikans and Hombrook, 1997; Girotti, 1998; Nedeljkovic 
et al., 2003). 
Xanthine oxidase generates 02-' by catalyzing hypoxanthine and xanthine to 
uric acid. Under pathophysiologic conditions, this is another major source of vascular 
oxidative stress (Droge, 2002). Xanthine oxidase exists in plasma, liver, kidney and 
endothelial cells but not in smooth muscle cells (Harrison et al., 2003). There is 
overwhelming evidence that serum xanthine oxidase levels are significantly increased 
in various pathological states, like hepatitis, inflammation, hypercholesterolemia, 
atherosclerosis, ischemia-reperfusion, carcinogenesis and aging and that free radicals 
generated in the enzymatic process are involved in oxidative damage (Borges et al., 
2002). In hypercholesterolemic rabbits, atherosclerosis resulting from diet was 
ascribed to xanthine oxidase activation-induced oxidative stress (Ross, 1999). In 
hypercholesterolemic patients, vasodilation is improved by using the xanthine oxidase 
inhibitor oxypurinol. The role of xanthine oxidase in atherosclerosis is further 
corroborated by the following observations (Spiekermann et al, 2003): in the 
coronary arteries of patients with CAD, electron spin resonance studies show 
significant activation of both NAD(P)H oxidase and xanthine oxidase. In these 
patients, endothelial xanthine oxidase is inversely proportional and positively related 
to the effect of vitamin C on endothelium-dependent vasodilation. In asymptomatic 
young individuals with familial hypercholesterolemia, the increase of vascular 
xanthine oxidase activity is an early event. Based on the above information, it may be 
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possible that the inhibition of this enzymatic pathway by compounds that have both 
antiradical as well as xanthine oxidase inhibitory properties could provide additional 
therapeutic benefit. It has been reported that some flavonoids and structurally related 
antioxidants inhibit xanthine oxidase activity (Nagao et al., 1999; Khan and Sultana, 
2004). 
Aerobic metabolism is always accompanied by the production of ROS. 
Therefore, all aerobic organisms possess some sort of antioxidant defense with 
enzymatic and nonenzymatic constituents (Sies, 1993). The quantity and quality of 
the reactive species is determined by metabolic pathways within the organism, 
influenced by exogenous factors such as stress, radiation, food etc. The adverse 
effects of free radicals are recognized in several disorders (Feher et al., 1987), but 
care should be taken when assessing their causative role (Halliwell, 1994). Damage 
caused by free radicals is possibly involved in P-cell destruction and in the 
pathogenesis of diabetes mellitus (Oberley, 1988). Alterations of metabolic processes 
in diabetes also influence enzymatic defenses, and these changes may be associated 
with late complications of diabetes. Antioxidant enzymes primarily account for 
intracellular defense, while several nonenzyme molecules, small molecular weight 
antioxidants, protect various components against oxidation in plasma. Antioxidant 
enzymes including superoxide dismutase, catalase, glutathione peroxidase, and 
glutathione reductase, convert ROS in to non-reactive oxygen molecules. Intracellular 
antioxidant defense is primarily provided by antioxidant enzymes, which catalyze 
decomposition of ROS. The three major antioxidant enzymes, superoxide dismutase 
(SOD), glutathione peroxidase (Gpx) and catalase, differ from each other in structure, 
tissue distribution and cofactor requirement. SOD catalyzes the conversion of 
superoxide anion to hydrogen peroxide and oxygen. SOD activity was discovered by 
McCord and Fridovich in 1969; they later proved that the enzyme is required to 
sustain life in aerobic conditions (McCord et al., 1971). Several classes of the enzyme 
have since been specified, each containing a transition metal in its catalytic centre. In 
humans, mitochondrial MnSOD, and extra-and intracellular-CuZnSOD have been 
identified. Gpx is a selenium-dependent enzyme (selenoprotein). The extracellular 
form is a glycoprotein; the intracellular and mitochondrial forms also possess 
different antigenic structures. The substrate of the enzyme is reduced glutathione 
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(GSH), and therefore it depends indirectly on the flavoprotein glutathione reductase 
(Gred) and cellular NADPH concentration. Gpx uses a specific H donor, GSH, for the 
reduction of non-specific substrates (hydrogen peroxide, lipid and non-Iipid 
hydroperoxides). The enzyme contains seleno-cysteine in its active centre, which is 
incorporated in to the polypeptide chain during translation. Selenium deficiency, both 
in vitro and in vivo, leads to enzyme deficiency. Thus, when assessing GPX fimction, 
it may be necessary to examine selenium status and fi^e GSH concentration, at least 
when looking for the cause of altered activity. Catalase is a heme-containing ubiquiter 
enzyme, in eukaryotes it is found in peroxysomes. The enzyme probably serves to 
degrade hydrogen peroxide produced by peroxisomal oxidases to water and oxygen. 
Several other enzymes are also involved in the prevention of oxidative damage or its 
repair, such as Gred, enzymes of NADPH production and DNA repair enzymes. 
Different cell types and cellular compartments contain antioxidant enzymes in varying 
quantities. Regulation of antioxidant enzyme activity in eukaryote organisms may be 
influenced by such factors as age, hormonal state, organ specificity, and amoxmt of 
cofactors present (Harris, 1992). 
The glutathione-S-transferases (GSTs) are a family of multifimctional proteins 
that function both as important enzymes of detoxification and intracellular binding 
proteins (Boyer, 1989). As enzymes, they catalyze the reaction between nucliophil 
reduced GSH and large number of electrophilic compounds such as polycyclic 
aromatic hydrocarbons, aromatic amines, azodyes, alkylating agents, carcinogens and 
neurotoxins (Boyland and Chasseaud, 1969; Habig et al., 1974; Jackoby, 1978; 
Chasseaud, 1979). They also bind a number of amphipathic compounds that they do 
not metabolize (non-substrate ligands) and have been suggested to act as intracellular 
transport proteins for compounds that have limited solubility in water (Levi et al., 
1969). Additionally, a number of endogenous compounds, including prostaglandins, 
leucotrienes, organic hydroperoxides (including lipid hydroperoxides and products of 
lipid peroxidation) and steroids act as substrate for GST (Mannervik, 1985; Jackoby, 
1978; Chasseaud, 1979; Kaplowitz, 1980). However, it is important to note that 
hydrogen peroxide is not a substrate for GST (Lawrence and Burk, 1976). Two types 
of products are produced by GST catalyzed reactions (Douglas, 1987). In one type of 
reaction, a stable glutathione conjugate is formed by the nucliophilic attack of GSH 
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on an electrophilic centre. These types of reactions occur with substrates such as 
epoxides (metabolites of benzo (a) pyrine and aflatoxin A) alkyl and amyl halides 
(sulfobromophthalein) and reactions with reactive products of P45o-catlayzed reactions 
(acetoaminophen), to name just a few. In the second type of reaction, a reduce 
substrate and glutathione disulfide (GSSG) are formed. In this second type of reaction 
an unstable intermediate is the enzymatic product, which is attached 
nonenzymatically by a second molecule of GSH, yielding the final product and 
GSSG. Examples of substrates for this second type of reaction are organic nitrates and 
organic hydroperoxides. The resulting glutathione conjugates that formed are more 
soluble than the original substrates and thus more easily exported fix)m the cell. The 
release of glutathione-S-conjugates from cells is an ATP-dependent process mediated 
by membrane glycoproteins belonging to multidrug-resistance protein (MRP) family. 
Proteins of the MRP family are essential for the transport of glutathione-S-conjugates 
into the extracellular space. They are also known as glutathione-S-conjugate pumps 
(Hayes and Strange, 2000). 
In animals including humans, and in plants glutathione (GSH) is the 
predominant non-protein thiol and functions as a redox buffer, keeping with its own 
SH groups those of proteins in a reduce condition among other antioxidant activities. 
GSH acts as a reducing agent and a vital substance in detoxification, also provides 
antioxidant protection in the aqueous phase of cellular systems (Rana et al, 2002); its 
antioxidant activity is through the thiol group of its cysteine residue. Like ascorbic 
acid another important water soluble antioxidant, GSH directly reduce a number of 
ROS and is oxidized to GSSG in this process. The liver is the principal site of GSH 
synthesis. In healthy tissue, more than 90 % of the total glutathione pool is in the 
reduced form and less than 10 % exists in the disulfide form. The enzyme glutathione 
disulfide reductase is the principal enzyme that maintains glutathione in its reducing 
form. This latter enzyme uses as its cofactor NADPH, which is generated by the 
oxidative reaction in the pentose phosphate pathway. GSH/GSSG ratio is the indicator 
of redox status of the tissues (Meister, 1992; Meister and Anderson, 1983; Schafer 
and Buettner, 2001). Intrahepatic glutathione is reported to afford protection against 
liver dysfunction by at least two ways: (i) as a substrate of Gpx, GSH serves to reduce 
large variety of hydroperoxides before they attack unsaturated lipids or convert 
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already formed lipid hydroperoxides to the corresponding hydroxyl compounds; (ii) 
as a substrate of GST, it enables the liver to detoxify foreign compounds or their 
metabolites and to excrete the products, preferably in to the bile. The consequences of 
a functional glutathione deficiency, which results in tissue oxidative stress, can be 
seen in some pathological conditions. For example, those with glucose-6-phosphate 
dehydrogenase deficiency produce lower amounts of NADPH and hence, lower 
amounts of GSH. This condition is characterized by hemolytic anemia. Conditions 
causing chronic glutathione deficiency all result in hemolytic anemia, among other 
pathological consequences. Oxidative stress caused by glutathione deficiency results 
fragile erythrocyte membranes. Chronic ftinctional glutathione deficiency is also 
associated with immune disorders, an increased incidence of malignancies and in the 
case of HIV disease probably accelerated pathogenesis of the disease (Hercbergs et 
al, 1992; Holoroyd et ai, 1993). Glutathione has also been shown to enhance insulin 
secretion in elderly subjects with impaired glucose tolerance (Paolisso et al., 1992). 
1.2.1 Antioxidant enzyme activity alterations in diabetes mellitus 
The metabolic alterations that accompany diabetes mellitus can affect 
prooxidant- antioxidant balance in several ways. 
(i) Induction: Response to Oxidative Stress: There are several proposed mechanisms 
of fi-ee radical production in diabetes, glycoxidation (Baynes, 1991; Wolff and Dean, 
1987), change in intracellular NADH/NAD ratio (hyperglycemic pseudohypoxia) 
(Williamson et al., 1993), and effects on prostaglandin biosynthesis (Tesfamariam, 
1994). Since expression of antioxidant enzymes may be induced at the transcriptional 
level by oxidative stress (Kullik and Storz, 1994), it is possible that the metabolic 
changes accompanying diabetes may induce these enzymes, (ii) Allosteric Effects: 
Influence of Glycation on Enzyme Activity: The characteristic feature of diabetes, 
hyperglycemia, enhances nonenzymatic binding of glucose to proteins: the glycation 
phenomenon causes structural and fimctional changes in the proteins like hemoglobin, 
albumin, lens crystalline proteins, basal membranes of glomeruli, etc. Thus, high 
extra-and intra-cellular concentration of glucose could cause glycation and 
consequently functional changes of the antioxidant enzymes, (iii) Activation-
inactivation: Changes in the Concentration of Cofactors: SOD requires manganese or 
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copper and zinc, Gpx needs selenium, and catalase contains heme as cofactor. 
Diabetes may influence antioxidant enzyme activity through disturbances in 
micronutrient status (Strain, 1991). The distribution and function of ions of vital 
importance may change in diabetes, and the potassium and calcium channels may 
work differently. Changes in iron metabolism leads to changes at the cofactor level. In 
a long-term experiment, Wohaieb and Godin (1987) observed a decrease of SOD 
activity in the liver and kidney and an increase in the pancreas of STZ-treated diabetic 
rats. They proposed that the increase in enzyme activity might be an adaptive 
response in the otherwise SOD-poor pancreas, while the reduction of SOD activity in 
liver and kidney might be due to the direct damaging effect of free radicals on the 
enzyme. Dohi et al. (1988) found no difference in the SOD activity of the kidneys in 
STZ-treated diabetic rats after four months of diabetes. Matkovics et al. (1982) 
observed decreased SOD activities in liver, kidney, spleen, brain, heart, muscles and 
pancreas, except lungs of STZ-and alloxan-treated diabetic rats. Loven et al. (1986) 
observed a decrease in CuZnSOD activity in liver, kidney and erythrocytes after 10 
days of STZ-induced diabetes. Sukalski et al. (1993) described the decrease of liver 
mitochondrial SOD activity in diabetic rats. A significant decrease of CuZnSOD 
activity in diabetic rabbit aorta endothelium was reported by Tagami et al. (1992), 
although others have not found any difference in aortic SOD activity between diabetic 
and control rats (Langenstroer and Pieper, 1992). Red blood cell SOD is frequently 
measured in humans as an index of defense against superoxide in blood. In diabetics, 
activity of erythrocytes SOD has been shown to be decreased (Matkovics et ah, 1982) 
increased (Godin et al., 1988) and unchanged (Bono et al., 1987; Kaji et al, 1985). 
Kawamura et al. (1992) showed that red blood cell CuZnSOD is glycated both in 
vitro and in vivo, leading to its inactivation, and the percentage of this glycated SOD 
is higher in type 1 diabetic children than in healthy individual. The percentage of 
extracellular glycated SOD has also been found to be higher in diabetics (Adachi et 
al, 1991), but its activity was comparable to that of the unmodified enzyme. 
Glycation was shown to affect the C-terminal end of the enzyme reducing its heparin-
binding affinity. Thus protection against extracellular radicals by cell surface attached 
SOD may be impaired in diabetes, leaving the endothelium more susceptible to 
damage by superoxide anion. 
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Mukheijee et al. (1994) observed a significant reduction of GSH content after 
15 days, and reduction of Gred activity after 3-weeks in liver, kidney, brain and blood 
of STZ-treated diabetic rats. Others have reported reductions in mitochondrial Gpx 
and Gred activity in liver of diabetic rats (Sukalski et al., 1993). Loven et al. (1986) 
studied intestinal mucosa and liver GSH content after 10 days of STZ-induced 
diabetes; there was a significant decrease of GSH in the liver while no change was 
noticed in the mucosa. Orally administered GSH restored, and intramuscular insulin 
even increased liver GSH above normal levels. Abnormal GSH synthesis was thought 
to be responsible for the changes. Wohaieb and Godin (1987) found that in the liver, 
which normally contains high amount of GSH and strong Gpx activity, induction of 
diabetes caused a decreased in both the parameters. While in the kidney, which is 
relatively poor in Gpx activity, diabetes led to an increase in activity. Insulin 
treatment reversed these alterations. Gred activity was shown to be increased in 
erythrocytes of spontaneously diabetic BB rats, while in alloxan-treated animals Gpx 
activity was also increased (Godin et ah, 1988). These workers also found similarly 
elevated erythrocytes Gred levels and resistance to peroxide-induced GSH reduction 
in type 1 and type 2 diabetic patients. They proposed that elevated glucose levels 
could increase NADPH production resulting in a more effective GSH reduction 
(Godin et al, 1988). Dohi et al. (1988) noticed significant reduction in Gpx activity in 
aorta homogenates of rats, 4 and 8 months after induction of diabetes. They also 
found higher serum selenium concentrations in diabetic rats. Tagami et al. (1992) 
found reduced GSH content and Gpx activity and unchanged Gred activity in aortic 
endothelial cells of diabetic rabbits. Langenstroer and Pieper (1992) found no 
alteration in Gpx activity in diabetic rat aorta. Blakytny and Harding (1992) observed 
that incubation of cow erythrocytes with glucose, glucose-6-phosphate and fiiictose 
results in a time-dependent reduction of Gred activity. The experiment suggested that 
glycation of the enzyme was responsible for the observed decrease. Decreased Gred 
activity in erythrocytes of diabetic children was reported by Stahlberg and Hietanen 
(1991), but Walter et a/. (1991) found no difference between Gpx and Gred activity of 
diabetics and nondiabetics. Murakami (1991) examined erythrocytes of diabetics 
(fasting glucose level > 140 mg/dl) and concluded that GSH reduction and glutathione 
increase in erythrocytes was caused by defective functioning of y-glutamyl-cysteine 
synthase due to its glycation, decrease in Gred activity and defect in glutathione 
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transport. Yoshida et al. (1995) confirmed that in erythrocytes of poorly controlled 
diabetics (HbAi = 10.6 ± 1.3 %) GSH synthesis and thiol transport is impaired, and 
cells become susceptible to oxidative damage. Jain and McVie (1994) found that 
erythrocytes GSH content was negatively correlated to HbAi, a good estimate of 
long-term hyperglycemia in diabetics. In diabetic patients with explicit hyperglycemia 
(HbAi = 11.5 ± 1.9 %), Uzel et al. (1987) found impaired Gpx activity and lower 
erythrocytes GSH, in addition, to elevated lipid peroxidation products, the alterations 
being more pronounced in patients with retinopathy. Reduced GSH and protein-SH 
content in erythrocytes of diabetics was reported by Bono et al. (1987). Kaji et al. 
(1985) reported no difference in erythrocytes Gpx activity but an increase in plasma 
Gpx activity of diabetic compared to nondiabetic women. Elevation of serum 
selenium levels and Gpx activity in diabetic children was reported by Cser et al. 
(1993). Similarly, higher Gpx activity has been reported in erythrocytes of diabetics 
(Matkovics er a/., 1982). 
Observations regarding catalase activity in the vasculature are rather 
controversial. Tagami et al. (1992) reported a decrease in aortic endothelial cell 
catalase activity in diabetic rabbits, which was restored by insulin. Dohi et al. (1988) 
observed no alteration in catalase activity of rat aorta homogenate, while Langenstroer 
and Pieper (1992) reported its increase. The activity of catalase in liver and kidneys of 
diabetic animals is generally believed to decrease (Wohaieb and Godin, 1987; Godin 
et al., 1988; Asayama et al, 1989), although there are also reports of its increase 
(Dohi et al, 1988; Matkovics et al., 1982). On the other hand, heart and pancreas 
tissue show increased catalase activity in the diabetic state (Wohaieb and Godin, 
1987; Godin et al, 1988; Asayama et al, 1989). Erythrocytes catalase activity seems 
not to be altered either in diabetic animals or in type 1 and type 2 diabetic patients 
(Wohaieb and Godin, 1987; Matkovics et al, 1982; Godin et al, 1988; Bono et al, 
1987; Kaji et al, 1985). It is apparent from the above reports that contradictory 
changes in the activities of particular enzymes in particular organs have been 
observed in many cases. These discrepancies may be partly explained by the 
variability in the diabetes models used, including the strain and sex of the animals, 
their age at the induction of diabetes, the severity of the resulting insulin deficiency, 
and the duration of diabetes. For the clinical observations similar confounding factors 
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exist, such as the type and duration of diabetes, mode of treatment, presence or 
absence of complications, which are not revealed by routine laboratory tests. Changes 
in enzyme activity (increased, impaired, unchanged) may depend on the above 
mentioned factors to a large extent. In type 1 diabetes, when blood glucose is strictly 
controlled by intensive insulin therapy, is not accompanied by remarkable changes in 
the prooxidant-antioxidant balance. It has been reported that erythrocytes SOD and 
catalase as well as whole blood Gpx activities of patients with well controlled type 1 
diabetes do not differ from those of healthy controls (Szaleczky et al, 1997). In an 
investigation of relationship between the duration of diabetes and various measures of 
antioxidant activity in blood, it was found that erythrocytes SOD was reduced in 
patients who had had diabetes for more than 10 years compared to patients whose 
disease was not so long-standing, while whole blood Gpx and erythrocytes catalase 
activities did not differ (Prechl et al, 1997). In recent years it has been definitely 
shown that lesser the diabetic metabolic control, higher the frequency of late 
complications (DCCTRG, 1993). Should oxidative stress play a role in the 
development of these complications, one would expect adaptive changes to be 
observed in the antioxidant defense system? 
Several abnormalities, such as reduced life span (Jones and Peterson, 1981), 
increased viscosity (Satoh et al, 1984), excessive aggregation (Schmid-Schonbein 
and Volger, 1976), and increased tendency to adhere to endothelial cells (Wali et al, 
1988) have been reported in the erythrocytes of diabetic patients. Changes in the 
levels of phospholipids (Faas and Carter, 1983), cholesterol (Dang et al, 1984), 
cholesterol to phospholipid molar ratio (Miossec et al, 1999), unsaturated fatty acids 
(Ruiz-Gutierrez et al, 1993) and altered membrane phospholipid asymmetry (Wali et 
al, 1988) have also been reported in the erythrocyte membranes of diabetic patients. 
Alterations in lipid composition can affect the physico-chemical properties of the 
erythrocytes membrane (Shiga et al, 1979), including plasma membrane Na ,^ K"^ -
ATPase and Mg^-ATPase activities (Tsakiris and Deliconstantinos, 1984). A 
decrease in the plasma membrane Na ,^ K -^ATPase activity has been reported in 
erythrocyte membranes of diabetics (Mimura et al, 1994). A defect in the ouabain-
sensitive Na ,^ K -^ATPase of erythrocytes from STZ-diabetic rats has also been 
reported. This defect was accompanied by an increase in cell volume an osmotic 
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fragility and a decrease in the cytosolic K^/Na* ratio. As a consequence of which Na^, 
K*-ATPase activity in erythrocytes membrane fragments from diabetic rats was 
significantly reduced. On the other hand, Mg^-ATPase activity was not diminished in 
erythrocytes of diabetic rats (Kowluru et al, 1989). Insulin, vvdthin a physiological 
range of concentration normalizes lipid composition and order in erythrocytes in 
diabetic patients (Kowluru et al, 1989). It stimulates Na^, K^-ATPase activity and 
translocation to plasma membrane via phosphorylation of the a-subunits by protein 
kinases (Kowluru et al, 1989; Al-Khalili et al., 2004). Erythrocytes are exposed to 
continuous oxidative stress, because oxygen radicals are continuously generated by 
the auto-oxidation of hemoglobin (Misra and Fridovich, 1972). Oxygen radicals 
formed over and above the detoxifying capacity of erythrocytes can cause 
peroxidative breakdown of phospholipids, fatty acids and accumulation of 
malondialdehyde (Halliwell and Guttteridge, 1984). Erythrocytes of diabetic patients 
and smokers are more susceptible to lipid peroxidation, when treated with hydrogen 
peroxide in vitro. (Uzel et al, 1987; Ismail et al, 2002). 
1.3 Cholesterol Dynamics in Diabetes/Hyperlipidemia 
Cholesterol, which is widely distributed in the animal kingdom, occurs in free 
form (unesterified) in all cell membranes (Myant, 1981) while in the plasma most of 
the cholesterol occurs in esterified form. Cholesterol has many biological fimctions. 
For instance, the concentration of cholesterol influences the fluidity of cell 
membranes and thereby biological activities of the cell. The cholesterol acts as a 
precursor for the synthesis of bile acids and steroid hormones. The total body 
cholesterol is derived from two sources: (i) dietary and (ii) de novo biosynthesis. 
Cholesterogenesis mostly occurs in the liver, which also regulates the level of 
circulating plasma cholesterol and serum lipoproteins. The biosynthesis of cholesterol 
also occurs in the other organs like the intestines, adrenal cortex, reproductive organs 
and skin. Although other cells and tissues do not synthesize cholesterol, they have the 
genomic information for its synthesis. Under normal circumstances, these cells and 
tissues take up cholesterol from serum lipoproteins. 
Starting from the 2-carbon unit acetyl-CoA, the biosynthesis of the cholesterol 
proceeds to several intermediates, including mevalonate and isopentenyl 
27 
pyrophosphate (Fig. 1.5). Isopentenyl pyrophosphate is fiirther processed in a series of 
steps to two branched pathways, one leading to isopentenyl tRNA and isopentenyl 
adenine, and the other to famesyl pyrophosphate. Famesyl pyrophosphate is in turn 
channeled to synthesis of cholesterol, ubiquinone or dolichols (Ross and CHomset, 
1973; Brown and Goldstein, 1983). The observation that cancer cells lose feedback 
control of cholesterol biosynthesis, show elevated cholesterol levels, and exhibit a 
higher rate of cholesterogenesis provided the first indication of the link between 
cholesterol biosynthesis and cancer cell growth (Coleman and Laviets, 1981). The 
subsequent realization that not only cancer cells but also preneoplastic and normal 
proliferating cells show elevated levels of cholesterol as well as higher rates of 
cholesterogenesis indicated that cholesterol biosynthesis is likely to play an important 
role not only in carcinogenesis but also in normal cell growth (Rao, 1986). Hepatic 
level of cholesterol are maintained by a precised balance between reactions catalyzed 
by 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase, EC 
1.1.1.34), cholesterol 7-a-hydroxylase, acyl CoA: cholesterol acyltransferase and 
cholesteryl ester hydrolase. The first two enzymes are the rate limiting enzymes for 
cholesterol and bile acid synthesis, respectively. Acyl CoA: cholesterol 
acyltransferase catalyzes esterification of free cholesterol, whereas cholesteryl ester 
hydrolase mediates release of fi-ee cholesterol fi"om stored cholesteryl esters. 
The primary feedback loop for regulation of cholesterol synthesis appears to 
be at the site where HMG-CoA is converted to mevalonic acid by the rate-limiting 
enzyme HMG-CoA reductase, cholesterol and other oxysterols inhibit the activity of 
HMG-CoA reductase. Because of the strong link between cholesterol and CHD and 
its link with cancer (Rao, 1986), there is currentiy a renewed interest in studying the 
regulation of HMG-CoA reductase and several other key enzymes in cholesterol 
biosynthetic pathway. HMG-CoA reductase regulates the synthesis of cholesterol and 
other polyisoprenoid compounds (Rodwell et ai, 1976; Goldstein and Brown, 1977; 
BrowTi and Goldstein, 1979; Brown and Goldstein, 1980; Beg et al., 1981; Beg and 
Brewer, 1982). In mammalian cells, HMG-CoA reductase is a transmembrane 
glycoprotein with its active site facing the cytosol and a carbohydrate containing site 
oriented toward the luminal surface of the endoplasmic reticulum (Liscum et al., 
1983a; Brown and Simoni, 1984). HMG-CoA reductase is an approximately 100 kDa 
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Fig. 1.5. The biosynthetic pathways of mevalonate, sterols and isoprenoid 
compounds in mammalian cells. 
(Adapted from Maltese, W. 1990. The FASEB. J. 4:3319-3328). 
protein (Chin et al., 1982; Edwards et al, 1983a; Hardeman et al., 1983; Chin et al., 
1984; Beg et al., 1985). Proteolysis of the native protein results in a 53 kDa molecular 
weight fragment that contains the active site of the enzyme (Chin et al., 1982; Liscum 
et al., 1983a; Edwards et al., 1983a; Hardeman et al., 1983; Chin et al., 1984; Beg et 
al., 1985). HMG-CoA reductase is a protein of 887 amino acids containing three 
potential sites for aspargine-linked glycosylation. The N-terminal half of the peptide 
is anchored to the membrane and contains seven hydrophobic regions, each of which 
is comprised of 20 amino acids and spans the microsomal membrane (Chin et al, 
1984). The N-terminal lacks the signal sequence and the hydrophilic C-terminal half 
of HMG-CoA reductase contains the catalytic site of the enzyme (Chin et al, 1984). 
Since, the catalytically active hydrophilic tail of the enzyme extends into the 
cytoplasm, it is more accessible to the action of modulators and permits the observed 
multifaceted regulation of HMG-CoA reductase and cholesterol synthesis. The 
complex homeostatic mechanism by which the enzyme activity of HMG-CoA 
reductase and cholesterol biosynthesis are coordinately regulated in response to 
various physiological stimuli has been extensively studied. Isolation, purification, and 
characterization of rat hepatic HMG-CoA reductase have been well documented 
(Kawachy and Rudney, 1970; Heller and Gould, 1973; Brown et al, 1973; Heller and 
Gould, 1974; Heller and Shrewsbury, 1976; Kleinsek et al., 1977; Srikantaiah et al., 
1977; Edwards et al., 1979). HMG-CoA reductase has also been studied in several 
other species including chicken liver (Beg et al, 1978; Beg et al, 1979), human liver 
(Beg et al, 1982; Beg et al, 1984) and human fibroblasts (Brown and Goldstein, 
1983; Beg et al, 1987). Several different mechanisms for the regulation of enzymes 
in metabolic pathways have been elucidated such as modulation by isosteric and 
allosteric effectors, regulation of enzyme synthesis and degradation, feedback control, 
and covalent modification (Siperstein, 1970; Holzer and Duntze, 1971; Segal, 1973; 
Carlson and Kim, 1973; Lee et al, 1976; Greengard, 1978). Three basic control 
mechanisms for HMG-CoA reductase have been reported, (a) Long-term regulation, 
which involves the modulation of HMG-CoA reductase activity by changes in 
enzyme concentration through the regulation at transcriptional level and post-
transcriptional regulatory mechanisms such as mRNA and enzyme protein 
degradation (Kirsten and Watson, 1974; Jakoi and Quarfordt, 1974; Chang et al. 
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1981; Koizumi et al, 1982; Faust et al., 1982; Edwards et al., 1983a; Edwards et al., 
1983b; Liscum et al., 1983b; Clarke et al., 1983; Sinensky and Logel, 1983; Clarke et 
al., 1984). For instance, the product feedback regulation by mavalonate (Kita et al., 
1987; Brown and Goldstein, 1980; Cohen et al., 1982), in vivo inhibition of HMG-
CoA reductase by cholesterol feeding (Arebalo et al., 1981), cholesterylamine and 
mevinolin (Eisenberg and Levy, 1975), and mevalonolactone (Arebalo et al., 1980; 
Beg et al., 1984) has been reported. Tocotrienols, a naturally occurring class of 
compounds of vitamin E family, have also been reported to regulate HMG-CoA 
reductase activity at the post-transcriptional level (Pearce et aL, 1992; Parker et aL^ 
1993). (b) Control of HMG-CoA reductase activity through changes in the membrane 
composition and membrane fluidity in the microsomal environment in the immediate 
vicinity of the enzyme (Finkel and Volpe, 1979; Mitropoulous et al., 1981; Siptal and 
Sabine, 1981; Richert et al., 1984). (c) Short-term regulation that involves reversible 
covalent modification (phosphorylation and dephosphorylation) of HMG-CoA 
reductase (Ingebritson and Gibson, 1980; Beg et al., 1981; Beg and Brewer, 1982; 
Kennelly and Rodwell, 1985). Three separate kinase systems for the regulation of 
HMG-CoA reductase involving short-term covalent modification have been 
demonstrated (Ingebritson and Gibson, 1980, Beg et al., 1987). Studies involving 
incubation of rat hepatocytes with insulin and glucagon or administration of glucagon 
to rats have been shown to modulate the bicyclic cascade system involving 
phosphorylation of both HMG-CoA reductase and HMG-CoA reductase kinase 
(Ingebritson and Gibson, 1980; Gibson, 1985; Beg et al., 1987; Gibson and Parker, 
1987). 
Although cholesterol is essential to life, excess or deficit of Iree cholesterol is 
known to be harmful. Several factors are known which cause an overall increase in 
cholesterol concentration in the liver (i) uptake of lipoproteins by receptor mediated 
endocytosis, (ii) non-receptor mediated intake of lipoproteins, (iii) uptake of fi-ee 
cholesterol fi"om the cholesterol rich lipoproteins by cell membranes, (iv) de novo 
synthesis of cholesterol, and (v) hydrolysis of cholesterol esters by cholesteryl ester 
hydrolase. Under above situations, not only increased cholesterol levels inhibits its 
own synthesis by inhibiting HMG-CoA reducts^e and suppressing low density 
lipoprotein (LDL) receptors (Russel et al., 1983), but also by activating cholesterol 7-
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a-hydroxylase and acyl CoA: cholesterol acyltransferase which utilize free 
cholesterol for bile acid synthesis and formation of cholesteryl esters, respectively. 
Conversely, some factors are involved in the decrease of hepatic cholesterol, they are 
(a) efflux of cholesterol from membrane to nascent high-density lipoproteins (HDL) 
and HDL3 which is catalyzed by lecithin: cholesterol acyltransferase, (b) esterification 
by acyl CoA: cholesterol acyltransferase and (c) utilization of cholesterol for 
synthesis of steroids and bile acids. Under these conditions, increase in cholesterol is 
achieved by activation of HMG-CoA reductase and cholesteryl ester hydrolase 
activities as well as ind\iction in synthesis of LDL receptors in order to receive 
cholesterol from non-hepatic tissues by receptor mediated endocytosis. However, 
under normal conditions an intricate balance is maintained between the biosynthesis, 
utilization and transport of cholesterol, keeping its harmfiil effects to minimum. 
Lipids are transported through plasma compartment in lipoproteins, which are 
complex water soluble molecules consisting of a core of cholesteryl esters and TG 
covered by a surface monolayer of phospholipids, free cholesterol and 
apolipoproteins. In the last two decades, there have been major advances in our 
understanding of the role of plasma lipoproteins, apolipoproteins, lipolytic enzymes, 
and lipoprotein receptors in cholesterol and lipoprotein metabolism. This new 
information has provided major insights into the role of cholesterol and lipoproteins in 
the pathogenesis of premature atherosclerosis. There are six major classes of human 
plasma lipoproteins, these include chylomicrons, very low density lipoproteins 
(VLDL), intermediate density lipoprotein (IDL), low density lipoprotein (LDL), high 
density lipoprotein (HDL) and lipoprotein (a) [Lp(a)] (Gofinan et al., 1954; Berg et 
al, 1974). HDL can be ftuther separated by hydrated density into HDL2a, HDL2b, 
HDL3a, HDL3b and HDL3c, (Kontush et al, 2003). These lipoproteins are 
distinguished on the basis of their lipid content, ulfracentriftigation size, 
electrophoretic mobility and surface proteins. Fourteen major human plasma 
apolipoproteins have been identified and their gene and protein structures determined 
(Brewer et al, 1988). The five most clinically relevant apolipoproteins are A-I, B-
100, B-48, C-II and E. The two major apolipoproteins on HDL are apoAI and apoAII 
(Suzuki et al, 1983). In human plasma apoB exist as two isopioteins designated 
apoB-100 and apoB-48, with molecular weights of 512 and 250 kDa, respectively 
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(Kane et al, 1980; Kane, 1983). ApoB-48 and apoB-100 are the principal structural 
apolipoproteins on chylomicrons, VLDL, IDL and LDL. ApoB-100 is virtually the 
only apolipoprotein on LDL. Three major physiological functions for the plasma 
apolipoproteins have been identified, (i) Apolipoproteins function as structural 
proteins for the biosynthesis and secretion of plasma lipoproteins. ApoB-100 and 
apoB-48 are required for the secretion of TAG-rich lipoproteins from the liver and 
intestine. ApoA-I has been proposed to be an important structural protein for the 
biosynthesis of HDL. Individuals with an inability to synthesize and secrete apoA-I 
have a virtual absence of plasma HDL (Schaefer et al., 1985). (ii) Apolipoproteins 
function as cofactors or activators of enzymes involved in lipid and lipoprotein 
metabolism. ApoC-lI is required for the enzymatic activity of lipoprotein lipase, 
which is responsible for the perivascular hydrolysis of lipoprotein TAG to free fatty 
acids and monoacylglycerols (La Rosa et al, 1970; Havel et al., 1970). Lipoprotein 
lipase is attached to the capillary endothelium by a heparin-like proteoglycan allowing 
direct interaction of the enzyme with the circulating TAG-rich lipoproteins. A 
deficiency of lipoprotein lipase or apoC-II results in defective TAG hydrolysis 
(Breckennidge et al, 1978). Clinically, patients have eruptive xanthomas, severe 
hypertriglyceridemia and recurrent bouts of pancreatitis. ApoA-1 activates lecithin: 
cholesterol acyltransferase, which catalyzes the esterification of plasma cholesterol to 
cholesteryl esters (Fielding et al, 1972). (iii) Apolipoproteins also play a critical role 
in lipoprotein metabolism as ligands on lipoprotein particles, which interact with 
cellular receptors for specific lipoproteins. ApoB-100 interacts with the LDL receptor 
to initiate absorptive endocytosis and cellular uptake of LDL (Brown and Goldstein, 
1986). ApoE has been proposed to interact with apoE receptor, which facilitates the 
hepatic removal of lipoprotein remnants, secreted by the intestine and liver (Hertz et 
al, 1988). 
The metabolic relationship of the major classes of lipoproteins containing 
apoB-48 and apoB-100 may be considered to consist of two major "apoB cascades". 
The first apoB cascade involves the stepwise delipidation of TG-rich chylomicrons 
secreted by the intestine. These lipoproteins transport dietary cholesterol and TG fi-om 
the intestine to the liver and peripheral tissues. Shortly after secretion, chylomicrons 
acquire apolipoproteins C-II and E primarily from HDL. As already outlined, apoC-II 
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activates lipoprotein lipase, which initiates TG hydrolysis and remodeling of the 
lipoprotein particles. With TG hydrolysis of the hydrated density the chylomicrons 
increases and chylomicron remnants are generated with a hydrated density of VLDL 
and then IDL. Chylomicron remnants are removed primarily by a hepatic remnant 
receptor. ApoE has been proposed to interact and initiate the hepatic uptake of the 
chylomicron remnants (Hertz et al., 1988). The second apoB cascade is a parallel 
cascade involving TG rich VLDL containing apoB-100 secreted by the liver. ApoC-II 
and apoE from HDL rapidly associate with the newly secreted hepatogenous VLDL. 
ApoC-II activates lipoprotein lipase, which hydrolyzes VLDL triglycerides, and the 
VLDL is serially converted to smaller VLDL remnants, IDL, and finally LDL. During 
the conversion of VLDL to LDL approximately 50 per cent of VLDL remnants and 
IDL are removed directly from the plasma by interaction of apoE and apoB-100 with 
the remnant and LDL receptors. 
Another lipolytic enzyme, hepatic lipase and apoE have also been proposed to 
be necessary for the conversion of IDL to LDL. Hepatic lipase functions as both a 
triglyceryl hydrolase and phospholipase. LDL, the end product of the VLDL cascade, 
contains almost exclusively apoB-100 as its only protein constituent. ApoB-100 on 
LDL interacts vsdth LDL receptor on the plasma membrane of cells in the liver, 
adrenal and peripheral cells, including smooth muscle cells and fibroblasts (Brown 
and Goldstein, 1986), where it supplies cholesterol to the intracellular cholesterol 
pool. The work of Brown and Goldstein (1979 & 1983) on the cellular metabolism of 
LDL elucidated the LDL Pathway. The high affinity receptors bind LDL particles and 
extract them from the fluid that bathes the cell. LDL is transported to lysosomes 
where the protein is degraded and the cholesterol is transferred to the intracellular 
cholesterol pool (Brown and Goldstein, 1986). The receptor displayed on the surface 
of the cells varies with the cellular demand for cholesterol. When the need is low, the 
cells make fewer receptors and take up LDL at a reduced rate, this protects the cells 
excess cholesterol but at a higher price, the reduction in the number of receptors 
decreases the rate of removal of LDL from the circulation, blood level of LDL rises 
and atherogenesis is accelerated. LDL receptor plays an important role in the 
maintenance of plasma LDL-cholesterol levels. The serum concentration of LDL, 
therefore, depends on the rate that liver removes IDL from the circulation, which in 
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turn, depends on the number of functioning LDL receptors on the liver cell surface. 
High blood cholesterol which results from the overproduction and/or underutilization 
of LDL, is known to be caused by two metabolic irregularities: (i) the genetic disease 
familial hypercholesterolemia (discussed in detail later); (ii) the consumption of high 
cholesterol diet. Familial hypercholesterolemia (FH) is a dominant genetic defect that 
results in a deficiency of functional LDL receptors. FH homozygotes, therefore have 
plasma LDL-cholesterol levels three to five times higher than average. FH 
heterozygotes, which are fer more common, have about one half of the normal 
number of functional receptors and plasma LDL-cholesterol levels of about twice the 
average. The ingestion of high cholesterol has an effect similar, although not as 
extreme, as FH. Excessive dietary cholesterol enters the liver cells in chylomicron 
remnants and represses the synthesis of LDL-receptor protein. The resulting 
insufficiency of LDL-receptors on the liver cell surface has consequences similar to 
those of FH. In Watanable hereditable hyperlipidemic (WHHL) rabbits, with a genetic 
deficiency of LDL receptor function, extremely high plasma LDL cholesterol levels 
are observed with the development of atherosclerosis early in life (Brown and 
Goldstein, 1983). LDL receptor activity is imder the metabolic regulation in vivo, 
such that receptor activity can be increased or decreased by appropriate interventions 
with diet and/or drugs (Mahley and Innerarity, 1983; Brown and Goldstein, 1983). 
Nascent HDL, primarily in the form of phospholipid-apolipoprotein A-I discs, 
are synthesized both in the human liver and intestine. As cell of the body die and as 
ceil membranes undergo turnover, free cholesterol is continually released in to the 
plasma. This cholesterol is immediately adsorbed on to high-density lipoproteins 
(HDL: diameter, 5 to 12nm), and in this location it is esterified with a long-chain fatty 
acid by an enzyme in plasma, lecithin: cholesterol acyltransferase (LCAT). The newly 
formed cholesteryl esters are rapidly transferred from HDL to VLDL or IDL particles 
by a chloesteryl ester transfer protein in plasma. The IDL particles are ultimately 
taken up by the liver or converted to LDL. The nascent HDL acquires cholesterol 
from tissues and the enzyme lecithin: cholesterol acyltransferase catalyzes the 
esterification of cholesterol to cholesteryl esters. With the increase in lipid content, 
the nascent HDL are converted to HDL3, these HDL3 lipoproteins are then converted 
to the larger HDL2 lipoproteins by the acquisition of lipids and apolipoproteins 
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released during the stepwise delipidation and remodeling of the TG rich chylomicrons 
and VLDL as well as the uptake of cholesterol fk)m peripheral tissues. HDL2 is 
converted back to HDL3 by the removal of TAG and phospholipids by hepatic lipase 
as well as by the transfer of cholesteryl esters into VLDL and LDL by the cholesteryl 
ester transfer protein (CETP) as well as the transfer of cholesteryl esters to the liver 
and other tissues. In this overall process, HDL are interconverted from HDL3 to HDL2 
and back to HDL3 as cholesterol is picked up and transferred from peripheral tissues 
to the liver. This process is termed as reverse cholesterol transport (Brewer et ah, 
1971; Eisenberg et al., 1984). In this proposed model, HDL interacts with a putative 
HDL receptor (Suzuki et al., 1983; Schmitz et al., 1988) that facilitates the transfer of 
intracellular cholesterol to HDL. HDL transports this cholesterol in plasma and 
delivers it to the liver via the HDL receptor for removal from the body by direct 
secretion into bile or following conversion to bile acids. A variable portion of tissue 
cholesterol has been proposed to be transported to the liver by HDL particles 
containing apoE, which may interact with the hepatic remnant and LDL receptors 
(Eisenberg et al., 1984). 
Atherosclerosis is a disease of large and medium-sized muscular arteries and 
the elastic arteries, such as the aorta and iliac vessels. The basic lesion-the atheroma 
or fibrofatty plaque consists of a raised focal plaque within the intima, having a core 
of lipid (mainly cholesterol, usually complexes to proteins, and cholesterol esters) and 
a covering fibrous cap. This plaque gradually blocks the arteries causing infarction of 
the tissues (Packer and Landvik, 1989). Several clinical and epidemiological studies 
indicate that diabetes mellitus is an independent risk factor for CVD. Both type 1 and 
type 2 diabetes mellitus are associated with a marked increase in risk of CHD, 
cerebrovascular, and peripheral vascular disease, and these disorders are major causes 
of morbidity and mortality in diabetes. In general, atherosclerosis and its 
complications occur earlier and are two to six times more frequent in diabetics than in 
nondiabetics, and that 80 % of all type 2 diabetics will die of an atherosclerotic event. 
In most studies the excess risk of CHD caused by diabetes is relatively greater in 
diabetic women than in diabetic men (Ruderman et al., 1992; Eastman et al., 1997; 
Kannel and McGee, 1979; Garber, 1995). There is debate about the relative roles of 
hyperglycemia and dyslipidemia in the excess CAD associated with diabetes 
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(Eschwege et al., 1994). Whereas, the Diabetes Control and Complications Trial 
(DCCT) indicated that blood glucose is highly predictive of microvascular disease 
(DCCTRG, 1993), the contribution of all the commonly measured risk factors can 
explain no more than 25 % of the excess macrovascular CAD associated with diabetes 
(Pyorala et al., 1987). Importantly, plasma lipoprotein profile may be most critical 
(Bierman, 1992; Stamler, 1987; Steiner, 1994) because at any total cholesterol level, 
diabetics have 3- to 5-fold higher CAD mortality rates than do nondiabetic individuals 
(Stamler, 1987). There is virtually uniform agreement that the diabetic dyslipidemia 
in type 1 and type 2 diabetes should be highly atherogenic (Ruderman et ah, 1992; 
Semenkovich and Heinecke, 1997; Bierman, 1992). However, underlying 
mechanisms for the accelerated atherogenesis in diabetes have remained poorly 
understood. Atherosclerosis vascular disease (ASVD) complications occur more often 
in patients with type 2 diabetes than in patients with type 1 diabetes. This is at least 
partly due to the fact that in type 1 diabetes, macrovascular disease usually appears 
only in the presence of renal complications, whereas in type 2 diabetes, 
atherosclerotic complications are already present at the time of diagnosis of diabetes. 
Several harmful effects of hyperglycemia are known which may contribute to 
atherothrombosis in type 2 diabetic patients. The onset of hyperglycemia in type 2 
diabetic patients with the metabolic syndrome, which is characterized by increased 
production of free radicals, appears to accelerate atherogenesis, possibly by enhanced 
formation of glycosylated proteins and advanced glycation products and/or by 
increasing endothelial dysfunction (Grundy et al, 1999; Maxwell and Lipd, 1997). 
Consistent with these findings, in patients with type 2 diabetes, the total plasma 
antioxidant capacity, susceptibility of LDL-C to oxidation and the excretion of 
oxidized products of arachidonic acid are all increased in proportion to the severity of 
hyperglycemia (Grundy et al, 1999; Maxwell and Lipd, 1997; Ceriello et al, 1997; 
Peuchant et al., 1997). Due to increased susceptibility of LDL to oxidation in these 
hyperglycemic patients, Sobenin et al. (1996) demonstrated that sera from type 2 
diabetic patients show increased atherogenic properties, as measured by the ability of 
LDL-C to accumulate in human aortic intimal cells. Many trials have been conducted 
to see the effect of correction of hyperglycemia on micro and macrovascular diseases. 
The recent trial, UKPDS was published in 1998 and showed a 12% reduction in any 
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diabetes related end point (microvascular and macrovascuiar complications), a 10% 
reduction in any diabetes related death, a 6% reduction in all cause mortality, a 16% 
reduction in myocardial infarction and a 25% reduction in microvascular 
complications, among intensively treated patients (HbAic = 7) than with 
conventionally treated patients (HbAic= 7.9) for hyperglycemia (UKPDS 33, 1998). 
Thus, it seems that type 2 diabetes may be a significant risk factor for diabetic 
macrovascuiar disease but intensive glucose control reduces only microvascular 
complications effectively but not macrovascuiar disease for which aggressive 
treatment of other risk factors like hypertension, dyslipidemia and smoking are also 
necessary. 
Modified lipoproteins, particularly different forms of oxidized LDL, have 
been reported to elicit humoral immune responses in both experimental animals and 
humans. In diabetes, the effects of glycation and oxidation are interwoven, and 
increased glycation results not only in increased susceptibility of LDL to oxidation 
but also in increased formation of glycoxidation products or AGEs. Modified LDL 
triggers the formation of autoantibodies, and both modified LDL and antibodies 
against modified LDL have been detected in circulation and in atheromatous plaques. 
Also, ICs containing modified LDL have been isolated fi-om the serum of diabetic and 
nondiabetic patients with manifestations of atherosclerosis. In addition, it has been 
demonstrated that in vitro formed LDL-IC and IC isolated fi^om patients are taken up 
mainly through Fcr receptors and cause intracellular accumulation of cholesterol 
esters in macrophages and smooth muscle cells. 
L4 Lipoprotein Metabolism 
Defects in the lipid and lipoprotein metabolism that is dyslipidemia or 
atherogenic dyslipidemia is more common in type 2 diabetes than in type I and occurs 
early even at the prediabetic stage of impaired glucose tolerance (Laakso and Barret-
Canner, 1995), Excess risk of CHD in patients with diabetes mellitus is not fiilly 
understood, but diabetic dyslipidemia is likely to be major contributor (Haffher, 
1998). Patients with type 2 diabetes have increased levels of total and VLDL 
triglycerides, decreased levels of HDL-C and smaller absolute elevations of LDL-C 
levels relative to nondiabetic patients (Haffiier, 1998). However, patients with type 2 
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diabetes tend to have total LDL-C values that do not meet the goal by National 
Cholesterol Education Programme Adult Treatment Panel II criteria (Alexander et al., 
1998), and have a greater preponderance of smaller, denser LDL-C (sd-LDL-C) that 
seems more atherogenic (Haffiier, 1998). Because of greater preponderance of sd-
LDL, a moderately high LDL-C (between 130 and 160 mg/dl) in a type 2 diabetic 
patient is equivalent to much higher LDL-C in terms of CHD risk for a nondiabetic 
subjects (Grundy et al, 1999; Haffher, 1998; NCEP Expert Panel, 1993). HDL-C also 
shows quantitative and qualitative changes in type 2 diabetes. Quantitatively type 2 
diabetes is associated with low HDL-C, particularly HDL2-C subfraction along with 
low apoprotein Ai concentration (Laakso et al, 1985; Garg and Grundy, 1990; 
Howard, 1994). These abnormalities in HDL persist despite good glycemic control of 
type 2 diabetes (Chen et al, 1987). The reason for decrease in HDL-C in type 2 
diabetes include reduced transfer of surface components to HDL during catabolism of 
triglyceride rich particles, increased activity of hepatic lipase and increased 
catabolism of apoprotein Ai (Golay et al, 1987; Bayes et al., 1991; Kasim et al., 
1987). 
Overall, 30-40 % of patients with diabetes have TG levels >200 mg/dl, and 10 
% have TG >400 mg/dl (Covde and Harris, 1995). However, in the UKPDS, despite a 
high frequency of modestly elevated base line TG levels (mean base line 159 mg/dl), 
a multivariate analysis showed that TG levels did not predict CHD events. LDL-C 
was the strongest independent predictor of CHD followed by HDL-C (Turner et al., 
1998), supporting current national guidelines in which LDL lowering is the primary 
lipid target. Low density lipoproteins (LDLs) are composed of distinct subspecies that 
differ in size, density, chemical composition, and their association with CVD (Austin 
et al, 1990; Stampfer et al, 1996; Gardner et al, 1996; Lamarche et al, 1997; Austin 
et al, 1988). Lipoprotein profiles that are relatively rich in smaller, more dense LDL 
particles (sd-LDL) are associated with up to 3-fold greater risk of myocardial 
infarction (MI), than those mainly consist of large buoyant LDL (Ib-LDL) particles 
(Austin et al, 1990; Stampfer et al, 1996; Gardner et al, 1996; Lamarche et al, 
1997; Austin et al, 1988). The increased risk of the sd-LDL phenotype is in part due 
to associated metabolic aberrations, including high TG and low HDL concentrations 
(Austin et al, 1990). However, the mass of sd-LDL is independently associated with 
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disease risk (Stampfer et al., 1996; Gardner et al., 1996; Lamarche et al., 1997; 
Austin et al., 1988), suggesting that these particles are more directly atherogenic than 
Ib-LDL. It has been shown that not only the prevalence of sd-LDL but also its 
concentration was substantially increased in type 2 diabetic patients with and without 
CHD, as well as subjects with various types of hyperlipidemia (Hirano et al., 2004). 
Since sd-LDL is generated from large triglyceride rich VLDL, several findings also 
suggest that subjects with the predominance of sd-LDL have higher TG and lower 
HDL-C and HDL2-C concentrations, similar to the levels seen in subjects with insulin 
resistance and are hyperinsulinemia (Tribble et al., 2001; Austin and Edwards, 1996). 
Therefore, it appears that there is a close association of sd-LDL with the insulin 
resistance (Bemeis and Krauss, 2002). It has been suggested that in comparison to Ib-
LDL, sd-LDL are highly atherogenic as a result of their enhanced susceptibility to 
oxidative modification, higher penetration in the arterial wall, their lower binding 
affinity for the LDL-receptor, and prolonged plasma half life (Chapman et al., 1998; 
Bjomheded et al, 1996). In contrast with native LDL, oxidized LDL particles initiate 
a series of events, including vascular inflammation and macrophage foam cell 
formation, that are central to the atherogenic process (Tribble, 1999). LDL particles 
with greater tendency to become oxidized might thus be more likely to participate in 
proatherogenic events. Differences in oxidative susceptibility between Ib-LDL and sd-
LDL have been attributed to differences in their physicochemical properties. Relative 
to Ib-LDL, sd-LDL have a reduced content of antioxidants (De Graaf e/ al., 1991; 
Tribble et al, 1992; Dejager et al, 1993; Tribble et al, 1994; Tribble et al, 1995), 
and free cholesterol (De Graaf e/ al, 1991; Tribble et al, 1992; Tribble et al, 1994), 
and are enriched with polyunsaturated fatty acids (De Graaf et al, 1991), and, 
possibly, hydroperoxides (Sevanian et al, 1996). Antioxidant concentrations and free 
cholesterol content have been shown to predict differences in the oxidative 
susceptibility of LDL density subfraction (De Graaf e/ al, 1991; Tribble et al, 1992; 
Tribble et al, 1994). Lipoproteins (VLDL and LDL) fix)m diabetic rats are more 
extensively oxidized in vivo and more toxic to certain cell lines than LDL from 
nondiabetic rats (Morel and Chisolm, 1989). A related finding was that correction of 
hyperglycemia with insulin therapy or supplementation with antioxidants decreased 
the extent of oxidation and cytotoxicity of diabetic rat lipoprotein (Morel and 
Chisolm, 1989). Increased rates of lipid peroxidation in type 2 diabetics may be 
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related in part to increased amounts of sd-LDL in their plasma (Feingold et al., 1992; 
Selby et al., 1993). Based on the above information, sd-LDL has been highlighted as a 
useful and potent new marker for the risk of CHD or type 2 diabetes (Austin et al., 
1995). 
1.4.1 Atherogenic properties of oxidized LDL 
The etiology of CVD is complex and multifactorial, but there is substantial 
evidence that oxidized lipoproteins play an important role in the pathogenesis of 
atherosclerosis (Diaz et al., 1997). It has been shown in rodents (Staprans et al., 1996) 
and humans (Staprans et al., 1994). Oxidized fatty acids in the diet are incorporated in 
to chylomicrons. In rodents, oxidized fatty acids are also incorporated into the 
endogenous serum VLDL+LDL fraction (Staprans et al., 1993). They have also 
demonstrated that the levels of oxidized fatty acids in the circulation correlate directly 
with the quantity of oxidized fatty acids in the diet and that oxidized fatty acids 
accelerate atherosclerosis in rabbits (Staprans et al., 1996). Staprans et al. (1998), 
have demonstrated that oxidized cholesterol in the serum of rabbits is both produced 
endogenously, and derived from food. After feeding rabbits a diet containing 
nonoxidized cholesterol that contains no detectable levels of oxidized cholesterol, 
cholesterol oxidation products were identified in serum VLDL and LDL. Feeding a 
diet enriched in oxidized cholesterol (Staprans et al., 1998), or injections of oxidized 
cholesterol (Rong et al., 1999), to cholesterol-fed rabbits resulted in a 2-fold increase 
in fatty sfreak lesions in the aorta (Zainuddin, 2004; Beg and Zainuddin, 2003). 
Therefore, dietary oxidized cholesterol may be a risk factor for atherogenesis. 
Cholesterol oxidation products are abundant in oxidatively modified LDL (Hodis et 
al., 1991) and high levels of circulating cholesterol oxidation products are found in 
rabbits fed a cholesterol containing diet (Hodis et al., 1991; Hodis et al., 1992). 
However, direct in vivo evidence linking circulating cholesterol oxidation products to 
early vascular lesion formation is only recently becoming available (Staprans et al., 
1998; Rong et al., 1999; Zainuddin, 2004; Beg and Zainuddin, 2003). These findings 
are supported by another report indicating that relative to normolipidemic LDL, LDL 
from homozygous familial hypercholesterolemic subjects exhibit distinctive 
physicochemical properties and biological activities that may contribute to initiation 
and progression of atherogenesis in vivo (Yang et al., 2003). Patients with diabetes 
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mellitus have a high incidence of CHD in comparison to nondiabetic CHD patients 
(Uusitupa et al., 1990). In light of this, the NCEP Expert Panel suggests that the goal 
of lowering LDL cholesterol (i.e. <100 mg/dl) in diabetic patients should be the same 
as subjects with CHD (EPDETHBCA, 1993). Moreover, the diabetic state is 
characterized by an increased rate of lipoprotein oxidation, which may play an 
important role in the development of atherosclerosis (Reaven, 1995). Diabetes can 
affect lipoprotein metabolism in multiple ways. In diabetic subjects, numerous 
potential mechanisms were able to mediate premature atherosclerosis. It has been well 
documented that diabetic patients have increased glycation and increased lipoprotein 
oxidation (Bellomo et al., 1995) and reduced antioxidant status (Maxwell et al., 
1997). Thus, oxidative modification of lipoproteins should be one of the mechanisms 
for an early development of atherosclerosis in diabetics. Oxidation of LDL is initiated 
by both enzyme mediated and nonenzymic mechanism in vivo, and oxidized LDL has 
many atherogenic properties. Oxidation of LDL in vivo is likely to be influenced by 
the local environmental factors such as pH. The composition of LDL is also 
important, including such factors as antioxidant content, fatty acid composition and 
particle size. Oxidized LDL (Ox LDL) has many characteristics that potentially 
promote atherogenesis, in addition to the ability to be taken up rapidly by 
macrophages to form foam cells. It is chemoattractant for circulating monocytes 
(Quinn et al., 1987), both directly and also via stimulation of the release of monocyte 
chemoattractant protein-1 from endothelial cells (Gushing et al., 19SK)). The 
chemoattaractant activity of LDL resides in its lipid moiety and is attributable to 
lysophosphatidylcholine generation during the conversion of LDL in to its oxidized 
fonn. Ox LDL promotes the differentiation of monocytes in to tissue macrophages by 
enhancing the release of macrophage colony stimulating factor from endothelial cells 
(Rajavashisth et al., 1990), and inhibits the motility of resident macrophages (Quinn 
et al., 1987). It is chemoattaractant for T-cells (McMurray et al, 1993), although not 
for p-cells, and consequently the atherosclerotic plaque contains primarily monocytes 
and T cells. Unlike native LDL, Ox LDL is immunogenic (Palinski et al, 1989), and 
it is also cytotoxic to various cell types including endothelial cells (Hessler et al, 
1983), resulting in loss of endothelial integrity. It inhibits tumor necrosis factor 
expression (Hamilton et al, 1990), stimulates release of interieukin-1 p (Thomas et al., 
1994) from monocyte/macrophages, and can inhibit endothelial cell-dependent 
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arterial relaxation (Ohgushi et al., 1993). Ox LDL also activates matrix-digesting 
enzymes, which may play a role in plaque instability (Xu et al., 1999). However, 
some cellular responses to jjeroxidation products appear to be protective, and it is 
possible that peroxidation is an essential intermediary in an effective response to an 
oxidative insult (Parthasarathy et al., 1999). 
1.4.2 Occurrence and mechanism of LDL oxidation in vivo 
Several lines of research support the occurrence of LDL oxidation in vivo 
(Steinberg, and Lewis, 1997). Oxidized apo B-lOO epitopes and increased levels of 
lipid peroxidation products can be detected in LDL extracted from both rabbit and 
human atherosclerotic lesions (Yla-Herttuala et al., 1989). Immunohistochemical 
staining of atherosclerotic lesions with specific monoclonal antibodies has 
demonstrated the presence of Ox LDL (Palinski et al., 1989). Circulating anti-OxLDL 
antibodies have been demonstrated in serum, and titers correlate with the progression 
of atherosclerotic lesions (Palinski et al, 1989). Several studies in different animal 
models of atherosclerosis strongly suggest that progression of the lesions can be 
delayed by intervention with antioxidants (Steinberg, and Lewis, 1997). The fact that 
several different antioxidants such as, probucol, vitamin E, butylated hydroxytoluene 
and diphenylphenylenediamine have been used, supports the implication that the anti-
atherogenic effect is due to the antioxidant properties of these drugs, rather than any 
other biological effect (Rajavashisth et al., 1990). Epidemiological evidence, 
including ecological, case-control and prospective studies, indicates low antioxidant 
consumption is associated with an increased risk of CVD (Gey and Puska, 1989; 
Rimm et al., 1993). The evidence is strongest in case of vitamin E, with less 
consistent support for the protective roles of vitamin C, carotenoids and flavonoids 
(McMurray et al., 1993). Several trials of antioxidant supplementation in patients at 
risk of vascular events have demonstrated a reduction in cardiovascular end points 
(Blot et al, 1995; Stephens et al, 1996; Gruppo Italino per lo Studio della 
Soprawivenzaneir Infarto miocardicol999; Salonen et al, 2000; Yusuf e/ al, 2000), 
while other studies have been negative (The Alpha-Tocopherol, Beta Carotene Cancer 
Prevention Study Group, 1994; Hennekens et al, 1996; Redlich et al, 1999; Walldius 
et al, 1993). The discrepancies in these trials may reflect differences in the dose and 
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mix of antioxidant used as supplements, the different dietary backgrounds of the 
subjects and intervention at relatively advanced stage of disease. 
Many cell types are capable of oxidizing LDL, including monocytes, 
macrophages, neutrophils, endothelial cells, smooth muscle cells and fibroblasts. 
However, cell types that are involved in the atherosclerotic lesion in wiiich OX LDL 
is found, i.e. macrophages, endothelial cells and smooth muscle cells, would seem to 
be the most likely to contribute to LDL oxidation in vivo. It appears likely that LDL is 
oxidized in microdomains in the arterial walls sequestered by proteoglycans and other 
extracellular matrix constituents, where it is protected fi-om plasma antioxidants 
(Carmena et al, 1996). It is still unclear which oxidative mechanisms or radical 
species are involved; potential candidates include NADPH oxidase, myeloperoxidase, 
cytchrome P450, the mitochondrial electron transport chain, peroxynitrite, xanthine 
oxidase, ceruloplasmin and lipoxygenase. The last enzyme has received much 
attention with the discovery that lipoxygenase modify LDL in vitro to a form taken up 
by the scavenger receptor (Steinberg, 1999). In addition, disruption of the 
lipoxygenase gene diminishes atherosclerosis in transgenic mice (Cyrus et al., 1999). 
Once initiated, oxidation of LDL is a free radical driven lipid peroxidation chain 
reaction. Lipid peroxidation is initiated by free radical attack on double bond 
associated with a polyunsaturated fatty acid (PUFA). This results in the removal of a 
hydrogen atom from a methylene (CH2) group, the rate of which determines the rate 
of initiation, a key step in lipid peroxidation. Molecular rearrangement of the resulting 
unstable carbon radical results in a more stable configuration, a conjugated diene. The 
conjugated diene reacts very quickly wath molecular oxygen, and the peroxyl radical 
thus formed is a crucial intermediate (Abuja and Esterbauer, 1995) (Fig. 1.6). A 
PUFA peroxyl radical in LDL may abstract a hydrogen atom from an adjacent PUFA 
to form a hydroperoxide and another lipid radical, a reaction which results in chain 
propagation. Removal of hydrogen atoms by the peroxyl radical from other lipids, 
including cholesterol, eventually yields oxysterols. Lipid hydroperoxides fragment to 
shorter-chain aldehydes, including malondialdehyde and 4-hydroxynonenal. These 
reactive aldehydes in turn may bind to 8-aminogroups of apo B-lOO, giving the 
protein an increased net negative charge. The classical LDL receptor recognizes a 
specific domain of positive charges from lysine, arginine and histidine residues on 
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Fig. 1.6. Basic reaction sequence of lipid peroxidation. 
(Adapted from Young, I. S. and McEney, J. 2001. Lipoprotein oxidation and atherosclerosis. Biochemical 
Society Transactions 29:358-362). 
apo B. Alteration of this domain results in failiire of binding by the apo B/E receptor 
and an increase in negative surface charge on apo B-lOO results in increased 
recognition by the scavenger receptor. 
In the presence of a lipid phase chain breaking antioxidant such as a-
tocopherol, the peroxyl radical may be scavenged. The tocopheroxyl radical thus 
formed has very low reactivity and will generally result in chain termination. LDL 
exposed to oxidative stress in vitro will not form significant amounts of 
hydroperoxides until it becomes depleted of chain breaking antioxidants. In vitro 
studies of LDL oxidation have verified the existence of "lag phase", during which 
significant oxidation of LDL can not be detected, prior to the onset of the 
"propagation phase", presumably after the endogenous antioxidants have been 
consumed. A steady increase in the detectable byproducts of oxidation continues, 
until the substrate, i.e. the PUFAs, has been depleted, and a plateau phase is reached. 
Assessment of resistance of LDL to oxidation has generally involved in measurement 
of the duration of the lag phase including other variables, such as the rate of 
propagation, are also noted. 
1.4.3 Factors influencing susceptibility of LDL to oxidation 
The susceptibility of LDL to oxidation in vivo is influenced by both LDL 
composition (intrinsic factors) and the microenvironment in which the LDL is found 
(extrinsic factors). Among the intrinsic factors, the fatty acid composition of LDL is 
of prime importance; a high proportion of PUFAs confers greater susceptibility to 
oxidation, while a high proportion of monounsaturated fatty acids (MUFAs) protects 
against oxidation (Reaven et ah, 1991; Reaven et al., 1993; Thomas and Rudel, 
1996). Since the propagation phase of LDL oxidation begins after the endogenous 
antioxidants have been consumed, susceptibility to oxidation is also higlily dependent 
on the antioxidant content, wtiich in lipoproteins is mainly a-tocopherol, although 
ubiquinol-10 and carotenoids are also important (Stocker et al., 1991). The molar 
ratio of PUFA to total antioxidants in LDL is approximately 150: 1. Since there is 
considerable variation in dietary fatty acid content between subjects, lipophilic 
antioxidant intake also varies significantiy fi-om individual to individual (Klatt and 
Esterbauer, 1996). Dietary supplementation with vitamin E results in increased LDL 
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resistance to copper-induced oxidation in vitro (Reaven and Witztum, 1993; Wiseman 
et al, 1995; Suzukawa et al., 1995; Ziouzenkova et al, 1996), an effect i.e. is dose 
dependent. LDL size is another factor that has been shown to affect oxidative 
susceptibility (Chait et al, 1993). The small, dense subfractions of LDL are more 
susceptible to oxidation than large, less dense LDL particles, which to a large extent 
may be due to differences in antioxidant content (Tribble et al., 1994). A 
preponderance of sd-LDL particles is found in subjects with moderately elevated 
triglycerides (1.5 mM), and is due to the metabolism of relatively large lipid rich 
VLDL particles. The concentration of preexisting fatty acid peroxides in LDL also 
exert an effect on the oxidative susceptibility of the particle, with higher levels of 
these peroxides being associated with a shorter lag time when transition metals are 
used to initiate oxidation (O'Leary et al, 1992). 
L5 Antiatherogenic Functions of High Density Lipoproteins 
Epidemiological studies have identified low density lipoproteins and high 
density lipoproteins as independent risk factors that modulate CVD risk. The role of 
HDLs in protecting against the development of CHD has been demonstrated in 
numerous clinical studies. The studies show an inverse relationship between the 
concentration of HDL-C and the development of premature CHD (Castelli et ah, 
1992; Gordon and Rifkind, 1989; Gordon et al, 1989; Assman et al, 2004), with a 
reduction in CHD risk of 2-4 % for each 1 mg/di increase in HDL-C. HDL is a class 
of heterogeneous lipoproteins containing approximately equal amounts of lipid and 
protein (Gordon and Rifkind, 1989). HDL particles are characterized by high density 
and small size. The various HDL subclasses vary in quantitative and qualitative 
content of lipids, apolipopropteins, enzymes, and lipid transfer proteins, resulting in 
differences in shape, density, size, charge, and antigenecity. Apo-Ai is the 
predominant HDL protein followed by apo-Ai. HDL fraction accounts for almost all 
of the cholesterol quantified as HDLC. HDL can be further fractionated by density 
into HDL2 and HDL3, by size, or by apolipoprotein composition. The origin of HDL 
particles is not entirely clear. Several mechanisms have been proposed, including 
direct secretion in to plasma from hepatocytes or enterocytes; release during the 
interconversion of various HDL subpopulations by phospholipid transfer protein 
(PLTP), cholesteryl ester transfer protein (CETP), or hepatic lipase (HL); or direct 
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interaction of free lipoproteins with cell membrane (von Eckardstein et al., 2000). 
Although our understanding of how HDL protects against CVD is still incomplete, 
there is evidence that supports at least three major atheroprotective mechanisms of 
HDL: 
1.5.1 HDL-mediated cholesterol efflux 
The reverse transport of cholesterol from peripheral cells to sites of 
catabolism, first described by Glomset and Norum in 1973, has been suggested to be 
the primary antiatherogenic mechanism of HDLs. Cholesterol efflux from 
macrophages to HDL can occur by passive diffusion (Yancey et ah, 2003), by 
interaction with the SR-Bl receptor (Williams et al, 1999), or by binding to the 
ABCAl transporter (Rubin et al, 1991; Takahashi and Smith, 1999; Remaley et al., 
2001; Oram and Lawn, 2001; Liu et al., 2003) (Fig. 1.7). The preferred acceptor for 
the ABCAl transporter-mediated cholesterol efflux is poorly lipidated apo-Al (Castro 
and Fielding, 1988), which is converted to spherical a-HDL after esterification of free 
cholesterol to cholesteryl esters by LCAT. Both the SR-Bl (Malerod et al, 2002) and 
ABCAl transporter (Costet et al, 2000; Schwartz et al, 2000; Venkateswaran et al, 
2000) pathways are modulated by the cellular content of oxysterols, which regulate 
the LXR pathway and expression of the SR-Bl and ABCAl transporter genes 
(Fig. 1.7). After accepting excess cellular cholesterol from arterial macrophages and 
other peripheral tissues HDL transports the excess cholesterol to the liver for disposal. 
HDL is thus an integral component of the atheroprotective reverse cholesterol 
transport process, ftinctioning as a carrier of excess cellular cholesterol from 
peripheral tissues to the liver, where it is excreted from the body as bile acids and 
cholesterol (Glomset, 1968). 
1.5.2 HDL and endothelial function 
The second mechanism by which HDL may protect against CVD is the 
selective decrease of endothelial cell adhesion molecules, which facilitate the binding 
of mononuclear cells to the vessel wall and promote lesion development (Barter et al, 
2002). The HDL-induced increase in NO production may be an important 
atheroprotective feature of HDL, as diminishing bioavailability of endothelial-derived 
NO has a key role in the early pathogenesis of hypercholesterolemia-induced vascular 
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disease and atherosclerosis (Cohen, 1995; Naruse et al, 1994; Cayatte et al., 1994). 
Apoptosis of endothelial cells has been demonstrated in atherosclerosis. The ability of 
HDL to inhibit apoptosis has been shown in several studies (Nofer et al., 2001; 
Sugano et ah, 2000). HDL exerts a protective effect by interfering with the apoptotic 
stimuli which endothelial cells are exposed. The mechanism is uncertain but this HDL 
function may contribute to longevity. 
LS.3 HDLs and antioxidative mechanisms 
A third mechanism by which HDL decreases atherosclerosis is to protect LDL 
from oxidation. Oxidized or modified LDL, unlike normal LDL, is readily taken up 
by the scavenger receptor SR-A or CD36 on macrophages, resulting in cholesteryl 
ester accumulation with foam cell formation. The cholesterol-loaded macrophage 
produces a number of inflammatory cytokines and stimulates MCP-1 as well as 
endothelial cell adhesion molecules. Mechanisms of LDL oxidation in vivo involve 
concerted modification by chemically diverse oxidants, employing that any single low 
molecular weight antioxidants, such as vitamins E and C, even at physiologically 
relevant doses, may not provide complete oxidative protection of LDL in vivo 
(Witztum and Steinberg, 2001; Gaut and Heinecke, 2001). Plasma HDLs possess a 
spectrum of antiatherogenic actions, including potent antioxidant and anti-
inflammatory activities (Van Lenten et al., 2001). Although HDLs can themselves 
undergo oxidative modification (Francis, 2000), several enzymes that may cleave 
oxidized lipids and thereby inhibit LDL oxidation are associated with HDL particles; 
these include paraoxonase (PON) in its major isoforms PON I (Durrington et al., 
2001), platelet-activating factor acetylhydrolase (PAF-AH) (Tselepis and Chapman, 
2002), LCAT (Goyal et al., 1997), and glutathione selenoperoxidase (Chen et al., 
2000). In addition, apo-Ai, a major HDL apolipoprotein can remove oxidized lipids 
from LDL, suggesting that HDL can function as an acceptor of oxidized lipids (Navab 
et al., 2000). Apo-A] was shown to reduce peroxides of both phospholipids and 
cholesteryl esters and to remove hydroperoxides, which are products of 12-
lipoxygenase, from native LDL (Navab et al., 2000). Other HDL apolipoproteins, 
such as apo-AII (Boisfer et al., 2002), apo-AIV (Ostos et al., 2001), apo-E (Miyata 
and Smith, 1996), and apo-J (Kelso et al., 1994), also function as antioxidants in vitro. 
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The diversity of antioxidative actions of HDL particles suggests that HDL provide 
efficient protection of LDL from oxidation in vivo. Plasma LDLs are heterogeneous in 
their physico-chemical properties and consist of three major particle subclasses, Ib-
LDL, intermediate LDL, and Sd-LDL; such LDL subfiractions are distinct in their 
atherogenic and oxidative properties (Chapman et al, 1998; Kontush et al., 2003). 
Similarly, circulating HDL particles are heterogeneous in physico-chemical 
properties, intravascular metabolism, and biological activity (von Eckardstein et al., 
1994; Lamarche et ah, 1999). Ultracentrifiigally isolated HDL3 exerts greater 
inhibition of adhesion protein expression in endothelial cells than HDL2 (Ashby et al., 
1998). Isopycnic density gradient centrifiigation allows reproducible isolation of 5 
physicochemically defined, highly purified, major HDL subfractions, HDL2b, 2a, 3a, 
3b, and 3c (Chapman et al, 1981; Goulinet and Chapman, 1997). Indeed, HDL 
particle phenotypes are qualitatively and quantitatively altered in dyslipidemias 
associated with premature atherosclerosis, including hyperlipidemias of types IIA, 
IIB, and IV, and type 2 diabetes (Lamarche et al, 1999). Significant differences 
between the HDL fractions derived from subjects with type 1 diabetes sind those 
derived from confrol subjects has been reported (Valabhji et al, 2001). The greater 
values for HDL esterified cholesterol and phospholipid in the subjects with type 1 
diabetes are attributable largely to increased concentrations of esterified cholesterol 
and phospholipid associated with larger, more buoyant HDL fractions (Valabhji et al, 
2001). Paraoxonase catalyzes the break down of oxidized phospholipids in LDL. 
Studies have found that transgenic animals deficient in this enzyme are significantly 
more susceptible to the development of diet-induced atherosclerosis (Shih et al, 
1998; Shih et al, 2000). On the other hand, PON transgene in mice produces HDL 
resistant to oxidation (Oda et al, 2002). Degradation of oxidized phospholipids has 
also been attributed to PAF-AH. Over expression of human apo-Ai in apo-E knockout 
mice increases PAF-AH activity and simultaneously reduces oxidative stress in 
plasma, decreases infracellular adhesion molecule (ICAM) and vascular cell adhesion 
molecule (VCAM) expression, and decreases monocyte recruitment in to the arterial 
wall (Theilmeier et al, 2000). 
Serum paraoxonase is a calcium-dependent esterase that is known to catalyze 
hydrolysis of organophosphates, and is widely distributed among tissues such as liver. 
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kidney, intestine, and also serum, where it is associated with HDL (La Ehi, 1996; 
Mackness et al., 1996). PON specificity towards endogenous serum and tissue 
substrates is not well characterized and therefore synthetic substrates, such as 
paraoxon and phenyl acetate are used to monitor the enzyme's activity. Serum PON 
activity was shown to be reduced in patients after MI (Ayub et al., 1999), in patients 
with familial hypercholesterolemia (Mackness et al., 1991), and in patients with 
diabetes mellitus (Mackness et al., 1991; Abbott et al., 1995), diseases that are 
associated with accelerated atherogenesis. Genetic variations of PON correlated with 
HDL-cholesterol and apo-Ai, suggesting antiatherogenic properties. Atherosclerosis 
occurs naturally in humans and rabbits but not in mice. Comparison of PON 
aryiesterase activity revealed that in humans and rabbits, > 95 % is HDL associated. 
In mice, about 30 % of PON activity is lipid poor; in the absence of apo-Ai in mice, 
total PON aryiesterase activity is reduced and > 60 % is lipid poor. It is striking that 
the rabbit has so much higher level of plasma PON activity than human and mice, 
especially in view of the fact that out of these three species, the rabbit is the most 
susceptible to cholesterol-induced atherosclerosis (Cabana et al., 2003). The PON 
activity is much more labile to the acute phase reaction in the rabbit than in the 
mouse, resulting in a substantial decrease in rabbits treated with croton oil (Cabana et 
al., 2003). Feingold et al. (1998) have demonstrated that administration of endotoxin 
lipopolysaccharide in Syrian hamsters was associated with a decline in serum PON 
concentration and activity as well as PON mRNA levels in the liver. A decrease in 
PON activity during the acute phase response could therefore be another factor 
linking the acute phase response with increased atherogenesis (Feingold et al., 1998). 
Boemi et al. (2001) have demonstrated that lower absolute PON concentrations and 
activities, higher LDL: PON concentration ratios and a lesser capacity to prevent LDL 
oxidation are consistent with the hypothesis that reduced serum PON in type 1 
patients, similar to type 2 diabetics, could contribute to increased risk of vascular 
disease. Although PON can offer protection against the toxicity of some 
organophosphates, its physiological role is still not clear; however, evidence exists for 
a protective effect of PON against oxidative damage (Mackness et al., 1996). PON 
was suggested to contribute to the antioxidant protection conferred by HDL on LDL 
oxidation (Mackness and Durrington, 1995; Mackness et al., 1991; Navab et al, 
1996). The effect of HDL-associated PON or of purified PON on the LDL oxidation 
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process, including its initiation (conjugated diene formation), propagation (peroxides 
formation), and decomposition (aldehydes formation) phases could be analyzed by 
using PON inhibitors. The inhibitory effect of HDL on LDL oxidation was suggested 
to be related to metal ion chelation, or to peroxidase, like activity. Under oxidative 
stress, not only LDL is susceptible to lipid peroxidation but all other serum-lipids, 
including those present in HDL, are also prone to oxidation. In fact, HDL has been 
shown to be the major carrier of lipid hydroperoxides in human serum (Bowry et al., 
1992; Hahn and Subbiah, 1994). hi this context it is interesting to mention that HDL-
associated cholesteryl ester hydroperoxides are more rapidly reduced to their less 
reactive hydroxides than are those associated with LDL (Christison et al., 1995). 
Oxidative modification of HDL has also been shown to impair the ability of the 
lipoprotein to promote cholesterol efflux (Nagano et al., 1991; Morel, 1994). Thus, 
inhibition of HDL oxidation by PON may preserve the antiatherogenic fimctions of 
HDL in reverse cholesterol transport, as well as its protection of LDL fi-om oxidation. 
Kontush et al. (2003) have demonstrated that both serum and plasma-derived small, 
dense HDL particles possess the most potent capacity among HDL subspecies to 
protect LDL fi-om both metal-dependent and metal-independent oxidation in 
normolipidemic subjects. The oxidative protection of LDL by ultracentrifiigally 
isolated HDL subiractions (at equal cholesterol or protein concentration or equal 
particle number) increased in the order HDL2b <HDL2a <HDL3a <HDL3b < 
HDL3c. HDL subtractions efficientiy protected not only total LDL but also 
intermediate LDL3 (typically the most abundant LDL subfiaction in normolipidemic 
subjects) and small, dense LDL5 (a highly atherogenic LDL subfraction) (Chapman et 
al, 1998), thereby suggesting that HDL can attenuate oxidation of atherogenic LDL 
subclass. When HDL subiractions were subjected to nonmetal or copper-induced 
oxidation in the absence of LDL, their oxidative resistance increased in the order 
HDL2b <HDL2a <HDL3a <HDL3b < HDL3c, thereby mirroring tiieir antioxidative 
activity during LDL oxidation. Similarly, PONl activity with phenyl acetate or 
paraoxon as substrate increased in the order HDL2b <HDL2a <HDL3a <HDL3b< 
HDL3c (Kontush et al., 2003). On a particle basis, contents of apo-A] and apo-A2 
were elevated in HDL3a and lowest in HDL3c. PAF-AH activity was significantiy 
increased in small, dense HDL3c. LCAT activity was higher in HDL3 relative to 
HDL2 subfi^ctions (Kontush et al., 2003). The present evidence for the differential 
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antioxidative properties of HDL subfractions may have important consequences for 
our understanding of tlie protective antiatherogenic action of HDL in vivo. Thus, 
although small, dense HDL3c typically accounts for <15 % of total HDL, HDL3c 
may nonetheless play a pivotal role in the protection of LDL against oxidation, 
significantly exceeding the protection afforded by low molecular weight antioxidants. 
Indeed, it has been shown that HDL3, rather than HDL2, is strongly correlated with 
the antiatherogenic action of gemfibrozil in the VA-HIT Study (Robins et a/., 2001). 
Considered together these findings identify small, dense HDL as a potential 
pharmacological target for the therapeutic attenuation of atherosclerosis in subjects 
had high cardiovascular risk associated with increased oxidative stress, as, for 
example, in the case of type 2 diabetes and metabolic syndrome. 
1.6 Management of Hypergtycemia/Dyslipidemia in Diabetes Mellitus. 
Improving glycemic control in individuals with moderate to severe 
hyperglycemia regardless of type of treatment is associated with improvement in lipid 
values. Treatment of hyperglycemia is stepwise and typically dependent on duration 
of disease. To prevent microangiopathy, neuropathy, and perhaps macrovascular 
disease, a prudent therapeutic goal is to reduce the glycohemoglobin to < 1 % above 
the upper limit of normal values (UKPDS, 1998). Weight loss and increased exercise 
are first-line therapy for reducing hyperglycemia. If hyperglycemia persists, a 
sulphonyl ureas or metformin can be used next. Metformin also proved efficacious, 
although an apparent increase in death rates on the combination of metformin and 
sulphonylureas has been reported. Another promising group of agents for treatment of 
type 2 diabetes includes the thiazolidenediones. These agents lower glucose levels by 
reducing insulin resistance. Troglitazone in combination with insulin therapy is used 
to improve glycemic control. Unfortunately, troglitazone produces rare but severe 
liver toxicity (Gitlin et ah, 1998). Nonetheless, despite its potential hepatotoxicity, 
troglitazone is currently being widely used to treat hyperglycemia. New drugs of the 
same class, rosiglitazone and pioglitazone, may have less potential hepatotoxicity A 
different type of drug available for glucose control is acarbose; this agent partially 
blocks glucose absorption. In patients who failed to achieve glucose control and near 
normal hemoglobin Ai levels by changes in life habits and oral hypoglycemic agents, 
insulin should be initiated. Metformin is the only antihyperglycemic agent that has 
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been shown to have a beneficial effect on the plasma lipid profile, by mediating a 
modest reduction in triglyceride levels in hj'periipidemic and hypertensive diabetic 
patients (Palumbo, 1998). In a head-to-head comparison study (Goldberg et al, 
2005), pioglitazone was associated with significant triglyceride reduction, whereas 
there was no net triglyceride change with rosiglitazone. Although both agents 
increased HDL-C and LDL-C, pioglitazone was associated with a greater increase in 
HDL-C and less LDL-C increase than rosiglitazone. 
Diet, exercise, and weight loss in over weight individuals are essential in the 
management of lipid disorders in diabetes. The NCEP and American Diabetes 
Association (ADA) concur in reducing the intake of saturated and trans-saturated fatty 
acids to lower LDL-C levels (NCEP ATP III, 2001; ADA, 2003). The NCEP Adult 
Treatment Panel III (ATP III) recommends limiting the intake of saturated fat to < 7 
% of daily calories and limiting the intake of cholesterol to < 200 mg per day. 
Additional dietary options to lower LDL-C include increasing the amount of soluble 
dietary fiber to 10-25 g daily, adding 2 g daily of plant stanols/sterols, and including 
soya proteins in the diet. These interventions have been associated with a 5-15 % 
reduction in LDL-C values. The ATP III also recommends limiting the intake of 
carbohydrates to < 60 % in individuals with elevated triglycerides and low HDL-C 
levels. The ADA also recommends replacing saturated fats, vv^ tih ki^bh^drate or 
monounsaturatedfat. ,'^,—r-^ C *^ 
. ) ' 0 ^ 
Diabetes is considered a CHD equivalent. Therefore, lipid targets for 
individuals with diabetes are the same as those for individu^s with established CHD 
(NCEP ATP III, 2001). The primary target is an LDL-C < 100 mg/dl^R^ntly, the 
NCEP and ATP III lowered the cut point for pharmacological intervention > 130 to > 
100 mg/dl and provided an optional lower target of 70 mg/dl for very-high-risk 
patients, such as those with diabetes and heart disease (Grundy et al, 2004). The 
second lipid strategy is to increase HDL-C levels, and the third is triglyceride 
lowering. For individuals with LDL-C levels between 100 and 129 mg/dl, both set of 
guidelines now support statin therapy to achieve at least a 30-40 % LDL-C reduction. 
In order to achieve a 30-40 % LDL-C lowering, at least moderate doses of statin 
(rosuvastatin 5-10 mg/day, atorvastatin 10-20 mg/day, simvastatin 20-40 mg/day, or 
pravastatin, lovastatin, or fluvastatin 40-80 mg/day) should be used. Individuals with 
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diabetes who have CVD should be considered for maximal intensity statin or 
combination therapy. When the NCEP LDL-C target is not achieved with a statin 
alone or where statins are not tolerable, combination therapy with etezimibe, bile acid 
sequesterants, or high dose niacin should be considered. The major clinical concerns 
with higher doses of statins are liver toxicity and myopathy. Non-HDL-cholesterol is 
the second therapeutic target according to the ATP III in individuals with TG levels > 
200 mg/dl. The therapeutic options for patients with LDL-C < 100 mg/dl (< 70 mg/dl 
if at a very high risk) on statins to lower non-HDL-C to target (< 130 mg/dl) include 
combination therapy with fibrate or niacin or alternatively increasing the dose of 
statin or switching to a more potent statin. Fibrates lower TG levels more efficiently 
than do statins and might be preferred in individuals with significantly elevated TGs 
(> 300 mg/dl). Fibrate therapy is the first line of treatment for individuals with TG 
levels > 500 mg/dl in whom TG lowering is given first priority. The ATP III and the 
ADA indicate that in high risk patients with HDL-C levels < 40 mg/dl (< 50 mg/dl in 
women), HDL-C raising should be considered, although neither guide lines defines a 
target level. Fibric acid derivatives and niacin, the two agents most commonly 
recommended for HDL raising. It has been clearly shown that the addition of 
ezetimibe to a statin will lower LDL-C to the designated target than statin alone 
(Gagne et al., 2002). Bile acid sequestrants may also help to lower LDL-C but should 
be used with caution because they have a TG raising effect in hypertriglyceridemic 
patients (Crouse, 1987). It is also clear that achievement of all three lipid goals is 
more likely with statin plus fibrate or statin plus niacin combinations. Fenofibrate 
appears to have significantiy lower pharmacokinetic interactions with statins 
compared with gemfibrozil, a consideration to take in to account when using fibrate 
plus statin combinations. Probucol has been reported to effectively reduce plasma 
cholesterol in human and a number of animal species (Martz, 1979). It also affects the 
composition and in vitro catabolism of LDL in Type Ila hypercholesterolemia 
(Baudet et al., 1986). It increases the activity of plasma lipoprotein lipase and 
decrease HDL- and LDL-cholesterol concentration in rats. Probucol prevents the 
development of macrophages into foam cells by inhibiting the lipid storage in 
macrophages (Yamamoto et al, 1986a). These observations probably accounts for the 
clinical findings that probucol causes a more marked regression of xanthomas than 
would be expected from the lowering of LDL-cholesterol levels alone. Probucol 
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seems to act by increasing LDL removal from the plasma by an LDL receptor 
independent mechanism (Kasaniemi and Grundy, 1984), as it causes moderate 
reduction in LDL-cholesterol in non-familial hypercholesterolemia and a smaller 
decrease in familial hypercholesterolemic patients (Durrington and Miller, 1985; 
Fellin, 1986). A marked decrease in cholesterol has been constant finding (Kasaniemi 
and Grundy, 1984; Fellin, 1986) but circulating HDL-cholesterol in probucol treated 
patients is less than in controls (Yamamoto et ah, 1986b), which minimizes the use. of 
probucol as a hypocholesterolemic agent. Omega 3 fatty acids (fish oils) lower TGs 
with minimal effects on HDL-C and LDL-C levels. They are well tolerated at the 
commonly used dosages of 1-2 capsules daily (2-4 g/day). At higher dosages there 
may be worsening of glycemic control. Omega 3 fatty acids are primarily used in the 
treatment of more marked hypertriglyceridemia usually as second line therapy after a 
fibric acid derivative. However, they can also be combined with statins. 
One of the areas, which have attracted a great deal of attention, is antioxidant 
nutrition in the control of degenerative diseases such as CVD in diabetics, 
nondiabetics with established CHD and cancer. Several epidemiological studies have 
demonstrated an association between increased intake of antioxidant vitamins such as 
vitamin E (tocopherols and tocotrienols) and vitamin C and reduced morbidity and 
mortality from CAD. Case-confrol, and prospective cohort studies have found inverse 
associations between the frequency of CAD and dietary intake of antioxidant 
vitamins. Randomized therapeutic trials have thus far shown no benefit with P-
carotene and possible benefit with vitamin E (Diaz et ah, 1997). Diabetes mellitus is 
associated with increased oxidative damage of various tissues and organs due to the 
accumulation of lipid peroxides and AGEs (Brownlee et al., 1984; Lyons, 1992). 
Dietary supplementation of vitamin E, specifically, tocopherol, has been shown to be 
effective in reducing the levels of lipid peroxides or AGE in diabetic patients 
(Ceriello et al, 1991; Frei et al, 1988; Jain, et al, 1996; Rifici and Khachadurian, 
1993) and in STZ-induced diabetic rats (Aoki et al, 1992; Vannucchi et al, 1999). 
Ceriello et al (1991) have demonstrated that vitamin E administration may reduce 
protein glycosylation and labile HbAj in diabetic subjects, independent of changes in 
plasma glucose. Similar beneficial effects have also been reported for vitamin C. 
Several studies showed that when pharmacologic doses of vitamin C or E were given 
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to group of diabetics, there was significant improvement in their glycemic control and 
insulin action (Paolisso et al., 1993a; Davie et al., 1992; Ceriello et al., 1991; Paolisso 
et al, 1993b). Supplementation of vitamin C was also associated with normalization 
of vasodilatory response in patients with hypertension (Taddei et al., 1998) and 
increased blood flow in type 1 and type 2 diabetic patients (Timmi et al., 1998; Ting 
et al, 1996). Several reports in poorly control diabetic subjects indicate increased 
levels of lipid peroxides (Sato et ah, 1979), increased LDL susceptibility to oxidation 
(Tsai et al, 1994; Bonet and Knopp, 1992), and decreased levels of antioxidants (Tsai 
et al, 1994; Otero et al, 1997; Jain et al, 1991) linking the oxidation of LDL to their 
accelerated atherosclerotic process. The mechanisms involved in the association 
between glucose, LDL oxidation, and atherosclerosis is not well understood. In a red 
blood cell model of oxidative damage, it has been shown that glucose may act either 
as an antioxidant or prooxidant, depending on the cell concentration of vitamin E 
(Wang et al, 1996), in a manner similar to shown for vitamin C, dehydroascorbic 
acid, and flavonoids (Otero et al, 1997; Ma et al, 1994; Stait and Leake, 1994; 
Wefers and Sies, 1988). Das et al (2006) have demonstrated that the serum lipid 
peroxidation level was significantly increased in hypercholesterolemic patients and 
their LDL has shown a greater propensity towards in vitro oxidation. 
Hypercholesterolemic LDL required a higher amount of ascorbic acid to reduce its 
oxidation level as compared to LDL isolated fi-om normocholesterolemic individuals. 
These compounds may act either as LDL antioxidant or prooxidant, depending on the 
LDL vitamin E content, when vitamin E is present in the LDL those compounds act as 
antioxidant, whereas when during the process of LDL oxidation, once vitamin E is 
consumed (Otero et al. (2002) or to minimally oxidized LDL (Ma et al, 1994; Stait 
and Leake, 1994), they act as prooxidant, accelerating the oxidation of LDL. It has 
been reported by Otero et al. (2002) that incubation of purified human LDL with 
glucose was associated with delaying the early phases of copper-mediated LDL 
oxidation, slowing the vitamin E consumption, but it accelerates the rate of LDL 
oxidation once LDL associated vitamin E has been consumed, these effects were 
concentration dependent (Otero et al (2002). These results also demonstrated that the 
concentration-dependent prooxidant effect of glucose is in agreement with the fact 
that type 1 diabetics with complications secondary to diabetes are related to the 
degree of metabolic control, those with the highest levels of glucose have the highest 
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risk of developing atherosclerosis and CVD (DCCTRG, 1993; Richard et al., 1993). 
In addition, the data also indicate (Otero et al., 2002) that increasing the vitamin E 
content of the LDL, the glucose prooxidant effects are markedly reduced. In contrast, 
the diabetic subjects with the lowest intake of vitamin E, and therefore, lower levels 
of vitamin E in their LDL would be more susceptible to the effects of the 
hyperglycemia. These results are consistent with earlier studies in type 1 diabetic 
patients with lower levels of vitamin E (Otero et al., 1997; Jain et al., 1991), making 
them more susceptible to the prooxidant effects of the hyperglycemia. Sever.il studies 
in the animal model have shown that some of the complications secondary to diabetes 
can be prevented with the administration of antioxidants including vitamin E 
(Srivastava and Ansari, 1988; Viana et al., 1996; Cameron et al., 1993), despite no 
improvement of the hyperglycemia. Based on the above results one can conclude that 
patients with type 1 and type 2 diabetes may benefit from a higher intake of vitamin E 
than the current recommendation. 
The greater stability of vegetable oils versus animal fats under oxidative 
conditions is known to be due to the higher levels of natural antioxidants in the oils. 
An important and commonly occurring class of natural antioxidants in vegetable oils 
is tocopherols (T) of vitamin E family. There are 8 naturally occurring forms of 
vitamin E; a-, p-, y-, 8-tocopherols and tocotrienols (T3). Tocotrienols are minor plant 
constituents especially abundant in cereal grains (such as barley, oat, wheat and rye), 
rice bran, palm oil and latex (Kasparek, 1980b). The vitamin E antioxidant property 
reflects the similarity in chemical structures of T and T3, which differ only in 
possessing a famesyl or unsaturated phytyl side chain, respectively (Kasparek, 1980a) 
(Fig. 1.8). Tocopherols predominate in certain oils such as com oil, soybean oil and 
olive oil. Whereas, the T3 series predominates in rice bran oil (RBO), palm oil and 
barley oil. Small amounts of T3 are found in carrots, sweetcom and germ oils (Shin 
and Godber, 1994). Several lines of research have established that populations, which 
consume large amounts of cereal grain and vegetable oils, tend to have a lower 
incidence of cardiovascular disease (Sacks et al., 1975; Burstem et al., 1978; Gould et 
al., 1980). Furthermore, studies on cereal grains demonstrated that barley is 
particularly effective in lowering lipid levels in animal models (Qureshi et al., 1980a; 
Qurcshi et al., 1980b; Qureshi et al., 1980c). The ability of barley extracts to lower 
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Fig. 1.8. Molecular structures of Socotiri ir of, tocopherol isomers and Lovastatin. 
lipids in vivo led to the purification and identification of biologically active 
compound tocotrienols (Qureshi et al., 1986). There are scattered reports that neither 
rice bran nor RBO lowered cholesterol levels. These findings may be explained by 
reports that some, but not all, rice cultivars contain tocotrienols, which exert a 
powerful hypocholesterolemic action (Qureshi et al, 1986; Qureshi et ah, 1989). 
Qureshi et al. (1986) have demonstrated the hypocholesterolemic effect of 
tocotrienols isolated fi"om barley, oats, rice bran and palm oil in various animal 
models. Anticholesterol impact of tocotrienols has also been demonstrated in 
hypercholesterolemic subjects (Qureshi et al, 1995). Out of a-, p-, y-and 5-T3,7- and 
5-T3 have been found to be most potent in terms of their HMG-CoA reductase 
inhibition as well as cholesterol lowering effects. The efficiency of 
hypocholesterolemic action as well as the degree of inhibition of HMG-CoA 
reductase activity mediated by a-Ts was substantially lower than y- and 5-T3 (Pearce 
et al., 1992). P-form of T3 failed to exhibit any anticholesterol activity. Rice bran oil 
is the richest source of T3, whereas com, groundnut, mustard, soybean and coconut 
oils and butter fat contain only T, which have no lipid lowering effect. The T3 are 
highly effective in lowering total blood cholesterol and LDL-cholesterol apparently 
by reducing the HMG-CoA reductase activity. The T on the other hand does not 
inhibit cholesterol synthesis and thus do not lower serum cholesterol. A dose 
dependent effect of tocotrienol rich fraction (TRF) isolated from palm oil was 
observed for lowering the serum cholesterol and LDL-cholesterol in normolipidemic 
and hypercholesterolemic swine, quail and chicken (Pearce et al., 1992; Qureshi and 
Qureshi, 1993). 
In several respects T3 appear to operate in similar manner to oxysterols. 
Certain oxysterols have been shown to regulate cholesterol biosynthesis by 
transcriptional down-regulation of reductase gene (Kandutsch et ah, 1978; Schroepfer 
et al, 1979; Schroepfer et al, 1981; Schroepfer et al, 1982). It has been postulated 
that endogenously produced oxysterols are natural regulators of cholesterol 
biosynthesis. These oxysterols are potent repressors of HMG-CoA reductase and bind 
strongly to cytosolic oxysterol binding protein (Spencer et al, 1985; Saucier et al, 
1985). Since oxysterols are natural regulators of cholesterol biosynthesis and act by 
suppressing HMG-CoA reductase gene, the T3 may have a similar function, but it acts 
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at post-transcriptional level as has been experimentally demonstrated in HepG2 cells 
(Parker et al., 1993). The human hepatoma HepG2 cell culture model was employed 
to compare the intrinsic activities of T3. In HepG2 cells, inhibition of sterol synthesis 
correlates v/ith rapid suppression of HMG-CoA reductase when incubated with T3. 
The recemic synthetic tocotrienols exhibit comparable biological activity to the 
natural tocotrienols in the cholesterol suppression activity. Gamma-Tocotrienol has 
been shown to mediate the suppression of enzymatic activity and protein mass of 
HMG-CoA reductase in HepG2 cells, through decreased synthesis (57% of control) 
and enhanced degradation (2.4 fold versus control) of the enzyme. This increased 
degradation was regulated through the increased cellular conversion of famesyl to 
famesol, which then signal the enhanced proteolytic degradation of HMG-CoA 
reductase. Thus, tocotrienols influence the mevalonate pathway in mammalian cells in 
vitro, by post-transcriptional suppression of HMG-CoA reductase, and appear to 
specifically modulate the intracellular mechanism for controlled degradation of the 
reductase protein (Parker et al., 1993). In addition, another report indicates that y-
tocotrienol influences apoB secretion by both cotranslational and posttranslational 
processes involving a decreased rate of apoB translocation and accelerated 
degradation of apoB in HepG2 cells. This activity correlated with a decrease in free 
and esterified cholesterol (Theriault et al., 1999a). Without or lower level of apo-B, 
VLDL, the precursor of LDL, is unable to assemble with core lipids and be secreted 
from the liver. Thus, the ability of tocotrienol to reduce apo-B plasma levels depends 
largely on both the clearance rate of LDL and the production rate of VLDL (Theriault 
et al., 1999b). Taken together, the information indicates an association between the 
suppression of hepatic cholesterol synthesis and apoB secretion, and the observed 
lowering of apoB and LDL-C levels in animal and human models (Theriault et al., 
1999b). However, elucidation of precise in vivo mechanisms of TRF-mediated 
inhibition of HMG-CoA reductase at molecular level remains to be investigated. It 
was observed that TRP preparations containing 25 % or more a-tocopherol could 
attenuate the cholesterol-suppressive action of y-tocotrienol by increasing HMG-CoA 
reductase activity but without affecting serum cholesterol level (Qureshi et al., 1995; 
Qureshi et al., 1996). Therefore, it appears that the attenuation observed in vivo might 
be related to a preferential transport of a-tocopherol in serum lipoproteins (Qureshi et 
al., 1996). Our laboratory has previously reported that feeding of TRF or purified 
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TRP, isolated from refined edible grade RBO, to normal rats for two weeks was 
associated with a significant decline in plasma TG, TC, LDL-C, including apoB 
levels. HDL3-C, which is considered as strong predictor of the presence and extent of 
CAD was significantly increased in TRF, treated normolipidemic rats. TRF feeding to 
rats along with an atherogenic diet for three weeks significantly prevented the rise in 
plasma TG, TC, LDL-C, apoB, HDL-C, apoA-1 and HDL3-C levels in comparison to 
rats fed atherogenic diet alone. Five and seven days after the withdrawal of 
atherogenic diet, plasma and lipoprotein lipid levels including apoB and apoA-1 were 
reduced. Treatment of hyperlipidemic rats with purified TRF resulted in a fiirther 
significant reduction in the above parameters indicating the efficacy of TRF in the 
treatment of experimental hyperlipidemia. The minimum dose of TRF or purified 
TRF required to exert the maximum hypolipidemic effect in normolipidemic and 
hyperlipidemic rats has been found to be 8 mg TRF or 5.2 mg purified TRF/day/Kg 
body weight. It has also been demonstrated that cholesterol lowering property of 
tocotrienols in normolipidemic and hyperlipidemic rats is due to suppression of 
enzymatic activity and protein mass of HMG-CoA reductase (Minhajuddin et al., 
1999; Minhajuddin et al., 2005). Administration of TRF enriched with tocotrienols 
and tocopherols, resulted in a significant decline in microsomal lipid peroxidation 
(TEARS) and plasma LDL oxidation (conjugated dienes) in nonnolipidemic as well 
as in response to oxidative stress, evoked in experimental hyperlipidemia in rats 
(Minhajuddin et al., 1999; Minhajuddin et al, 2005). These results also demonstrate a 
differential hypolipidemic impact of purified TRF isolated from four cultivars of rice, 
raw Basmati, Saket-4, Sarju-52, and Mansuri, due to the difference in their y- and 5-
T3 content, in hyperlipidemic rats. Based on total content of y- and 5 -T3 present in 
the purified TRF of each cultivar, hypolipidemic efficacies at an equivalent dose of 3 
and 6 mg TRF/day/Kg body weight (calculated on the basis of combined content of y-
and 5 -T3 present in 3 and 6 mg of TRF) caused a dose-dependent decline in plasma 
and lipoprotein lipids including apoB, HMG-CoA reductase activity and it's protein 
mass, formation of TEARS and conjugated dienes of plasma LDL (Beg et ah, 2000a; 
Beg et al, 2000b). Our laboratory has also demonstrated a long-term therapy of a FH 
patient with severe xanthomas. Treatment at a dose of 8 mg TRF/day/Kg body weight 
for 20 weeks caused a significant reduction in plasma TG, TC, LDL-C, and apoE 
levels with a substantial increase in the levels of HDL-C, HDL2-C and apoA-1. TRF 
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also caused a substantial improvement in the ratios of LDL-C/HDL-C, apoB/apoA-1 
and HDL-C/TC, indicating the normalization of lipid parameters. Consistent with 
reduction in lipid parameters, after TRF treatment rapid growth of skin xanthomas 
was arrested. In addition, a significant regression of xanthomas on buttocks extending 
to thighs, elbows and knee was observed (Beg et ai, 1997). 
Based on strong hypocholesterolemic and antioxidant properties of 
tocotrienols, our laboratory has also investigated antitumour activity of tocotrienols in 
experimental carcinogenesis of mammary gland and liver. The carcinogen, 7, 12-
dimethylbenz (a) anthracene (DMBA), which is known to induce both mammary 
carcinogenesis and hypercholesterolemia in rats, was utilized. As expected, six 
months after administration of DMBA, a significant increase in plasma TG, TC, LDL-
C, including apoB, HMG-CoA reductase activity, microsomal lipid peroxides 
(TBARS), conjugated dienes of LDL oxidation, plasma, liver and mammary gland 
alkaline phosphatase and glutathione-S-transferase levels. DMBA treatment also 
resulted in the formation of neoplastic nodules as multiple tumors on mammary 
glands and greyish white patches on the livers of rats. Feeding of TRF to rats, during 
pre-and post-intiation stages, was associated with a significant decline in the above 
parameters. In addition, examination of gross morphology and histology suggested 
that dietary TRF did offer a significant protection and did reduce the severity and 
extent of neoplastic transformation during both initiation and/or promotion in both 
mammary glands and livers of carcinogenic rats. TRF treatment, in addition to its 
anticancer and antioxidant impacts also exerted a strong hypocholesterolemic action, 
indicating a linkage between atherosclerosis and cancer. The dual chemopreventive 
actions of TRF in atherosclerosis and cancer are apparently mediated by reducing 
HMG-CoA reductase, thus limiting the availability of mevalonate derived products 
required for cholesterol production and tumor growth (Iqbal et al, 2003). 
Our laboratory has also reported a strong hypolipidemic action of TRF, when 
administered to type 2 diabetic patients with hyperlipidemia. In particular TC and 
LDL-C, which are positively associated with CHD, were significantly reduced to 
normal levels (Baliarsingh et al, 2005). However, hypoglycemic effect of TRF was 
not observed in these patients because they were glycemically stable and their glucose 
and HbAi levels were close to normal values. Recently, our laboratory has also 
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demonstrated that feeding of 16.2 mg % TRF (isolated from rice bran oil) or 6.97 mg-
% Tocomin together with a cholesterol-rich diet to rabbits for 22.4 weeks 
significantly prevented the increase in Plasma TG, TC, VLDL-C, and LDL-C levels 
with no effect on elevated plasma HDL-C, HDL3-C and HDL2-C levels. In response 
to oxidative stress evoked in experimental hyperlipidemia in rabbits, as refflected by 
increased formation of plasma lipid peroxides, higher base line levels of diene 
conjugation of LDL, as modified in vivo, increased rate of conjugated diene formation 
in LDL and decrease in lag phase time of LDL oxidation in vitro, was substantially 
blocked by TRF or Tocomin when fed together with cholesterol-rich diet. Consistent 
with above results, feeding of the cholesterol rich diet was also associated with the 
formation of fatty streak lesions in the aortas of hyperlipidemic rabbits, which was 
significantly reduced in TRF or Tocomin supplemented groups. We have also 
demonstrated that after 10 weeks of feeding to rabbits either a 0.33 % cholesterol-rich 
diet or the same diet containing 0.33 % cholesterol of which 5 % was oxidized, 
plasma TG, TC including FC and EC, VLDL-C, LDL-C, HDL-C and its subfractions, 
HDL2-C and HDL3-C were substantially increased but to a similar extent 
supplementation of 50 mg % TRF to these diets significantly blocked the increase in 
the above lipid parameters except HDL-C, HDL2-C and HDL3-C levels were not 
reduced significantly. The oxidative stress, evoked in oxidized cholesterol-fed rabbits 
was significantly higher than nonoxidized cholesterol-fed rabbits. This differential 
effect was reflected in several indices of oxidative stress, such as plasma and liver 
lipid peroxides, base line levels of ex vivo diene conjugation of LDL, rates of 
conjugated diene formation and TBARS of LDL, and lag phase time of in vitro LDL 
oxidation. These oxidative parameters were substantially more pronounced in rabbits 
fed oxidized cholesterol, apparently due to the presence of cholesterol oxidation 
products. Tocotrienols being very potent antioxidants, significantly blocked the above 
mentioned oxidative parameters in both groups. However, tocotrienols were 
significantly more potent in blocking the above parameters when supplemented with a 
diet enriched in oxidized cholesterol. Consistent wdth the above results, feeding of 
oxidized cholesterol-rich diet resulted in the formation of fatty streak lesions in the 
aorta of rabbits, which was 2-fold higher than rabbits fed a nonoxidized cholesterol-
rich diet. Consistent with a strong hypolipidemic and antioxidant action of tocotrienol, 
supplementation of TRF with oxidized cholesterol blocked the formation of fatty 
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streak lesions by 4.1-fold, whereas, TRF feeding together with nonoxidized 
cholesterol caused a reduction of 2.4-fold only (Zainuddin, 2004: Beg and Zainudin, 
2003). In another report, Teoh et al. (1994) have demonstrated that feeding of an 
atherogenic diet containing tocotrienols to rabbits for 12 weeks significantly reduced 
serum lipid peroxides and mediated a significant protection against atheroma in rabbit 
aorta. Nazaimoon and Khalid (2002) have reported that feeding of TRF-rich diet 
effectively prevented increase in AGE in normal rats, and caused decrease in blood 
glucose and HbAi in diabetic rats. Despite the fact that TRF-rich diet mediated a 
significant decrease in blood glucose and HbAilevels, the values measured at week-8 
and week-12 were still within the diabetic range. 
During the past few years, two novel tocotrienols were isolated fi-om stabilized 
and heated rice bran, apart fi-om the known a-, p-, y-, and 5-, tocopherols and 
tocotrienols. These new tocotrienols were separated by HPLC, using a normal phase 
silica column. Their structures were determined by ultraviolet, infi:ared, nuclear 
magnetic resonance, circular dichroism, and high resolution mass spectroscopies and 
established as desmethyl tocotrienol and didesmethyl tocotrienol. These tocotrienols 
significantly lowered serum total and LDL cholesterol levels and inhibited HMG-CoA 
reductase activity in chickens. They had much greater in vitro antioxidant activities 
and greater suppression of B16 melanoma cell proliferation than a-tocopherol and 
known tocotrienols. These results indicated that the number and position of methyl 
substituents in tocotrienols affect their hypochoiesterolemic, antioxidant and 
antitumour properties (Qureshi et al., 2000). Feeding of these two novel tocotrienols 
to hereditary hypercholesterolemic swines for 6 weeks caused a significant reduction 
in TO, TC, LDL-C, apo-B, platelet factor 4, thromboxane B2 and hepatic HMG-CoA 
reductase activity (Qureshi et al., 2001a). These resuhs are consistent with the 
hypochoiesterolemic effects of these two novel tocotrienols in chickens (Qureshi et 
al., 2000). The reduction in cholesterol level may be due to inhibition of cholesterol 
biosynthesis at the level of HMG-CoA reductase through a post-transcriptional 
mechanism involving protein degradation as shown earlier for other tocotrienols 
(Parker et al., 1993). Desmethyl tocotrienol and didesmethyl tocotrienol also 
mediated a significant decrease in serum TG, TC, LDL-C, apoB, Lp(a), platelet factor 
4 and thromboxane B2 levels of hypercholesterolemic humans after a double blind, 
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12-week study (Qureshi et al., 1997). Steiner et al. (1995) reported a greater reduction 
in platelet adhesiveness with a concomitant reduction in ischemic events in the patient 
group who were taking a-tocopherol plus asprin compared to those taking asprin 
alone. In several epidemiological studies, tocotrienols, both as a TRP and purified y-
tocotrienol, was shown to reduce the synthesis of an eicosanoid, namely thromboxane 
B2. The mechanism(s) involved for tocotrienols-mediated antithrombotic effect 
remains uncertain, but may be similar to that reported for a-tocopherol (Theriault et 
ah, 1999b). In addition, 8-tocotrienol improves vascular fimctions, reducing adhesion 
molecules over that of a-tocopherol (Chao et al, 2002). These studies support the 
concept that tocotrienols mediate a potentially important and novel mechanism(s) in 
controlling atherogenesis. It is interesting to note that these two newly discovered 
tocotrienols are more effective in terms of cholesterol lowering activity than a-, y-
and 5-tocotrienols (Qureshi et al, 2000; Qureshi et al, 2001a). Recently, a dose-
dependent effect of tocotrienol rich fraction containing mixture of the novel 
desmethyl- and didesmethyl tocotrienols (TRF25) has been investigated in 
hypercholesterolemic humans (Qureshi et al, 2002). The results showed that intake of 
a dose of 100 mg/day of TRF25 for 35 days caused maximum decrease in senmi TC, 
LDL-C, apoB and TG levels when compared to baseline values (Qureshi et al, 2002). 
Administration of a 4-week dietary supplement of either 58 mg Y-T3 or mixture of 
tocotrienols as TRF (29.5 % a-Tj, 3.3 % P-T3, 41.4 % y-Tj and 0.1 % 5-T3) per day 
per Kg body weight to hamsters receiving a high fat diet revealed that y-T3 was more 
potent hypocholesterolemic agent than TRF (Raederstorff et al, 2002). The 
synergistic effect of TRF25 has been reported in hypercholesterolemic htmians. 
Administration of TRF in combination with lovastatin to hypercholesterolemic 
humans for 35 days exerted a synergistic lipid lowering effect, when compared to 
values obtained from subjects given TRF25 or lovastatin alone (Qureshi et al, 2001b). 
The other beneficial effects of tocotrienols include inhibition of angiogenesis, which 
is important in tumor growth, diabetic retinopathy, rheumatic arthritis, wet-type 
macular degeneration via vascular endiothelial growth factor (VE(JF) inhibition 
(Miyazawa, et al 2004). Delta-tocotrienol and secondarily y-tocotrienol are reported 
to be involved in the correction of genetic defects in nerve protein synthesis in 
children vsdth familial dysautonomia, a neurodegenerative genetic disorder (Anderson 
et al, 2003). Tocotrienols at concentrations well below their antioxidative properties 
67 
(4-10 times lower) are effective in preventing glutamate-induced neuronal cell deaths 
(Sen, et al., 2000; Khanna et al., 2003). Other unique beneficial effects of 
tocotrienols, especially the desmethyl isomers, not shared by a-tocopherol include 
natriuresis, antihypertension, anti-inflammatory and antiosteoporesis (Tan, and 
Llobrera, 2005). An encouraging development in the treatment of hyperlipidemia has 
been the introduction of a new class of fimgal-derived compounds (statins) that are 
potent competitive inhibitors of HMG-CoA reductase, the rate controlling enzyme in 
the biosynthetic pathway for cholesterol. Statins have been described as the most 
potent class of drugs to reduce serum cholesterol levels and coronary morbidity and 
mortality in patients with or without CAD (Maron et al, 2000; Vaughan et al, 2000). 
It is also effective in patients with hypercholesterolemia associated with diabetes 
mellitus or with the nephrotic syndrome. The main effect of statins on the lipid profile 
is therefore to lower LDL-C levels, which they do by increasing efficacy on a per mg 
basis from fluvastatin to pravastatin to simvastatin and lovastatin to atorvastatin 
(Jones et al., 1998). These agents also reduce triglycerides by upregulating the hepatic 
LDL receptor and probably by reducing VLDL production. Initially, statins showed to 
be beneficial in patients with substantially elevated cholesterol (The Scandinavian 
Simvastatin Survival Study (4S), 1994; Shepherd, 1995), their benefits have currently 
been extended to use in patients with average cholesterol levels (LIPID Study Group, 
1998; Downs et al., 1998). Although there is no association between blood cholesterol 
levels and the incidence of stroke (PSC, 1995), statins reduce the risk of stroke in 
patients with CAD (Vaughan et al, 2001; Schwartz et al, 2001). In addition, recent 
studies showed that statin therapy over a six month period markedly inhibits the 
inflammatory components of multiple sclerosis (Vollmer et al. 2004) and that statin 
therapy is associated with a decrease rate of severe sepsis (Almog et al. 2004), two 
pathological conditions thought to be independent of cholesterol levels. All these 
observation lead to the speculation that statins might influence vascular biology 
through non-lipid mechanisms (Vaughan et al., 1996; Bellosta et al, 2000). Being 
competitive inhibitors of HMG-CoA reductase, statins, block synthesis of cholesterol 
in the liver, thereby triggering compensatory reactions that lead to a reduction in 
plasma LDL. Consequently, statins also prevent the catabolism of important 
isoprenoid intermediates of the cholesterol biosynthetic pathway such as famesyl 
pyrophosphate and geranyl geranyl pyrophosphate (Goldstein and Brown, 1990), and 
68 
thus exert effects completely independent of cholesterol synthesis. These isoprenoid 
intermediates serve as important lipid attachments for the post-translational 
modification (prenylation) of a large variety of proteins, including small GTP-binding 
proteins Ras and Ras-like proteins (Rho, Rab, Rac, Ral, and Rap) (Van Aelst and 
D'Souza-Schorey, 1997). Prenylation of these proteins are necessary for a large 
number of physiological functions such as cell shape, cell mobility and proliferation 
(Casey, 1995; Laufs and Liao, 2000; Takai et al., 2001). In endothelial cells, Ras 
activity is dependent on famesylation, whereas Rho is dependent on 
geranylgeranylation (Van Aelst and D'Souza-Schorey, 1997). By inhibiting HMG-
CoA reductase, statins, prevent Ras and Rho isoprenylation, leading to the 
accumulation of inactive proteins in the cytoplasm. Increasing evidence suggest that 
statins exert some effects that are totally independent of LDL-C reduction. Pleiotropic 
effects of statins include beneficial effects on endothelial function, as well as anti-
inflammatory and immunomodulatory properties, most of these effects seem to be 
mediated by the inhibitory effect of statins on isoprenoid intermediates, and in 
particular by the inhibition of Rho signaling pathway. Finally, statins may also 
improve endothelial function through their antioxidant effects. It has been shown that 
statins inhibit the production of ROS, such as superoxide or hydroxyl radicals 
(Rikitake et al., 2001). Recently, Haendeler et al. (2004) have demonstrated that 
statins mediate S-nitrosylation of thioredoxin, which enhances the enzyme activity, 
resulting in a significant reduction in intracellular ROS in endothelial cells. Statins 
also attenuate Ang Il-induced ROS production by inhibiting Rac-1-mediated NADH 
oxidase activity (Wassmann et al., 2001). Wassmann et al. (2002) have demonstrated 
that atorvastatin exerts cellular antioxidant effects in cultured rat vascular smooth 
muscle cells and in the vasculature of spontaneously hypertensive rats mediated by 
decreased expression of essential NAD(P)H oxidase subunits and by upregulation of 
catalase expression. 
As discussed above increased oxidative stress in diabetes meilitus results in 
increased lipid peroxidation. Oxidized lipoproteins, particularly LDL and other lipid 
peroxidation products may accelerate atherosclerotic process. Therefore, the favorable 
effect of statins in preventing or reducing atherosclerosis may be partially due to a 
reduction of lipid peroxidation. Indeed, some reports suggest that statins have an 
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antioxidant potential (Kleinveld et al, 1993; Human et ai, 1997). Singh et al. (1997) 
have demonstrated that feeding of a trans-fatty acids-rich diet supplemented with 
lovastatin to rabbits for 24 weeks was associated with a low but significant decrease 
in lipid peroxides and conjugated dienes, indicating that lovastatin may have 
antioxidant activity. In another study, Chen et al. (1997), have reported that feeding of 
a cholesterol-rich diet to rabbits supplemented with lovastatin for 14 weeks caused a 
substantial and significant decline in serum MDA levels. In addition^ lovastatin 
mediated a restoration in the plasma SOD activity, which was significantly decreased 
in rabbits fed only cholesterol. In both the studies the fatty streak lesion areas were 
significantly reduced in lovastatin treated rabbits. In a combined model of STZ-
induced diabetes and high saturated fat and cholesterol fed hypercholesterolemia in 
Syrian hamsters, lovastatin supplementation may contribute to the prevention of foam 
cell formation by inhibiting the oxidation of lipoproteins. Lovastatin decreased 
plasma lipid peroxide level, increased the lag time, and reduced conjugated diene 
formation during in vitro LDL oxidation (El-Swefy et al, 2000). Yamaguchi et al. 
(2004) have demonstrated that aqueous extract of cigarette smoke facilitates oxidative 
modification of LDL via peroxynitrite in vitro and in hypercholesterolemic WHHL 
rabbits, and that this oxidation and nitration of LDL can be effectively prevented by 
treatment with fluvastatin. Fluvastatin has an efficient peroxynitrite scavenging 
ability, which may be potentially beneficial to hypercholesterolemic patient with 
oxidative stress, such as smoking and inflammation. In a recent study (Manuel-y-
Keenoy et al, 2004), treatment of type 1 diabetic patients with 20 mg/day atorvastatin 
revealed a significant decline in plasma MDA levels after 3- and 6 months of 
treatment. However, total TBARS production, which is a measure of in vitro lipid 
peroxidation, was significantly increased after 3- and 6 months of treatment. 
The efficacy of statins for prevention of cardiovascular events has been 
established in a number of landmark randomized clinical trials (Shepherd et al. 1995; 
HPSCG, 2002; Sever et al. 2003), however, whether statin has beneficial effects on 
glucose metabolism still remains controversial. The West of Scotiand Coronary 
Prevention Study (WOSCOPS) demonstrated a significant risk reduction in the 
development of type 2 diabetes in hypercholesterolemic patients treated with 
pravastatin (Freeman et al, 2001), while several studies with other statins have not 
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shown this beneficial effect on glucose metabolism (HPSCG, 2002; Sever et al., 
2003). In addition, it has recently been reported that intake of high concentrations of 
atorvastatin was significantly associated with worsening of glycemic control after 
acute coronary syndrome (Sabatine et al., 2004), suggesting the protective effect 
unique to pravastatin. Many CAD patients with abnormal lipid metabolism also have 
impaired glucose metabolism; together these are key component of metabolic 
syndrome. Postprandial metabolic disorder including hyperglycemia and 
hyperinsulinemia, are involved in the process of atherogenesis, which can lead to 
major clinical cardiovascular events. Postprandial hyperglycemia is defined as 
impaired glucose tolerance (IGT), following an oral glucose tolerance test (OGTT). 
IGT has been shown to be a significant risk factor for CVD, and is also considered to 
presage the onset of type 2 diabetes meilitus, which is associated with a significantly 
worse prognosis in patients with CAD (DECODE Study Group, 1998). Now, it is 
recognized that IGT may be a practical treatment target to prevent the development of 
overt diabetes and a modifiable risk factor for CVD (ADANIDDKD, 2002). 
Adiponectin is an adipocyte-derived secreted protein that has several important 
metabolic and endocrinologic fiinctions, which are of particular relevance to glucose 
metabolism and the development of type 2 diabetes (Matsuzawa et al., 2004). Patients 
with CAD have decreased adiponectin levels (Hotta et al., 2000) and 
hypoadiponectinemia is associated with an increased risk of MI (Pischon et al., 2004). 
In humans, increased serum concentrations of adiponectin are associated with 
increased insulin sensitivity and glucose tolerance (Goldfine, and Kahn, 2003). 
Sugiyama et al. (2006) have recentiy reported that pravastatin treatment of type 2 
diabetics with IGT and CAD was associated with a significant improvement in 
glucose tolerance and significant increase in plasma levels of adiponectin. Therefore, 
pravastatin therapy may be an advantageous clinical option to improve hyperlipidemia 
and glucose metabolism in patients with CAD. 
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1.7 Scope of the Present Study 
As discussed above, hyperglycemia is the most important factor in the onset and 
progress of diabetic complications mainly by producing oxidative stress (Giugliano et 
al., 1996). Altered cellular metabolism caused by hyperglycemia has been suggested to 
play an important role in increasing the risk of cardiovascular, renal, ophthalmic and 
neurological complications of diabetes mellitus (Brovsoilee ei al., 1984; Brownlee et al., 
1988; Nathan, 1993). The hyperlipidemia and hyperketonemia associated with diabetes 
may also lead to increased lipid peroxidation. The excessive nonenzymatic 
glycosylation of proteins including LDL, associated with substantially increased 
superoxide, hydrogen peroxide, and hydroxyl radical production, stimulate formation of 
advanced glycosylation end products and foam cells, which cause extensive cellular 
and tissue damage, including vascular injury (Lyons, 1991; Epstein, 1989). Since most 
animal studies of diabetes are induced by administration of STZ or alloxan, toxic agents 
that target p-cells, they are thus essentially considered as models of type 1 diabetes. 
Nevertheless, such animals show increased lipid peroxidation, hyperlipidemia and other 
diabetic complications seen in type 2 diabetes (Halliweli, 2002). In addition, 
hyperglycemia causes cellular dysfunctions (Koya and King, 1998; Nishikawa et al., 
2000), glycation (Brownlee, 1994) and oxidative stress (Wolf, 1993). All these factors 
aggravate the consequences of the diabetic dyslipidemia by increasing susceptibility to 
lipid peroxidation. This leads to accumulation of products of oxidative damage to lipids 
(Griesmacher et al., 1995), foam cell formation and eventually increased atheroma 
plaque deposition (Ross, 1990). In normal subjects, oxidative stress is reduced or 
prevented by the "free radical scavengers" present in plasma. Enzymes such as SOD, 
catalase, Gpx and nonenzymatic scavengers, such as GSH, vitamins A, C, and E are 
known to readily react with free radicals and minimize the damage. Thus, the overall 
antioxidant status in plasma including erythrocytes and other tissues seems to have an 
important role in the etiology of diabetic complications. Increased lipid peroxidation 
can be detected in early stages of type 2 diabetes, well before the development of 
diabetic complications (Halliweli, 2002). Since lipid peroxides are well known to cause 
tissue damage, it is likely that nephropathy, retinopathy, endothelial dysfunction and 
peripheral neuropathy associated with poor diabetic control involve free radical damage 
(Halliweli and Gutteridge, 1984; Oranje and Wolffenbuttel, 1999; Devraj and Jialal, 
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2000; Bursell et ai, 1999; Low et ai, 1997). Published reports (Halliwell, 2002) 
indicate beneficial effects of antioxidants such as vitamin E (a-T) on enhanced 
oxidative stress associated with diabetes, when 600-1200 units of a-T/day were given 
to diabetic patients for 2-6 months. The protective impacts of a-T include decrease in 
lipid peroxidation, free radical production, C-reactive protein; improved retinal blood 
flow and renal dysfimction and improved nerve function with no effect on protein 
glycation and HbAi levels. In contrast, Skrha et al. (1999, 1997) found that intake of 
600 mg of a-T by type 2 diabetics for 3 months appeared to worsen diabetic control 
and raised HbAi levels. The effectiveness of a-T supplementation in preventing 
glomerular dysfunctions (Koya and King, 1998) and normalizing the abnormal retinal 
blood flow (Kunisaki et ah, 1998) has also been reported in diabetic rats, where a-T 
has been shown to act directly on the diacylglycerol-protein kinase-C pathway. Vitamin 
E could also exert it's protective effects indirectly by reducing free radical mediated 
damage to islet of p-cells and thus improving insulin action (Slonim et al., 1983; 
Paolisso et al, 1993a; Tanaka et al., 1982). However, published reports indicate that 
vitamin E treatment during diabetes failed to reduce blood glucose levels in 
hyperlipidemic-diabetic hamsters (El-Swefy et al., 2000) and in diabetic rats 
(Nazaimoon and Khalid, 2002). Similarly, in diabetics, vitamin E intake was not 
associated with any decline in blood glucose levels (Cerriello et al, 1991). 
Improved glycemic control has been shown to retard the progression of diabetic 
complications particularly microvascular disease (UKPDS, 1998; Cusick et al, 2002). 
Different types of oral hypoglycemic agents, such as begunoids and sulphonylureas are 
available along with insulin for the treatment of diabetes mellitus (Holman and Turner, 
1991). However, these drugs commonly used in the treatment of hyperglycemia in 
diabetics, but they are unable to lower glucose concentration to normal levels. In 
addition, these drugs are unable to restore normal pattern of glucose homeostasis on 
permanent basis. Furthermore, use of these hypoglycemic agents is restricted by their 
pharmacokinetic properties, secondary failure rates and host of side effects 
(Kameshwara et al, 1997; Valiathan, 1998; Melinda, 1988). Imperfect normalization of 
glucose metabolism by replacement insulin therapy may alter the concentrations and 
compositions of potentially atherogenic lipoproteins (Bierman and Glomset, 1992). 
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Thus, there is a need to seek newer and alternative approaches for effective therapy in 
the management of hyperglycemia. 
Although DCCT indicated that blood glucose is highly predictive of 
microvascular disease (DCCTRG, 1993), the contribution of all the commonly 
measured risk factors can explain no more than 25 % of the excess macrovascular CAD 
associated with diabetes (Pyorala et al., 1987). The dyslipidemic profile of diabetics 
includes increased levels of TG, TC, VLDL-C and LDL-C, increased sd-LDL, 
glycation of LDL and decreased plasma HDL concentration (Grundy et al, 1999). 
Recent reviews indicate that altered plasma lipoprotein profile in the excess 
atherosclerosis associated with diabetes may be most critical, because at any TC level, 
diabetics have 3-to 5-fold higher CAD mortality rates than do nondiabetic subjects 
(Steiner, 1994). Consistent with these findings, in type 2 diabetics, the total plasma 
antioxidant capacity, susceptibility of LDL to oxidation and excretion of oxidized 
products of arachidonic acid are all increased in proportion to the severity of 
hyperglycemia (Grundy et al, 1999; Ceriello et al, 1997; Peuchant et al, 1997). The 
involvement of increased oxidative stress in diabetes is supported by several data such 
as increased concentrations of lipid peroxidation products (conjugated dienes, 
hydroperoxides and TBARS) and decreased levels of antioxidants in the plasma of 
patients (Sato et al, 1979; Karpen et al, 1984; Wolf, 1987). In addition, an elevated 
glucose concentration in plasma could promote LDL oxidation by leading to glycated 
forms of the particle, which are more sensitive to transition metal-dependent 
autooxidation (Sakurai et al, 1991). High glucose concentrations have been reported to 
enhance in vitro LDL oxidative modification induced by copper ions (Hunt et al, 1990; 
Hunt et al, 1994). A number of reports described shortened oxidative lag phase during 
copper-catalyzed oxidation of LDL and glycated LDL fi-om diabetic patients. Increased 
TBARS were found in LDL and erythrocyte membranes of type 1 and type 2 diabetic 
patients after exposure to phenylhydrazine (Rabini et al, 1994). Vitamin E 
supplementation of glycated LDL during in vitro oxidation decreases it's susceptibility 
to oxidation (Li et al, 1996). Oxidative reactions also can contribute to enhanced 
glycation. Hovs'ever, a number of studies failed to show an effect of a-T on LDL 
glycation (Reaven, 1995; Li et al, 1996; Rabini et al, 1994). Elevated glucose 
concentrations in the culture medium enhances superoxide production and the 
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subsequent ability of endothelial and smooth muscle cells to oxidatively modify LDL 
(Mazeri et al., 1995). Otero et al. (2002) have demonstrated that the consumption of 
vitamin E in normal human LDL subjected to Cu^-induced oxidation was delayed by a 
glucose concentration frequently found in subjects with poorly controlled type 1 
diabetes. However, high glucose concentration accelerated the LDL oxidation once 
LDL associated vitamin E was consumed. This prooxidant effect of glucose was 
reflected by increased formation of conjugated dienes, TBARS and a decreased lag 
phase (Otero et al, 2002). Although lipid oxidation in the vessel wall is thought to 
occur as result of local deficiency of endogenous antioxidants or an excess of free metal 
ions, only limited data support these hypotheses (Jialal and Devraj, 1996; Steinberg, 
1997). Research has shown that human atherosclerotic plaques contain massive 
amounts of lipid peroxidation products, despite the presence of large quantities of a-
tocopherol and ascorbate (Suama et al., 1993). Thus, it is imclear whether oxidized 
lipoproteins originate in the arterial wall or are produced in the circulation and then 
enter the intimal space. In another study, vitamin E decreased LDL susceptibility to 
oxidation and reduced the plasma level of lipid peroxides with no change in plasma 
lipoprotein profiles in hyperlipidemic-diabetic hamsters. In addition, vitamin E, despite 
it's effect on reducing oxidative stress markers and lowering plasma TG levels, was not 
effective in inhibiting foam cell formation in the aortic arch of hyperlipidemic-diabetic 
hamster model (El-Swefy et al., 2000). However, hypolipidemic drug coupled with 
antioxidant properties were more effective in reducing clinical manifestations of long-
term diabetes in experimental animals (Cameron et al, 1993). Similarly, several 
intervention trials (GISSI-Prevenzione Investigators, 2001; Keith et ah, 2001) with high 
doses of vitamin E for prolonged periods failed to positively affect cardiovascular 
events in diabetics with CHD. Nevertheless, oxidative modification of LDL is one 
possible mechanism for an early development of atherosclerosis in diabetes. It is 
possible that increased atherogenecity of LDL during diabetes is associated with a 
preponderance of sd-LDL subpopulation, that is more prone to oxidative modification 
than Ib-LDL (Chancharme et al., 1999). Several studies have reported a 2- to 3-fold 
increase in CHD risk among patients with a predominance of sd-LDL particles (Austin 
et al, 1988; Austin et al, 1990; Austin et al, 1994). Recently, Koba et al (2006) have 
reported that prognosis of CHD was closely linked not to the LDL particle size but to 
the concentration of sd-LDL. Therefore, sd-LDL has been highlighted as a new and 
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useful marker for the risk of CHD or type 2 diabetes with and without CHD. In 
addition, because of greater preponderance of sd-LDL, a moderately high LDL-C 
(between 130 and 160 mg/dl) in a type 2 diabetic patient is equivalent to a much higher 
LDL-C in terms of CHD risk for a nondiabetic subject (Grundy et al., 1999; Haffiier et 
al., 1998; NCEP Expert Panel, 1993). Therefore, the primary target of therapy in type 2 
diabetic patients is lowering LDL-C to a level < 100 mg/dl as suggested by NCEP 
Expert Panel for patients with preexisting CHD (Haffher et al., 1998). Similarly, the 
substantial increase in more atherogenic sd-LDL in diabetic patients with and without 
CHD requires an immediate attention. At present, the most common LDL-C lowering 
agents are statins. However, they have been reported to exhibit host of side effects 
(Haffner et al., 1998; Assmann et al., 1998). To the best of our knowledge, no 
therapeutic interventions to specifically reduce the elevated levels of highly atherogenic 
sd-LDL in diabetic-hyperlipidemic patients or animals have been reported (Hirano et 
al., 2004; Hirano et al., 2005; Koba et al., 2006). 
Several alterations in structural and dynamic properties of erythrocytes 
membrane have been reported in type 1 and type 2 diabetes (Watala, 1993). Of 
particular interest has been the observation of an altered activity of erythrocytes 
membrane Na^, K"-ATPase in type 1 and typ^ 2 diabetes (Rizvi and Zaid, 1998; 
Kiziltunc et al., 1997). Impaired Na^ K^-ATPase is a feature of diabetes in many cell 
types and is believed to be a pivotal regulator of various cell functions (Mahesh and 
Menon, 2004). Increased erythrocytes MDA concentrations are known to cause a 
decrease in the fluidity of the membrane lipid bilayer and increased osmotic stability of 
cells (Raccah et al., 1996). It is widely believed that oxidation process and MDA 
accumulation can contribute directly to changes in the properties of diabetic 
erythrocytes including decrease in Na^, K'^ -ATPase activity, and may cause the 
development of long-term diabetic complications (Mahesh and Menon, 2004). 
During long-term diabetes, oxidant stress may be increased owing to a higher 
production of ROS and/or deficiency in the antioxidant defense system (Baynes, 1991). 
The levels of ROS are controlled by antioxidant enzymes, SOD, catalase, Gpx, Gred 
and nonenzymatic scavengers such as GSH. An impaired radical scavenger fiinction 
has been linked to decreased activity of enzymatic and nonenzymatic scavengers of free 
radicals. Reports about the status of antioxidants and scavengers as defense mechanism 
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during diabetes are very contradictory. Increase, decrease oi no change in enzymatic 
antioxidant concentrations have been reported (Siddiqui et al, 2005; Bukan et al., 2003; 
Kinalski, 2000). Therefore, status of Hpid and Hpoprotein peroxidation and the status of 
oxidants, enzymatic and nonenzymatic antioxidants in plasma, erythrocytes and other 
tissues such as Hver of chronic diabetic rats with hyperlipidemia, nephropathy and 
retinopathy, and other abnormahties of membrane-Hnked functions are highly 
important. Furthermore, chronic diabetes may enhance oxidative stress not only 
through the increased production of ROS but also through weakening the antioxidant 
defense system. In this context, antioxidant role of serum HDL-complexed paraoxonase 
(PON)/arylesterase enzyme in the protection of LDL as well as HDL from oxidative 
modification is noteworthy. In contrast to PON, xanthine oxidase is known to be an 
important biological source of free radicals. Serum and liver xanthine oxidase activity 
is significantly increased in diabetes and hyperlipidemia and that free radicals generated 
in the enzymatic processes are involved in oxidative damage (Desco et al., 2002). Thus, 
the antioxidants that have both antiradical and xanthine oxidase inhibitory properties 
may have additional therapeutic benefit in the treatment of diabetes with and without 
CHD. Finally, risk of diabetic complications including CHD would be further 
exacerbated by an inadequate dietary intake of antioxidants s ^ ^ §§.ya-tocopher6l 
The tocotrienol isomers (a-, (3-, y-, 5-) or naturally occurring analogues of 
tocopherol isomers (vitamin E) found mainly in cereal grains, rice bran and palm oil. 
Tocotrienols (T3s) differ from tocopherols (Ts) by possessing three double bonds in 
phytyl side chain. Published reports indicate that both in vitro and in intact membranes 
including LDL particles T3s exert significantly greater protection against CAD (Packer, 
1995; Qureshi et al., 2000). Unlike Ts, T3s have been shown to have an intrinsic 
hypocholesterolemic activity in animals and humans. The cholesterol lowering effect of 
T3s was attributed mainly to their down regulation of HMG-CoA reductase -the rate 
limiting enzyme in the cholesterol biosynthetic pathway (Parker et al, 1993; 
Minhajuddin et al, 1999; Minhajuddin et al., 2005). The tocopherol isomers do not 
inhibit cholesterol synthesis and thus do not lower serum cholesterol (Qureshi et al, 
1986; Parker et al, 1993). Qureshi and coworkers have demonstrated a sfrong 
hypolipidemic effect of tocotrienol rich fraction (TRF)/tocotrienols in various animal 
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models as well as hyperlipidemic hxunans (Qureshi et ah, 1986; Qureshi et ah, 1991a; 
Qureshi et al, 1991 \ Qureshi et al, 2000; Qureshi et al, 2001a). Our laboratory has 
also reported a strong hypolipidemic impact of TRF in normal and hyperlipidemic rats 
and humans as well as in hyperlipidemic rabbits with accelerated aortic atherosclerosis 
induced by feeding oxidized cholesterol (Minhajuddin et al., 1999; Minhajuddin et al., 
2005; Beg et al, 2000a; Beg et al, 2000b; Beg and Zainuddin, 2003). However, a 
detailed investigation pertaining to combined hypolipidemic, anti-lipid-/lipoprotein-
peroxidative and hypoglycemic as well as antidiabetic impacts of tocotrienols in 
diabetic patients or diabetic animals has been lacking. There is only one report 
indicating some hypoglycemic activity of TRF in STZ-induced diabetic rats 
(Nazaimoon and Khalid, 2002). In this report, feeding of a TRF-rich diet to diabetic rats 
for 12 weeks caused a significant decrease in blood glucose (32 %) and glycated 
hemoglobin (gHb, 24 %) levels with no change in serum AGE and MDA levels. 
However, this hypoglycemic effect of TRF was minimal and both the glucose and gHb 
levels after TRF treatment were in diabetic range. Recently, our laboratory has reported 
that TRF administration to type 2 diabetic patients with hyperlipidemia for 60 days was 
associated with a significant decline in serum total lipids, TC, VLDL-C and LDL-C. 
However, potential hypoglycemic effect of TRF was not seen in these patients because 
they were glycemically stable and their base line blood glucose and HbAi levels were 
close to normal values (Baliarsingh et al, 2005). In contrast to our results, Nazaimoon 
et al. (1996) have reported that intake of TRF by type 2 diabetics for 180 days caused 
no significant change in serum TG, TC, LDL-C, HDL-C and blood HbAi levels. Statins 
including Lovastatin are potent competitive inhibitors of HMG-CoA reductase and are 
highly effective lipid lowering agents. They are universally marketed and used by both 
nondiabetic and diabetic hyperlipidemic patients with and without CHD. Scattered 
reports indicate antioxidant properties of Lovastatin in hyperlipidemic-diabetic 
hamsters (El-Swefy et al, 2000), atherosclerotic rabbits (Chen et al, 1997; Singh et al, 
1997) and in vitro as well as ex vivo studies in patients with hypercholesterolemia 
(Aviram et al, 1992). However, no hypoglycemic effect of Lovastatin has been 
reported. 
Since chronic hyperglycemia coupled with dyslipidemia is responsible for both 
microvascular and macrovascular diabetic complications, in the present study, we used 
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STZ-induced diabetic-hyperlipidemic rats. These rats during a 14-week long-term 
diabetes had a fully developed nephropathy and retinopathy. We have investigated the 
hypoglycemic, hypolipidemic, antioxidant and antidiabetic impacts of Tocomin and 
Lovastatin when fed to diabetic-hyperlipidemic rats for 14 weeks and compared with 
diabetic control rats. The efficacy of feeding 6 mg Tocomin or 0.50 mg 
Lovastatin/rat/day in preventing the increase in fasting plasma glucose, glycosylated 
HbA,, TG, TC, non-HDL-C, VLDL-C, LDL-C, sd-LDL-C, Ib-LDL-C, HDL-C, and its 
subfractions, HDL2-C and HDL3-C levels in diabetic-hyperlipidemic rats was 
investigated. In addition, quantification of cholesterol and apoB content in LDL and its 
subfractions, sd-LDL and lb-LDL isolated from plasma of diabetic-hyperlipidemic rats 
treated with and without Tocomin or Lovastatin has been done. In order to understand 
the mechanism(s) of lipid lowering actions of Tocomin and Lovastatin in diabetic-
hyperlipidemic rats, we have measured the enzymatic activity of hepatic HMG-CoA 
reductase. The effect of long-term diabetes on plasma total antioxidants, arylesterase 
activity, plasma and hepatic xanthine oxidase activity; plasma, erythrocytes and hepatic 
lipid peroxidation products, that is, conjugated dienes, lipid hydroperoxides and 
TEARS as well as MDA release in intact erythrocytes and membrane associated Na"^ , 
K -^dependent ATPase activity was determined. Furthermore, therapeutic role of 
Tocomin and Lovastatin in the normalization of the above parameters was investigated. 
Moreover, antioxidant impacts of Tocomin and Lovastatin on base line levels of ex vivo 
diene conjugation and lag phase time of in vitro Cu" -^induced oxidation of LDL, sd-
LDL and Ib-LDL both in the presence and absence of glucose was undertaken. In 
addition, the efficacy of tocotrienols (Tocomin) and Lovastatin in the protection and 
restoration of the altered enzymatic and nonenzymatic antioxidant defense system in 
erythrocytes and liver as well as abnormalities of membrane linked functions including 
histopathological changes in nephropathy and retinopathy of chronic diabetic-
hyperlipidemic rats has also been investigated. 
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^Ej^erimentaC 
MATERIALS 
2.1.1 Chemicals 
The chemicals and reagents were obtained from various sources listed below. 
Chemical Source 
1 -Chloro 2,4-Dinitrobenzene 
1, 1,3, 3-Tetra Methoxy Propane 
2, 2-Diphenyl-l-Picryl Hydrazyl 
2, 4, 6-Tripyridyl-s- Triazine 
Adenosine Triphosphate 
Bovine Serum Albumin 
Butylated Hydroxyl Toluene 
Cholesterol (Extra pure) 
Coommassie Brilliant Blue G 250 
Dextran Sulfate 
5, 5'-Dithiobis (2-Nitrobenzoic Acid) 
Glucose Assay Kit (GOD-POD) 
Glutathione Oxidized 
Glutathione Reduced 
Hemoglobin Assay Kit 
Hydroxylamine Hydrochloride 
NADP 
NADPH 
Nitroblue Tetrazolium Salt 
Ouabain 
Phenazine Methosulfate 
Phenyl Acetate 
Phosphotungstic Acid 
Rat Chow 
Sodium Dodecyl Sulfate 
Streptozotocin 
Thiobarbituric Acid 
Triphenyl Phosphine 
Triglyceride Assay Kit 
Xanthine 
Xylenol Orange 
Central Drug House, Pvt. Ltd., India 
Sigma-Aldrich Inc., USA 
Sigma-Aldrich Inc., USA 
HiMedia Laboratories Pvt. Ltd., India 
Sigma-Aldrich Inc., USA 
Miles Ltd. Inc., USA 
HiMedia Laboratories Pvt. Ltd., India 
Sisco Research Laboratories, India 
Ploysciences Inc., USA 
Sochibo s.a., France 
Sisco Research Laboratories Pvt. Ltd., India 
Autospan kit SPAN Diagnostics, India 
Sisco Research Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
Ranbaxy Diagnostics, India 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
Sigma-Aldrich Inc., USA 
HiMedia Laboratories Pvt. Ltd., India 
Sigma-Aldrich Inc., USA 
Loba Chemie, India 
Ashirwad Industries, Chandigarh, India 
Bio-Rad Laboratories, USA 
Sigma-Aldrich Inc., USA 
Sigma-Aldrich Inc., USA 
HiMedia Laboratories Pvt. Ltd., India 
Recombigen Laboratories, India 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
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Twenty five percent palmvitae oil suspension of tocotrienols containing d-a-
tocopherol and purified individual d-a-tocotrienol (80 %), d-y- tocotrienol (90 %), d-
§-tocotrienol (60 %), and d-a-tocopherol (60 %) as well as RBD palm olein were 
supplied as a gift fi-om CAROTECH BHD, Chemor, Malaysia. Tocomin'^ suspension 
(250 mg/g) contained 6.4 % d-a-tocotrienol, 1 % d-p-tocotrienol, 10.2 % d-y-
tocotrienol, 3.2 % d-8-tocotrienoI and 5.7 % d-a-tocopherol. Cholesterol lowering 
drug, Lovastatin, was a gift fi-om Saimira Innoform Pvt. Ltd., Chennai, India. 
All other chemicals and reagents used in this study were of analytical grade. 
2.1.2 Animals 
Male albino rats, weighing about 200-220 g were purchased fi-om Central 
Drug Research Institute, Lucknow, were conditioned to animal house environment 
prior to the experiment. 
2.1.3 Diet/Injection 
The rats were given pelleted rat chow and water ad libitum. In order to induce 
experimental diabetes, twenty five overnight fasted rats were injected with 
streptozotocin (STZ, freshly dissolved in 10 mM citrate buffer, pH 4.5, 60 mg/kg 
body weight) intraperitonially (Zhang et al, 2004). Rats in normal control group were 
injected with buffer only. After 12 days, twenty two rats showed an average plasma 
glucose level of 257 mg/dl. These rats were classified as diabetic and included in the 
present investigation. Both Tocomin (600 mg) and Lovastatin (50 mg) were 
solubilized in 5 ml ethanol and diluted to 100 ml in palmvitae oil. Tocomin and 
Lovastatin suspension was administered through gastric intubation in two divided 
doses (morning and evening) of 0.5 ml each /rat/day. 
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METHODS 
2.2.1 Experimental Design 
For investigating the hypoglycemic, hypolipidemic, ex vivo and in vitro 
overall antioxidant impacts of Tocomin and Lovastatin, rats were divided in the 
following groups: 
> Normal Control (N-C) 
Eight rats were given 0.5 ml palmvitae oil through gastric intubation for fourteen 
weeks. 
> Diabetic Control (D-C) 
Eight rats in this group were administered 0.5 ml palmvitae oil through gastric 
intubation for fourteen weeks. 
> Diabetic Tocomin Treated (D-TT) 
Seven rats in this group were given 6.0 mg (0.5ml each) Tocomin/rat/day, through 
gastric intubation for fourteen weeks. 
> Diabetic Lovastatin Treated (D-LT) 
Seven rats in this group were fed 0.50 mg (0.5 ml each) Lovastatin/rat/day, through 
gastric intubation for fourteen weeks. 
2.2.2 Analytical Procedures 
2.2.2.1 Collection of blood and packed erythrocytes 
At the end of the treatment, overnight fasted rats in each group were 
anaesthetized and blood drawn by cardiac puncture. The blood from each rat in a 
given group was collected using heparin as anticoagulant. Blood was mixed gently by 
inversion 2-3 times and immediately cooled to 4°C in a refrigerator. The samples 
were centrifijged at 2,500 rpm for 30 min. Plasma was aliquoted and either stored at 
4°C or frozen at -20°C for friture use. 
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The hemolysate of packed erythrocytes was prepared as described by Lakshmi 
and Rajagopal (1998). After removal of plasma and buffy coat, the packed 
erythrocytes obtained were washed thrice with physiological saline and a portion of 
washed erythrocytes was lysed in hypotonic (lOmM) sodium phosphate buffer, pH 
7.4. A portion of the washed packed erythrocytes was stored at 4°C for use in other 
experiments. 
2.2.2.2 Isolation of erythrocytes membrane 
The erythrocytes membrane was isolated as described elsewhere (Hanahan 
and Ekholm, 1974). Two ml of washed packed erythrocytes was suspended in a tube 
containing 12.0 ml of 11.09 mM tris buffer, pH 7.4. The tubes were allowed to stand 
at room temperature for 5 min and centrifuged at 20,000 g for 40 min at 2°C. The 
supernatant was decanted without loosing the membrane. The procedure was repeated 
four times in order to obtain a colorless membrane fraction. The membrane was 
resuspended in 2.0 ml of 11.09 mM tris buffer, pH 7.4 and used for the assay. 
2.2.2.3 Collection of different organs 
In addition to the blood, liver, kidney and eyeball were excised. Liver and 
kidney were kept in ice-cold saline. A portion of kidney and whole eyeball were 
immediately fixed in 10 % neutral formalin for histopathological studies. 
2.2.2.4 Preparation of liver, kidney homogenate and post-mitochondrial 
supernatant 
Liver and kidney from each rat were blotted and weighed. Each liver and 
kidney were cut into pieces, mixed, and 10 g of wet tissue was homogenized with 90 
ml of chilled 0.1 M sodium phosphate buffer, pH 7.4, containing 1.17 % KCl in a 
waring blender. The volume of each homogenate was recorded and centrifuged at 
1,000 rpm for 10 min at 4°C. After centrifugation, a portion of each homogenate from 
liver and kidney thus obtained was aliquoted and stored at -20°C. The remaining 
portion of the liver and kidney homogenates were centrifuged at 12,000 rpm for 20 
min at 4°C. The post-mitochondrial supernatant thus obtained was aliquoted and 
stored at -20°C for future use. 
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2.2.2.5 Determination of free radical scavenging activity (antioxidant capacity) 
of Tocomin, a-tocotrienol, y-tocotrienol, 6-tocotrienol, a-tocopherol, 
and Lovastatin. 
Free radical scavenging activity of Tocomin, a-Ts, y-Ts, 5-T3, a-T and 
Lovastatin was determined by the method of Mellors and Tappel (1966) as modified 
by Khanduja and Bhardwaj (2003). The assay was carried out in a medium containing 
40 mM tris buffer, pH 7.4 and 125|uM ethanolic solution of 2, 2-diphenyl-l-picryl 
hydrazyl (DPPH). The reaction was started by the addition of ethanolic solution of 
Tocomin, a-Ts, y-Ts, 6-T3, a-T and Lovastatin (5-100 \iM) in a total volume of 2.0 
ml. The samples were mixed thoroughly and the absorbance was recorded in dark at 
517 nm (27±2°C) at 1 min time interval up to 10 min against absolute ethanol. A 
control blank containing all the above ingredients except the test compounds was 
used in order to monitor the absorption of DPPH. The percent inhibition of the DPPH 
by the above antioxidants was calculated according to the formula reported by Yen 
and Duh (1994). 
2.2.2.6 Determination of blood glucose 
Fasting plasma glucose levels were determined by using an enzymatic 
Autospan kit. The method uses a modified Trinder color reaction (Trinder, 1969; 
Tietz, 1976). The red color thus formed was measured at 505 nm in a Beckman DU 
640 spectrophotometer, which is directly proportional to the concentration of glucose 
in the sample. The plasma glucose level was calculated by using a standard glucose, 
2.2.2.7 Determination of plasma triglycerides 
Triglycerides in plasma samples were determined by using an enzymatic kit. 
The method uses a modified Trinder color reaction to produce a fast, linear, end point 
reaction (Trinder, 1969). The intensity of the color produced is directly proportional 
to the concentration of triglycerides in the sample when measured at 500 nm in a 
Beckman DU 640 spectrophotometer. Triglycerides in plasma samples were 
calculated by using a triolein standard. 
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Plasma very low density lipoprotein-cholesterol (VLDL-C) was determined 
by dividing plasma triglyceride values (mg/dl) by a factor of 5 as described by 
Friedewalde/a/. (1972). 
2.2.2.8 Fractionation of plasma lipoproteins 
Plasma low density lipoprotein (LDL) was isolated by precipitation method as 
described by Wieland and Seidel (1989). The precipitation buffer consisted of 64 mM 
trisodium citrate adjusted to pH 5.05 with 5 N HCl, containing 50,000 lU/L heparin. 
Before precipitation of LDL, plasma samples and precipitation reagent were allowed 
to equilibrate to room temperature. One ml of plasma sample was added to 7.0 ml of 
heparin-citrate buffer. After mixing with a vortex mixer, the suspension was allowed 
to stand for 10 min at 22°C. The insoluble LDLs were then sedimented by 
centrifugation at 1,500 rpm for 10 min at 22°C. The pellet was resuspended in 1.0 ml 
of 0.1 M sodium phosphate buffer, pH 7.4, containing 0.9 % NaCl. 
Our method for the isolation of small dense (sd)-LDL and large buoyant (Ib)-
LDL from isolated LDL is based on the two-step procedure of Hirano et al. (2004), 
which employs quantification of sd-LDL from serum by heparin-Mg^ precipitation. 
In our modified method of sd-LDL and Ib-LDL isolation, 0.1 ml of precipitation 
reagent containing 15 lU of heparin and 90 mM MgCb was added to a 0.1 ml of 
isolated LDL sample as described above. After mixing, the sample was incubated at 
37°C for 10 min. Then each sample was incubated in an ice-bath for 15 min and 
centrifiiged at 10,000 rpm for 15 min at 4°C. The supernatant containing sd-LDL was 
carefully removed and saved. The pellet containing Ib-LDL was dissolved in 0.1 M 
sodium phosphate buffer, pH 7.4, containing 0.9 % NaCl. Appropriate aliquots of 
LDL, Sd-LDL and Lb-LDL fractions were used for the analysis of their cholesterol 
and apoB content. 
Isolation of high density lipoprotein (HDL), HDL2 and HDL3 subfractions 
were done by dual-precipitation method as described by Patsch et al. (1989). 
According to this method 100 \i\ of reagent containing 1.0 g of dextran sulfate 
dissolved in 100.0 ml of 0.5 mM MgCla solution was added to I.O ml of plasma, and 
vortexed-mixed for 3 sec. After an incubation period of 10 min at 22°C, the mixture 
was centrifiiged at 1500 rpm for 15 min at 22°C and the supernatant containing HDL 
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was removed. The clear supernatant was used for the analysis of HDL-cholesterol as 
well as for the isolation of HDL2 and HDL3 subfractions. For HDL fractionation, 100 
|il of a reagent containing 1.0 g of dextran sulfate dissolved in 100.0 ml of 1.5 mM 
MgCb solution was added to 1.0 ml of HDL supernatant, and vortexed-mixed for 3 
sec. Following an incubation of 10 min at 22°C, the mixture was centrifuged at 1500 
rpm for 20 min at 22°C and the supernatant containing HDL3 fraction was removed, 
whereas the HDL2 precipitate was dissolved in 0.1 M sodium phosphate buffer, pH 
7.4, containing 0.9 % NaCl. 
2.2.2.9 Determination of cholesterol 
Total cholesterol in plasma, LDL, sd-LDL, Ib-LDL, HDL, HDL2 and HDL3 
subfractions were estimated as described by Annino and Giese (1976), with a minor 
modification. For the determination of plasma total cholesterol, O.1 volume of plasma 
was mixed with 1.0 volume of isopropanol, allowed to stand for 5 min and 
centrifuged at 3000 rpm for 10 min. A suitable aliquot of isopropanol extract was 
used for cholesterol determination in a total volume of 0.75 ml. To each tube 0.25 ml 
of 7.02 mM ferric chloride dissolved in glacial acetic acid, was added, mixed 
instantly, followed by the addition of 0.8 ml of sulphuric acid with thorough mixing. 
After 5 min, the absorbance was read at 550 nm in a Beckman DU 640 
spectrophotometer. The cholesterol content in the samples was determined by using a 
cholesterol standard. 
2.2.2.10 Measurement of ex vivo and in vitro Cu^-mediated susceptibility of 
LDL, sd-LDL and Ib-LDL to oxidation 
The susceptibility of isolated LDL, sd-LDL and Ib-LDL to oxidation was 
assessed by determining the lag phase of conjugated diene formation using the 
method of Esterbauer et al. (1989; 1992). The incubation mixture contained 50 |ig of 
LDL, sd-LDL and Ib-LDL in 1.0 ml of 10 mM phosphate buffered saline, pH 7.0. At 
time zero, before the initiation of Cu'^ -mediated oxidation, 1.0 ml aliquot of each 
sample was added to a tube containing 0.5 |iM EDTA, pH 7.4, along with 0.5 ^M 
BHT, for the assessment of ex vivo levels of conjugated diene. Then, lipoprotein 
samples were mixed with CUS04 to a final concentration of 5 fiM and incubated at 
37°C. At the indicated time, 1.0 ml aliquots were taken out and oxidation of LDL, sd-
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LDL and Ib-LDL was terminated by the addition of EDTA and BHT (0.5 [iM each), 
pH 7.4. At the end of incubation, the formation of conjugated dienes in each aliquot 
was measured by monitoring absorbance at 234 nm in a Beckman DU 640 
spectrophotometer. The formation of conjugated dienes was calculated by using an 
extinction coefficient of 2.52 xlO"* M''cm''and expressed as nmole malondialdehyde 
(MDA) equivalents per mg LDL, sd-LDL or Ib-LDL protein. 
In another experiment, susceptibility to Cu^-mediated oxidation of LDL, sd-
LDL and Ib-LDL, isolated from normal rat plasma enriched with Tocomin, 
Lovastatin, or a-tocopherol was studied. Enrichment of plasma LDL with above 
compounds was carried out as described by Esterbauer et al. (1991). In brief, 4.0 ml 
of heparinized plasma was incubated with 1 mM of an ethanolic solution of Tocomin, 
Lovastatin or 0.23 mM a-tocopherol (equivalent concentration of a-tocopherol 
present in Tocomin) for 4 h in a shaking water bath at 37°C. In parallel, the same 
volume of plasma was incubated with 40 |il of ethanol (untreated control). At the end 
of incubation, sd-LDL and Ib-LDL were fractionated from LDL isolated from the 
above plasma samples. The Cu^-mediated oxidation of LDL, sd-LDL and Ib-LDL 
was carried out as described above. In experiments, where effect of glucose on in 
vitro oxidation of the above lipoproteins was assessed, 2.5 mg glucose per ml was 
added. ApoB protein associated with LDL, sd-LDL and Ib-LDL was determined as 
described by Bradford (1976). 
2.2.2.11 Measurement of plasma "total antioxidant power" (FRAP) 
The ferric reducing ability of plasma, the FRAP assay, which estimates 
"total antioxidant power" was measured as described by Benzie and Strain (1996) 
with minor modification. Ferric to ferrous ion reduction at low pH results in the 
formation of a colored ferrous-tripyridyl triazine complex. The assay was carried out 
in a total volume of 1.0 ml containing a suitable aliquot of plasma in 0.1 ml and 900 
^I of freshly prepared FRAP reagent, prepared by mixing 10.0 ml of 22.78 mM 
sodium acetate buffer, pH 3.6, 1.0 ml of 20 mM ferric chloride and 1.0 ml of 10 mM 
2, 4, 6-tripyridyl-s- triazine solution prepared in 40 mM HCl. Both FRAP reagent and 
pJasma samples were preincubated for 5 min at WC before starting the reaction. 
Incubation was done for 5 min at 30°C and absorbance was recorded at 593 nm 
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against a reagent blank in a Beckman DU 640 spectrophotometer. The "total 
antioxidant power" (FRAP value) was calculated by utilizing a standard ferrous 
sulfate. 
2.2.2.12 Determination of arylesterase activity in plasma 
Arylesterase activity in plasma was determined by using phenyl acetate as the 
substrate (Ayub et ah, 1999). The assay mixture included 100 mM tris buffer, pH 8.0, 
1 mM CaCb, suitable aliquots of plasma and ImM phenyl acetate. After a 5 min 
preincubation at 25°C, the reaction was started by the addition of phenyl acetate and 
the samples were incubated for different time intervals at 25°C. The initial rates of 
hydrolysis (within linear range) were determined spectrophotometrically at 270 nm 
against a reagent blank. Nonenzymatic hydrolysis of phenyl acetate was subtracted 
from the total rate of hydrolysis. Arylesterase activity in the above samples was 
calculated by using the molar extinction coefficient of 1.31 x 10^  M"' cm"' (La Du and 
Eckerson, 1984). 
2.2.2.13 Assay of xanthine oxidase activity 
The activity of xanthine oxidase in plasma and liver homogenate was assayed 
by the method described elsewhere (Noro et ai, 1983) with suitable modification. 
The reaction mixture consisted of 70 mM sodium phosphate buffer, pH 7.4, 10-40 ^ il 
of plasma or 100-200 |il of 10 % liver homogenate and 8 mM xanthine. After a 5 min 
preincubation, the reaction was started by the addition of xanthine and incubation was 
carried out for 15 min at 37°C. The reaction was terminated by the addition of 0.5 ml 
ice-cold 10 % perchloric acid, followed by incubation for 10 min at room 
temperature. Samples were then centriftiged at 4,000 rpm for 10 min. The absorbance 
of the supernatant was recorded at 290 nm against a reagent blank in a Beckman DU 
640 spectrophotometer. Xanthine oxidase activity was calculated by using a standard 
uric acid. 
2.2.2.14 Determination of hemoglobin content in blood 
The quantitative determination of hemoglobin in blood was done according to 
the procedure described in the instruction sheet enclosed with the reagent kit supplied 
by Ranbaxy Laboratories (Van Kampen and Zijistra 1961). The percent blood 
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hemoglobin was determined by measuring the absorbance of cyanomethemoglobin at 
540 nm in a Beckman DU 640 spectrophotometer using a hemoglobin standard. 
2.2.2.15 Determination of glycosylated hemoglobin 
The quantitative determination of glycosylated hemoglobin (HbAj) in 
erythrocytes hemolysate was done by the colorimetric method of Nayak and 
Pattabiraman (1981). The washed erythrocytes obtained from 4.0 ml of blood were 
hemolysed by the addition of 2.0 ml of water and 0.5 ml of toluene. The hemolysate 
was dialysed against 500 voliraie of water for 12 h at 4°C. Aliquots of the dialysate 
were made up to 2.0 ml with water. To this solution 4.0 ml of 1 M oxalic acid in 2 M 
HO was added and heated in a boiling water bath for 4 h. After cooling, 2.0 ml of 40 
% TCA was added to each hydrolysate and centrifiiged at 2,500 rpm for 10 min. 
Suitable aliquots of the supernatant were made up to 1.0 ml with water. To this 
solution 50 i^l of 80 % phenol and 3.0 ml concentrated sulphuric acid were added. 
After 30 min incubation at room temperature, the absorbance of the color was 
measured at 480 nm against a reagent blank in a Beckman DU 640 
spectrophotometer. Standard fructose was used for the calculation of glycosylated 
hemoglobin (HbA|) content. 
2.2.2.16 Measurement of malondialdehyde release from intact erythrocytes 
The determination of malondialdehyde (MDA) release from erythrocytes was 
carried out according to the procedure reported previously (Cynamon et al., 1985). 
Two aliquots of 0.22 ml of washed packed erythrocytes in duplicate were taken in 
two separate tubes. One series of aliquots were suspended in 4.18 ml of phosphate 
buffered saline, pH 7.4, and the second series of aliquots of erythroc>tes were 
suspended in 4.18 ml of phosphate buffered saline, pH 7.4, containing 4 mM sodium 
azide. Both the suspensions were vortexed for 15 seconds. One ml of erythrocytes 
suspension of series one was taken in triplicate and mixed with 1.0 ml of freshly 
prepared 3 % hydrogen peroxide, whereas, 1.0 ml of 0.75 % hydrogen peroxide was 
added to the second series of erythrocytes suspension. The samples were mixed for 10 
seconds and incubated for 1 h at 37°C. At the end of incubation, 1.0 ml of 28 % TCA 
containing 100 mM sodium arsenite was added to each tube and centriftiged at 3,000 
rpm for 10 min. Two ml of the supernatant from each tube was taken in triplicate and 
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mixed with 0.5 ml of 1 % thiobarbituric acid prepared in 50 mM NaOH. The samples 
were then boiled for 15 min at 95 °C, cooled to room temperature and the absorbance 
was recorded at 535 run against a reagent blank in a Beckman DU 640 
spectrophotometer. The concentration of MDA released from erythrocytes in the 
samples was calculated from a standard absorption curve for MDA (1, 1,3, 3-tetra 
methoxy propane) (Liu et al., 1982). 
2.2.2.17 Determination of malondialdehyde in erythrocytes 
For the determination of TBARS in erythrocytes, the method of Stocks and 
Dormandy (1971) was employed. Briefly, 0.25 ml of packed erythrocytes in 
quadruplet was made up to 1.0 ml in phosphate buffered saline, pH 7.4. To each tube, 
BHT in ethanol (0.75mM) was added, followed by the addition of 0.5 ml of 30 % 
TCA. Tubes were vortexed and allowed to stand in ice-bath for 2 h. Tubes were then 
centrifuged at 2,000 rpm for 15 min and 1.0 ml of the supernatant of each tube was 
transferred to another tube. To each tube, 75 ^1 of 100 mM EDTA and 250 yd of 1 % 
thiobarbituric acid in 50 mM NaOH was added, mixed and kept in a boiling water 
bath for 15 min. After cooling the tubes to room temperature the absorbance of each 
sample was read against a reagent blank at 532 nm in a Beckman DU 640 
spectrophotometer. The, concentration of MDA was calculated by using a standard 
malondialdehyde (Liu et al., 1982). 
2.2.2.18 Assay of total and magnesium-dependent ATPase activities in 
erythrocytes membrane 
Total and Mg""-dependent ATPase enzyme activities in freshly isolated 
erythrocytes membrane was done as described by Quigley and Gotterer (1969), where 
as inorganic phosphate released in the medium by the action of ATPase enzymes was 
quantified by the method of Chen et al. (1956). For the assay of total ATPase activity, 
the incubation mixture consisted of 50 mM imidazole buffer, pH 7.4, 3.0 mM MgCb, 
120 mM NaCl, 20 mM KCl and 5 mM ATP. Whereas, for the assay of Mg^-
dependent ATPase activity, the reaction mixture in addition to the above ingredients 
also contained I mM ouabain. The reaction was started by the addition of 100-300 fig 
erythrocytes membrane protein suspension and the samples were incubated for 30 
min at 37°C. At the end of incubation, reaction was stopped by the addition of 1.0 ml 
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of 10 % TCA. The tubes were then centriftiged at 3,000 rpm for 3 min and 0.5 ml of 
the supernatant from each tube was taken out for the assay of inorganic phosphate. 
The supernatant volume was made up to 4.0 ml with water followed by the addition 
of 4.0 ml of a reagent containing 1 volume of 20 mM ammonium molybdate, 1 
volume of 567 mM ascorbic acid, 1 volume of 6 N H2S04 and 2 volimies of water. 
The tubes were incubated for 2 h at 37°C and the absorbance was recorded at 820 nm 
against a suitable reagent blank in a Beckman DU 640 spectrophotometer. Total and 
Mg'^ -dependent ATPase activities were calculated by using standard phosphorous 
calibration curve. The enzymatic activity of Na ,^ K"^ -ATPase was then calculated as 
the difference between total and Mg" -^dependent ATPase activities. 
2.2.2.19 Estimation of lipid peroxides in plasma, liver and kidney homogenates 
Lipid contents in plasma and tissues were extracted according to the method 
of Folch et al. (1957). One volume of plasma or tissue homogenate was mixed with 
5.0 volume of chloroform: methanol (2:1), followed by centrifugation at 1,000 rpm 
for 5 min to separate the phases. Most of the upper layer was removed; and 3.0 ml of 
the lower chlorofonn layer was recovered. The chloroform layer was placed in a test 
tube and incubated at 45°C till dryness. For the determination of conjugated dienes in 
plasma, liver and kidney, corresponding lipid residues were dissolved in 1.5 ml of 
cyclohexane and the absorbance was recorded at 234 nm against a cyclohexane blank 
in a Beckman DU 640 spectrophotometer. The concentration of conjugated diene 
formation was calculated by using a molar extinction coefficient of 2.52x10'*M''cm"'. 
In another experiment, dried residues extracted from liver and kidney 
homogenates were dissolved in methanol and used for the quantification of lipid 
hydroperoxides by employing the procedure reported by Nourooz-Zadeh at al. 
(1996). Ninety microliter of these samples or plasma were transferred into 1.5 ml 
microcentrifuge vials together with 10 i^l of methanol (in triplicate) or 10 |il of 10 
mM triphenyl phosphine (TPP) in methanol (in triplicate). The samples were then 
vortexed and incubated for 30 min at 25°C, followed by the addition of 900 1^ of a 
reagent containing 250 p,M ammonium sulphate, 100 ]xM xylenol orange, 25 mM 
sulphuric acid and 4 mM BHT in 90 % methanol. The samples were incubated for 
additional 30 min at 25°C, and centriftiged at 12,000 rpm for 10 min prior to the 
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determination of the absorbance of the supematants at 560 nm in a Beckman DU 640 
spectrophotometer. The levels of lipid hydroperoxide in tissue homogenates and 
plasma samples was then determined using the difference between the mean 
absorbance of samples with and without TPP pretreatment. Hydroperoxide contents 
were determined using a molar absorption coefficient of 4.3 xlO** M"' cm''. 
Lipid peroxide contents in plasma were assayed by the method of Yagi 
(1987). Plasma (100 |al) was mixed with 4.0 ml of 0.083 N H2S04 followed by the 
addition of 0.5 ml of 10 % phosphotungstic acid. The samples were mixed and 
incubated for 5 min at room temperature and then centrifliged at 3,000 rpm for 10 
min. The supernatant was discarded and the sediment was mixed with 2.0 ml of 0.083 
N H2S04 and 0.3 ml of 10 % phosphotungstic acid. The mixture was centrifliged at 
3,000 rpm for 10 min, the sediment was suspended in 4.0 ml of water and 1.0 ml of 
thiobarbituric acid (TBA) reagent (a mixture containing equal volumes of 0.67 % 
aqueous TBA solution and glacial acetic acid) was added. The reaction mixture was 
heated for 60 min at 95°C, cooled and the tubes were centrifuged at 3,000 rpm for 10 
min. The absorbance of the supernatant was determined at 532 nm against a reagent 
blank in a Beckman DU 640 spectrophotometer. The MDA values in the samples 
were calculated by using a standard absorption curve for MDA (1, 1, 3, 3-tetra 
methoxy propane) (Liu et ai, 1982). 
Lipid peroxides in liver and kidney homogenates were determined by the 
method of Ohkawa et al. (1979). To 200 \i\ of 10 % liver or kidney homogenate 
samples, 200 i^l of 8.1 % SDS, 1.5 ml of 20 % acetic acid (pH 3.5) and 1.5 ml of 0.8 
% aqueous solution of TBA were added and mixed. The mixture was made up to 4.0 
ml with water and heated in a water bath for 60 min at 95°C. After cooling, the 
samples were centrifuged at 3,000 rpm for 5 min and the supernatant of each sample 
was read at 532 nm against a reagent blank in a Beckman DU 640 spectrophotometer. 
The MDA values in the samples were calculated by using a standard absorption curve 
for MDA (1, 1,3, 3-tetra methoxy propane) (Liu et al, 1982). 
2.2.2.20 Assay of HMG-CoA reductase activity in liver homogenate 
Enzymatic activity of HMG-CoA reductase in liver homogenate was 
determined by an indirect method as reported earlier (Rao and Ramakrishnan, 1975). 
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HMG-CoA and mevalonate concentrations in the liver homogenate were estimated in 
terms of absorbances and the ratio between the two was taken as an index of activity 
of the enzyme. One ml of liver homogenate containing 0.1 % sodium arsenate was 
mixed with 1.0 ml of 5 % perchloric acid, kept for 5 min at room temperature, and 
centrifuged at 2,000 rpm for 10 min. One ml of the supernatant from each tube was 
taken out and mixed with 0.5 ml of freshly prepared 1 M aqueous hydroxylamine 
hydrochloride, whereas, for the assay of HMG-CoA, 0.5 ml of alkaline 
hydroxylamine hydrochloride were added and mixed. After an incubation of 5 min at 
room temperature, 1.5 ml of a 0.616 M ferric chloride reagent containing 5.2 % TCA, 
prepared in 0.65 N HCl was added, mixed and absorbance was read at 540 nm against 
a reagent blank in a Beckman DU 640 spectrophotometer after 10 min of incubation 
at room temperature. 
2.2.2.21 Activities of antioxidant enzymes 
2.2.2.21.1 Determination ofcatalase activity in erythrocytes and liver 
Enzymatic activity of catalase in erythrocytes hemolysate and post-
mitochondrial supernatant (PMS) of liver was carried out according to the procedure 
described by Sinha (1972). The reaction was carried out in a total volume of 1.0 ml 
containing 10 mM phosphate buffer, pH 7.0 and erythrocytes hemolysate equivalent 
to 49-148 |ag hemoglobin or 9-19 \xg of PMS protein. After a preincubation of 10 min 
at 30°C, the reaction was started by the addition of hydrogen peroxide resulting in a 
final concentration of 100 mM and the tubes were incubated for 5 or 10 min at SO'C. 
At the end of incubation, the reaction was terminated by the addition of 1.0 ml of 
potassium dichromate-acetic acid reagent, prepared by mixing 1 volume of 5 % 
aqueous solution of potassium dichromate wdth 3 volumes of glacial acetic acid. For 
zero time control, hydrogen peroxide was added after stopping the reaction. The tubes 
were heated in a boiling water bath for 15 min, cooled and the optical density was 
measured at 590 nm against a reagent blank in a Beckman DU 640 
spectrophotometer. Hepatic and erythrocytes catalase activity was calculated by using 
a standard hydrogen peroxide calibration curve. 
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2.2.2.21.2 Determination of superoxide dismutase activity in erythrocytes and liver 
Enzymatic activity of superoxide dismutase (SOD) in erythrocytes hemolysate 
and PMS fraction of liver was determined by the method as described by Kakkar et 
al. (1984). The assay mixture containing 52 mM sodium pyrrophospahte buffer, pH 
8.3, 300 |iM nitroblue tetrazoHum, 186 i^M phenazine methosulphate and 
erythrocytes hemolysate equivalent to 49-74 |ag hemoglobin or 899-944 |ig PMS 
protein was preincubated for 5 min at 30°C and the reaction was initiated by the 
addition of NADH (780 |iM), by incubating the samples for different time intervals at 
30°C. The reaction was stopped by the addition of 0.5 ml of glacial acetic acid at 1 
min time interval up to 4 min. For zero time control, to the above incubation mixture, 
0.5 ml of glacial acetic acid was added prior to the addition of NADH. To each tube 
including reagent blank 2.0 ml of n-butanol was added, rigorously extracted and 
centrifuged at 3,000 rpm for 5 min, color intensity of the chromogen in the butanol 
extract was measured at 560 nm against a reagent blank in a Beckman DU 640 
spectrophotometer. SOD activity was calculated in terms of an arbitrary unit, which is 
defined as the enzyme concentration required to inhibit the chromogen formation by 
50 % in one min under the above assay conditions. 
2.2.2.21.3 Determination of glutathione peroxidase activity in erythrocytes and liver 
Glutathione peroxidase (Gpx) activity in erythrocytes hemolysate and liver 
homogenate was assayed by a modification of Mill's procedure 2 (1959) as reported 
by Hafeman et al. (1974). The reaction mixture contained 80 mM sodiimi phosphate 
buffer, 80 \M EDTA, pH 7.0, 1 mM sodium azide, 400 |iM GSH and erythrocytes 
hemolysate equivalent to 25-74 \x% hemoglobin or 615-1529 \x.g of liver homogenate 
protein in a total volume of 0.5 ml reaction mixture. After a 5 min preincubation at 
37°C, the reaction was started by the addition of hydrogen peroxide (250 ^M) and the 
tubes were incubated for 2, 4, 6 and 8 mins at 37°C. At the indicated time intervals, 
the reaction was terminated by the addition of 0.5 ml 10 % TCA. The tubes were 
centrifuged at 3,000 rpm for 10 min and 0.5 ml supernatant from each tube was added 
to tubes containing 2.0 ml of 0.4 M sodium phosphate buffer, 0.4 mM EDTA, pH 7.0 
and 0.5 ml of 1 mM 5, 5'-dithiobis(2-nitrobezoic acid, DTNB). The samples were 
mixed and optical density was recorded at 412 nm against a reagent blank within 2 
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min of DTNB addition in a Beckman DU 640 spectrophotometer. The erythrocytes 
and liver glutathione peroxidase activity was calculated after deducting the OD value 
of samples from the zero time control values by utilizing a standard glutathione. 
2.2 2.21.4 Assay of glutathione reductase activity in erythrocytes and liver 
Glutathione reductase (Gred) activity was determined by the method of 
Carlberg and Mannervik (1975). The incubation mixture consisted of 82.5 mM 
sodium phosphate buffer containing 25 \xM EDTA, pH 7.6, 25 |iM oxidized 
glutathione and erythrocytes hemolysate equivalent to 25-74 |ig hemoglobin or 899-
944 \ig of PMS protein. After a 5 min preincubation at 25°C, the reaction was started 
by the addition of NADPH (5 |iM) and the tubes were incubated for 1-4 min at 25°C. 
The reaction was terminated at 1 min time interval by incubating the samples in an 
ice-bath. Zero time control tubes were prepared as above except 5 \xM. NADPH was 
added after stopping the reaction. The absorbance of each sample was recorded at 340 
run against a reagent blank in a Beckman DU 640 spectrophotometer. By using the 
zero time control value the enzyme activity was calculated on the basis of a molar 
extinction coefficient of NADPH (6.22 x 10' M' cm''). 
2.2.2.21.5 Determination of glutathione-S-transferase activity in liver 
The enzymatic activity of glutathione-S-transferase (GST) in liver PMS 
fraction was carried out according to the procedure of Habig et al. (1974). The assay 
was carried out in a total volume of 1.0 ml containing 100 mM potassium phosphate 
buffer, pH 6.5, 1 mM GSH and 252-472 ^g PMS protein. The samples were 
preincubated for 10 min at 30°C, the reaction was started by the addition of 1-chloro 
2, 4-dinitrobenzene (CDNB) prepared in absolute ethanol (ImM) followed by an 
incubation for 2 and 4 min at 30°C. At the end of incubation the tubes were placed in 
an ice-bath for 15 min, after which the optical density was recorded at 340 nm against 
a reagent blank in a Beckman DU 640 spectrophotometer. The GST activity was 
calculated on the basis of molar extinction coefficient of CDNB (9.6 x 10" M"' cm'') 
after an appropriate deduction of zero time control values. 
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2.2.2.22 Determination of total, free and protein-bound -sulfhydryl content of 
glutathione in liver 
The total sulfhydryl content of glutathione in liver homogenate was 
determined by the method of Ellman (1959) as modified by Sedlak and Lindsay 
(1968). The incubation mixture contained 60 mM tris buffer and 6 mM EDTA, pH 
8.2, 1.23-3.06 mg protein and 0.2 mM DTNB. The reaction mixture was mixed and 
made up to 5.0 ml by the addition of 3.2 ml absolute methanol. The tubes were 
centrifuged at 6,000 rpm for 5 min at 4°C and the absorbance of the clear supematants 
were read at 412 nm against a reagent blank in a Beckman DU 640 
spectrophotometer. The total glutathione content was calculated by using a standard 
curve of reduced glutathione. 
For the determination of free sulfhydryl group of glutathione content in liver 
homogenate, the method of Ellman (1959) as modified by Sedlak and Lindsay (1968) 
was employed. In order to assay free sulfhydryl content of glutathione, 0.5 ml of 10 
% homogenate was precipitated by the addition of 0.5 ml of 4 % sulphosalicylic acid 
(Jollow et al., 1974). The samples were incubated for 1 h at 4°C, centrifuged at 6,000 
rpm for 5 min and 0.5 ml aliquots of the supernatant were used for the assay of free 
sulfhydryl group. The reaction mixture contained 267 mM tris buffer, 13 mM EDTA, 
pH 8.9 and 0.33 mM DTNB (prepared in absolute methanol). The absorbance of the 
sample was read against a reagent blank at 412 nm within 2 minutes of DTNB 
addition. Free sulfhydryl content in the samples were calculated using a standard 
calibration curve of reduced glutathione. The protein bound sulfhydryl content of 
glutathione was calculated as the difference between total and free sulfhydryl content 
of glutathione. 
Free sulfhydryl group of glutathione content in packed erythrocytes was 
determined essentially by the method of Ellman (1959) as modified by Sedlak and 
Lindsay (1968). Briefly, to 100 and 200 ^1 of washed packed erythrocytes, 1.0 ml of 
10 % TCA was added, mixed and incubated for 1 h at 4°C. At the end of incubation, 
the tubes were centrifuged at 1,200 rpm for 20 min at 4°C and 0.5 ml of the 
supernatant was used for the quantification of free sulfhydryl group. The free 
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sulfhydryl group of erythrocytes was determined according to the procedures 
described above for Uver homogenate, except 1.7 mM DTNB was used. 
2.2.2.23 Protein estimation 
The protein was determined by the method of Bradford (1976), using bovine 
serum albumin as standard. Aliquots of liver and kidney homogenates, PMS, LDL, 
sd-LDL, Ib-LDL, HDL, HDL2 and HDL3 were first precipitated with 10 % TCA. The 
protein pellets were dissolved in 0.5 N NaOH and suitable aliquots were used for 
protein determination. 
2.2.2.24 Histopathological studies 
For histopathological studies related to nephropathy and retinopathy, a portion 
of kidney and whole eyeball were used. For microscopic preparation of the above 
tissues, method of Disbrey and Rach (1970) was used. Two formalin fixed samples 
from each tissue were embedded in paraffin and sectioned after block preparation. 
The sections were double-stained with Ehrlich's hematoxylin, eosin, studied 
microscopically and photographs were taken. 
2.2.2.25 Statistical evaluation 
Statistical analysis of data was done by employing two-tailed Student t- test as 
described by Bennet and Franklin (1967). P values less than 0.05 were considered 
significant. 
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3.1 Antioxidative Activities of Tocomin, a-TocotrienoI, y-Tocotrienol, 
8-Tocotrienol, a-TocopheroI, and Lovastatin 
Antiradical activity or hydrogen donating ability of Tocomin, a-tocotrienol, y-
tocotrienol, 5-tocotrienol, a-tocopherol and Lovastatin was measured by using DPPH, 
which reflects the antioxidative properties of these compoimds. As shown in Fig. 3.1, 
the half quenching concentrations (IC50) were as follows: Tocomin, 49.95 |iM; a-
tocotrfenof, 46.46 \xM; y-tocotrienol, 47.43 |iM; 5-tocotrienoI, 37.62 |iM; and a-
tocopherol, 71.22 i^M. These findings indicate that as compared to a-tocopherol, y-, a-
and S-tocotrienols were more efficient scavengers of peroxyl radicals by 33 %, 34 % 
and 47 %, respectively. Since Tocomin is a mixture of a-tocotrienol (25.6 %), y-
tocotrienol (40.8 %), 5-tocotrienol (12.8 %) and a-tocopherol (22.8 %), its efficiency as 
a scavenger of peroxyl radical was higher by 30 %, in comparison to a-tocopherol. The 
reduction in the quenching efficiency of Tocomin in comparison to a-, y- and 5-
tocotrienols is apparently due to the presence of 23 % a-tocopherol, which has a lowest 
peroxyl radical scavenging efficiency of 71.22 jiM. Under the above experimental 
conditions, used for Tocomin and different tocotrienols including a-tocopherol, 10 min 
incubation of 5-100 \xM of Lovastatin did not exhibit any DPPH radical scavenging 
activity (data not shown). 
3.2 Average Body Weight and Plasma Glucose Levels of Normal and Diabetic 
Rats after 12 Days of Streptozotocin Injection 
As shown in Table 1, after 12 days of STZ (60 mg/kg) injection, the average 
body weight of diabetic rats assigned to diabetic control (D-C), diabetic Tocomin 
treated (D-TT) and diabetic Lovastatin treated (D-LT) groups was 189, 200 and 189 
g, respectively, whereas, for N-C rats the average body weight was 248 g. The 
average fasting plasma glucose levels in D-C, D-TT and D-LT were 274, 236 and 264 
mg/dl, respectively. In comparison to a control plasma glucose value of 99.2 mg/dl, 
the glucose levels of D-C, D-TT and D-LT rats were significantly increased by 177 
%, 138 % and 166 %, respectively. These results demonstrate that 12 days after a 
single injection of STZ to rats was associated with an induction of diabetes. 
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Fig. 3.1. Free radical scavenging activities of Tocomin, a-tocotrienol, y-tocotrienol, 5-
tocotrienol and a-tocopherol. The antioxidant activities of the above 
compounds at the indicated concentrations were carried out as described in 
methods. The assay is based on the reduction of 2, 2-diphenyl, 1-picryl-
hydrazyl (DPPH), which gives strong absorption maxima at 517 nm. Values 
represent the mean of triplicate determinations. The average error in the data 
points in these assay were mean ± less than 2 %. The average absolute 
absorbance value of 100 % DPPH activity was 0.00783 + 0.00028. 
TABLE 1 
AVERAGE BODY WEIGHT AND PLASMA GLUCOSE LEVELS OF 
NORMAL AND STZ-INDUCED DIABETIC RATS 
Group 
N-C 
DC 
D-TT 
D-LT 
Body Weight 
(g) 
247.5±20.4* 
188.8±12.5* 
200.0±17.3^ 
189.3±21.9^ 
Glucose 
(mg/dl) 
99.2±8.8* 
274.3±52.7* 
(+176.5 %)" 
235.6±58.9^ 
(+137.5 %)" 
263.6+62.4^ 
(+165.7 %)" 
Values are mean ± SD from 8 rats each in N-C and D-C. 
^ Values are mean ± SD from 7 rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, diabetic Tocomin treated and 
D-LT, diabetic Lovastatin treated. 
Significantly different from N-C at *p<0.05. 
3.3 Impact of Tocomin and Lovastatin on Plasma Glucose, Hemoglobin and 
Glycosylated Hemoglobin in Diabetic Rats Treated for 14 Weeks 
Data presented in Table 2, indicate the average body weight, fasting plasma 
glucose, hemoglobin (Hb) and its glycosylated form (HbAi). After 14 weeks, there was 
no significant change in body weight of diabetic (D-C), Tocomin treated (D-TT) or 
Lovastatin treated (D-LT) rats, in comparison to their initial body weight, whereas, the 
average body weight of rats in N-C group showed a significant gain of 56 % after 14 
weeks. At the end of experiment (14 weeks) plasma glucose level in D-C group was 
further increased from an initial value of 274 mg/dl to 329 mg/dl (Table 1). On the other 
hand, the plasma glucose levels were significantly reduced in D-TT and D-LT in 
comparison to D-C after 14 weeks of Tocomin or Lovastatin treatment. In both the 
groups, Tocomin and Lovastatin mediated a decrease of glucose level fi"om 329 mg/dl 
in D-C to 92 and 96 mg/dl, respectively, which are similar to glucose value of N-C 
group. As expected, after 14 weeks, hemoglobin level in D-C rats was significantly 
reduced (34 %) in comparison to normal rats in N-C. However, a highly significant 
increase in Hb concentration was observed in diabetic rats treated with Tocomin (39 %) 
or Lovastatin (45 %) for 14 weeks when compared to D-C rats. Both Tocomin and 
Lovastatin administration to diabetic rats mediated an increase in Hb levels close to 
normal value. Glycosylated hemoglobin levels, an index of the mean blood glucose 
level for the preceding 2-3 months, was significantly increased by 179 % in D-C rats 
when compared to a value of 3.16 mg/dl of N-C rats. After 14 weeks of Tocomin or 
Lovastatin treatment, the mean HbA| level was significantly increased to 4.88 mg/dl (45 
%) and 3.88 mg/dl (56 %), respectively, which is similar to a control value of 3.16 
mg/dl in N-C. These results demonstrate that both Tocomin and Lovastatin act as a 
potent hypoglycemic agent in diabetic rats. 
3.4 Impact of Tocomin and Lovastatin on Plasma Lipids, Plasma Lipoprotein 
Lipids, Hepatic HMG-CoA Reductase Activity, Lipid Peroxidation Status in 
Plasma, Liver, Kidney, Erythrocytes and Erythrocytes Membrane Bound 
ATPase Activities in Diabetic-Hyperlipidemic Rats Treated for 14 Weeks 
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TABLE 2 
IMPACT OF TOCOMIN AND LOVASTATIN ON BODY WEIGHT, PLASMA 
GLUCOSE, BLOOD HEMOGLOBIN AND ITS GLYCOSYLATED FORM IN 
DIABETIC RATS AFTER 14 WEEKS OF TREATMENT 
Group 
N-C 
D C 
D-TT 
D-LT 
Body Weight 
(g) 
385.7±22.9* 
205.0+17.3" 
195.0±25.0^ 
190.0±2.7^ 
Glucose 
(mg/dl) 
82.517.2 
329.3±32.1 
(+299.3 %)* 
91.6±16.4 
(-72.2 %)* 
95.6±14.6 
(-71.0 % ) ' 
Hemoglobin 
(g/dl) 
14.80±0.09 
9.84±0.17 
(-33.5 %)" 
13.7110.14 
(+39.3 %)" 
14.3010.07 
(+45.3 % ) ' 
HbA, 
(mg/dl) 
3.1610.05 
8.8210.68 
(+179.1 %)" 
4.8810.04 
(-44.70 %)• 
3.8810.05 
(-56.0 %)" 
Values are mean 1 SD from 7 rats in N-C. 
Values are mean 1 SD from 4 rats in D-C. 
^ Values are mean 1 SD from 5 rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/day and 
D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at V<0.001 and ''p<0.05. 
Significantly different from D-C at ''p<0.001. 
3.4.1 Effect on plasma lipids 
Experimental diabetes induced in rats by STZ had a profound impact on the 
lipid parameters when compared to normal rats. As shown in Table 3, triglycerides, 
total cholesterol and non-HDL-cholesterol increased from 92, 140 and 114 mg/dl in N-
C to 162, 247 and 182 mg/dl, respectively, in D-C. After 14 weeks of Tocomin 
treatment, levels of triglyceride, total cholesterol and non-HDL-cholesterol were 
decreased to 117 mg/dl (28 %), 177 mg/dl (28 %) and 138 mg/dl (24 %), respectively, 
when compared to corresponding D-C values. Whereas, in Lovastatin treated rats, 
triglyceride, total cholesterol and non-HDL-cholesterol levels were significantly 
reduced by 35 %, 35 % and 38 %, respectively, in comparison to values of these 
parameters in D-C group. These results demonstrate that feeding of 6 mg 
Tocomin/rat/day for 14 weeks was associated with a significant reduction in lipid 
parameters; whereas, administration of 0.50 mg Lovastatin/rat/day for 14 weeks was 
more effective in reducing the above lipid parameters, particularly non-HDL-
cholesterol level. 
3.4.2 Effect on plasma lipoprotein lipids 
As seen in Table 4, all the plasma lipoprotein lipids were significantly 
increased in diabetic (D-C) rats, when compared to N-C values. VLDL-C, LDL-C, 
HDL-C, HDL2-C and HDL3-C levels were increased from 18, 99, 34, 9 and 23 mg/dl 
in N-C to 32 mg/dl (76 %), 172 mg/dl (74 %), 64 mg/dl (91 %), 20 mg/dl (112 %) 
and 44 mg/dl (97 %), respectively, in D-C. After 14 weeks of Tocomin or Lovastatin 
treatment, both VLDL-C and LDL-C levels showed a significant reduction of 28 % in 
D-TT, whereas, in D-LT, both VLDL-C and LDL-C were equally reduced by 35 %, 
in comparison to values in D-C rats. In comparison to D-C group, the decline in 
HDL-C, HDL2-C and HDL3-C was 41 %, 36 % and 45 % (p<0.001), respectively, in 
D-TT. Similarly, HDL-C, HDL2-C and HDL3-C levels showed a significant reduction 
of 32 %, 37 % and 31 %, respectively, in D-LT. It is interesting to note that the 
decline in HDL-C and HDL3-C mediated by Tocomin was significantly higher than 
the decline registered in Lovastatin treated rats. These results demonstrate that the 
decline in total cholesterol after 14 weeks of Tocomin or Lovastatin treatment was 
due to a significant decrease in VLDL-C, LDL-C and HDL-C levels. 
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TABLE 3 
IMPACT OF TOCOMIN AND LOVASTATIN ON PLASMA 
TRIGLYCERIDES, TOTAL CHOLESTEROL AND NON-HDL-
CHOLESTEROL OF DIABETIC-HYPERLIPIDEMIC RATS AFTER 
14 WEEKS OF TREATMENT 
Group 
N-C 
D C 
D-TT 
D-LT 
Triglycerides 
92.115.1* 
162.0+2.0** 
(+75.9%)" 
117.1±1.7^ 
(-27.7 % ) ' 
104.7±2.0* 
(-35.4 %f 
Total Cholesterol 
139.9±10.0 
246.5±3.1 
(+76.2%)' 
176.713.2 
(-28.3%)" 
159.313.6 
(-35.4%)" 
Non-HDL-chloesterolf 
113.617.4 
182.413.3 
(+60.5 %)" 
137.913.8 
(-24.4 %)" 
114.013.8 
(-37.5 %)" 
t For the calculation of non-HDL-cholesterol, data is taken from Table 3 and 4. 
* Values are mean (mg/dl) 1SD from plasma of 7 rats in N-C. 
Values are mean (mg/dl) 1 SD from plasma of 4 rats in D-C. 
^ Values are mean (mg/dl) 1 SD from plasma of 5 rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/ rat/ day and 
D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at "p<0.001. 
Significantly different from D-C at "p<0.001. 
TABLE 4 
EFFECT OF TOCOMIN AND LOVASTATIN ON PLASMA VLDL-C, LDL-C, HDL-
C, HDL2-C AND HDL3-C IN DIABETIC-HYPERLIPIDEMIC RATS AFTER 
14 WEEKS OF TREATMENT 
Parameters N-C D-C D-TT D-LT 
VLDL-cholesterol 18.42±1.01* 32.39±0.40" 23.41±0.34^ 20.94±0.41^ 
(+76.0 %) ' (-27.7 % ) ' (-35.4 %)* 
LDL-cholesterol 98.93±5.96 172.14±L54 123.84±L90 in.20±L35 
(+74.0 %)" (-28.0 %)* (-35.4 %)* 
HDL-cholesterol 33.64±0.82 64.30±0.70 38.15±L24 43.86±0.98 
(+9L1%)'' (-40.7%)' (-3L8%)'' 
HDLz-cholesteroI 9.32+0.40 19.76±0.58 12.62±0.65 12.36±0.35 
(+112.0%)* (-36.1%)* (-37.4%)* 
HDLj-cholesterol 22.49±0.52 44.30±0.88 24.23±0.56 30.77±0.43 
(+97.0 %)* (-45.3 %)* (-30.5 %) a 
Values are mean (mg/dl) ± SD from pooled plasma of 7 rats in N-C. 
Values are mean (mg/dl) ± SD from pooled plasma of 4 rats in D-C. 
^ Values are mean (mg/dl) ± SD from pooled plasma of 5 rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/ day and 
D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at *p<0.001. 
Significantly different from D-C at *p<0.001. 
3.4.3 Effect on plasma small dense LDL and large buoyant LDL fractions ofLDL 
Table 5 shows levels of plasma small dense low density lipoprotein-
cholesterol (sd-LDL-C), sd-LDL-apoB, large buoyant low density lipoprotein-
cholesterol (Ib-LDL-C) and Ib-LDL-apoB fractionated from LDL. In normal rats, 
LDL-C and its apoB content were 99 and 134 mg/dl, respectively. The cholesterol 
and apoB content of sd-LDL isolated from LDL particle, was 32 and 36 mg/dl, 
respectively, whereas, cholesterol and apoB concentrations associated with Ib-LDL 
were 65 and 91 mg/dl. In comparison to control values, diabetic-hyperlipidemic rats, 
showed an increase in plasma LDL-C from 99 to 172 mg/dl (74 %) and LDL-apoB 
content from 134 to 149 mg/dl (11 %), whereas sd-LDL-C was increased from 32 
to 109 mg/dl (245 %) and its apoB content was increased from 36 to 92 mg/dl (154 
%). In contrast, no change in Ib-LDL-C level in D-C was observed when compared to 
N-C value, whereas, apoB content of Ib-LDL in D-C registered a significant decline 
of 40 % in comparison to N-C value. Following 14 weeks of Tocomin or Lovastatin 
treatment to diabetic rats, cholesterol level of LDL was reduced by 28 % and 36 %, 
respectively. Whereas, LDL-apoB content was reduced by 9 % in D-TT and 16 % in 
D-LT. These values are very similar to the LDL-apoB content of N-C (134 mg/dl). 
The cholesterol and apoB associated with sd-LDL decreased from 109 and 92 mg/dl 
to 52 mg/dl (53 %) and 52 mg/dl (44 %), respectively, in D-TT, whereas, sd-LDL-C 
and its apoB content in D-LT was reduced to 48 mg/dl (56 %) and 55 mg/dl (41 %), 
respectively. On the other hand, the cholesterol level of Ib-LDL fraction in both the 
treated groups was 70 and 61 mg/dl, which is similar to a value of 65 mg/dl of D-C 
and N-C groups. As indicated above, apoB associated with Ib-LDL fraction was 
reduced from a N-C value of 91 to 55 mg/dl in D-C, whereas, a significant increase of 
81 mg/dl (47 %) and 71 mg/dl (29 %) was registered after 14 weeks of Tocomin or 
Lovastatin treatment (Table 5). 
In normolipidemic rats, the percent wise distribution of cholesterol and apoB 
from LDL particle to sd-LDL and Ib-LDL fractions were 32 %, 27 %, 66 % and 68 
%, respectively. In diabetic-hyperlipidemic rats the percent sd-LDL-C and sd-LDL-
apoB was significantly increased by 98 % and 128 %, when compared to the 
corresponding percent values from normal rats. Similarly, the percent Ib-LDL-C and 
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TABLE 5 
IMPACT OF TOCOMIN AND LOVASTATIN ON PLASMA SMALL DENSE 
LDL AND LARGE BUOYANT LDL FRACTIONS OF LDL IN DIABETIC-
HYPERLIPIDEMIC RATS AFTER 14 WEEKS OF TREATMENT 
Parameters N ^ D^C D-TT D-LT 
LDL-C 98.93±5.92* 172.4011.54** 123.84±1.90^ 111.20±1.35* 
(+74.3 %)" (-28.2 %)" (-35.5 %)" 
LDL-apoB ]33.64±9.44 148.80±1.60 135.20±1.70 124.50±2.00 
(+11.3 %)*" (-9.1 %)" (-16.3 % ) ' 
Sd-LDL-C 31.55±1.84 108.77±0.61 51.46+0.82 47.94±0.62 
(+244.8 %)* (-52.7 %)" (-55.9 %)* 
% LDL-C 31.8910.82 63.0210.31 41.5511.27 43.0710.46 
(+97.6 %)" (-34.1 %)" (-31.7 %)" 
Sd-LDL-apoB 36.4015.59 92.3813.70 51.8312.30 54.7611.50 
(+153.8 %)" (-43.9 %)" (-40.7 %)" 
% LDL-apoB 27.2312.92 62.0810.93 38.31l0.72 44.0110.39 
(+128.0 %)" (-38.2 %)" (-29.1 %)" 
Lb-LDL-C 65.2412.00 65.29l0.49 70.0010.58 60.7910.63 
(+0.07 % ) ' (+7.2 %)" (-6.9 %)" 
% LDL-C 65.9011.79 37.9410.35 56.5410.50 54.6711.03 
(-42.5 %)* (+49.0 %)" (+44.0 %)" 
Lb-LDL-apoB 91.1617.10 54.6412.60 80.48l2.60 70.6611.90 
(-40.1 %)" (+47.3 %)" (+29.3 %)* 
% LDL-apoB 68.2411.12 36.7211.41 59.5411.57 56.7811.21 
(-46.2 %)" (+62.1 %f (+54.6 %)" 
* Values are mean (mg/dl) 1SD from pooled plasma of 7 rats in N-C. 
"Values are mean (mg/dl) 1 SD from pooled plasma of 4 rats in D-C. 
^ Values are mean (mg/dl) 1 SD from pooled plasma of 5 rats each in D-TT and 
D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/day and 
D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at ^p<0.001, ''p<0.05 and ""not significant. 
Significantly different from D-C at ''p<0.001. 
Ib-LDL-apoB in D-C rats was increased by 43 % and 46 %, in comparison to 
corresponding percent values of N-C rats. The percent increase in sd-LDL-C and sd-
LDL-apoB registered in diabetic rats was significantly reduced by 29-38 % after 14 
weeks of Tocomin or Lovastatin treatment. In contrast, percent Ib-LDL-C and Ib-
LDL-apoB in both the treated groups was significantly increased by 44-62 %, when 
compared to the corresponding percent values of diabetic-hyperlipidemic rats. These 
results demonstrate that a homogeneous preparation of sd-LDL and Ib-LDL can be 
obtained by employing heparin-Mg^-mediated precipitation of purified plasma LDL. 
In addition, the results also show that the prevalence and concentration of sd-LDL, 
which is considered more atherogenic than LDL, was substantially increased in 
diabetic-hyperlipidemic rats. In diabetic-hyperlipidemic rats treated with Tocomin or 
Lovastatin for 14 weeks, the sd-LDL concentration was significantly reduced to a 
level similar to control value (N-C). 
3.4.4 Impact on the ratios ofHDL-C/TC, HDL-C/LDL-Q TC/HDL-C, LDL-C/HDL-
C, HDL-C/sd-LDL-C, and sd-LDL-C/HDL-C 
Table 6 represents different ratios calculated from the data presented in Table 3, 
4 and 5. Since total cholesterol, LDL-C, and HDL-C levels were significantly increased 
in D-C and differentially decreased following treatment of diabetic-hyperlipidemic rats 
with Tocomin or Lovastatin, no consistent pattern in HDL-C/TC, HDL-C/LDL-C, 
TC/HDL-C and LDL-C/HDL-C ratios was obtained. However, in D-LT, HDL-C/TC 
and HDL-C/LDL-C, ratios were positively increased, whereas TC/HDL-C and LDL-
C/HDL-C ratios were significantly decreased when compared to the corresponding 
ratios in N-C. In N-C, when HDL-C values were divided by sd-LDL-C, a ratio of 1.063 
was obtained, which is strikingly higher than HDL-C/LDL-C ratio of 0.339. In diabetic-
hyperlipidemic rats, HDL-C/sd-LDL-C ratio was decreased by 44 % in comparison to 
N-C value. As expected, in D-TT and D-LT rats, HDL-C/sd-LDL-C ratio was 
significantly increased by 25 % and 55 %, respectively, when compared to the 
corresponding ratio in N-C. Similarly, in N-C, sd-LDL-C/HDL-C ratio of 0.940 was 
significantly lower than a ratio of 2.943 of LDL-C/HDL-C, which was significantly 
increased to 3.692 (m %) in D-C group. Sd-LDL-C/HDL-C ratio in D-TT and D-LT 
groups were significantly reduced by 20 % and 36 %, when compared to the 
108 
TABLE 6 
IMPACT OF TOCOMIN AND LOVASTATIN ON THE RATIOS OF HDL-C/TC, 
HDL-C/LDL-C, TC/HDL-C, LDL-C/HDL-C, HDL-C/Sd-LDL-C AND Sd-LDL-
C/HDL-C IN DIABETIC-HYPERLIPIDEMIC RATS AFTER 14 WEEKS OF 
TREATMENT 
Group 
Ratiof 
N-C D-C D-TT D-LT 
HDL-C/TC 0.240±0.011 0.261±0.002 
(+8.8 %)" 
HDL-C/LDL-C 0.339±0.015 0.374±0.002 
TC/HDL-C 
(+10.3 %)" 
4.16310.197 3.83±0.04 
(-7.9 %)" 
LDL-C/HDL-C 2.943±0.140 2.676±0.015 
(-9.1 %)" 
HDL-C/Sd-LDL-C 1.063±0.025 0.591±0.002 
(-44.4 %)" 
Sd-LDL-C/HDL-C 0.940±0.023 1.692±0.005 
(+80.0 %)" 
0.216±0.008^ 
(-11.2 %)" 
0.308±0.008 
(-17.6 %)" 
4.625±0.18 
(+20.8 %)" 
3.240±0.093 
(+21.1 %)" 
0.741±0.030 
(+25.4 %)" 
1.348±0.053 
(-20.3 %)" 
0.27610.010^ 
(+5.7 %)" 
0.39410.013 
(+5.3 %)" 
3.62810.14 
(-5.3 %)•' 
2.53310.085 
(-5.3 %)" 
0.91610.022 
(+55.0 %)" 
1.0910.026 
(-35.5 %)'' 
t For the calculation of ratios, data is taken from Table 3,4 and 5. 
Values are mean + SD from pooled plasma of 7 rats in N-C. 
Values are mean 1 SD from pooled plasma of 4 rats in D-C. 
^ Values are mean 1 SD from pooled plasma of 5 rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/day and 
D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at ''p<0.001. 
Significantly different from D-C at ''p<0.001 and ''p<0.05. 
corresponding ratios of N-C rats. These results indicate that HDL-C/sd-LDL-C and sd-
LDL-C/HDL-C ratios, which may be considered as a better and novel predictor for 
CAD risks than HDL-C/LDL-C and LDL-C/HDL-C ratios. The ratios related to sd-
LDL-C and HDL-C in Tocomin or Lovastatin treated rats were positively modulated, 
indicating normalization of cholesterol levels. 
3.4.5 Hypolipidemic impact on liver triglycerides and total cholesterol 
As shown in Table 7, both triglyceride and total cholesterol levels were 
increased in diabetic-hyperlipidemic rats by 61 % and 26 %, respectively, when 
compared to corresponding values in N-C. Feeding of Tocomin or Lovastatin to 
diabetic rats for 14 weeks was associated with a significant decline in hepatic TG levels 
by 19 % and 16 % respectively, whereas TC levels were reduced by 14 % in D-TT and 
15 % D-LT groups. These results demonstrate that like plasma TG and TC', liver TG 
and TC were increased to a higher level in diabetic rats. In addition, feeding of Tocomin 
or Lovastatin to diabetic rats resulted in a significant decline of both TG and TC to a 
level similar to values in N-C. These results demonstrate that increased levels of plasma 
and hepatic lipids as well as plasma lipoprotein lipids in diabetic rats were significantly 
reduced to a level similar to normal values, following 14-week treatment of 6 mg 
Tocomin/rat/day or 0.50 mg Lovastatin/rat/day. 
3.4.6 Regulation of enzymatic activity of hepatic HMG-CoA redctase 
As seen in Table 8, hepatic HMG-CoA reductase activity in diabetic-
hyperlipidemic rats was significantly reduced by 57 % when compared to N-C value. In 
comparison to HMG-CoA reducatse activity in D-C, feeding of Tocomin or Lovastatin 
to rats resulted in a significant increase of 30 % and 35 %, respectively. These results 
demonstrate that apparently due to insulin deficiency in STZ-induced diabetic rats, 
hepatic HMG-CoA reductase activity is significantly reduced. In addition, treatment of 
diabetic-hyperlipidemic rats with Tocomin or Lovastatin for 14 weeks was associated 
with an increase in HMG-CoA reductase activity to a level similar to N-C value. This 
increase in HMG-CoA reductase activity in D-TT and D-LT rats may be due to 
restoration of insulin levels. 
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TABLE 7 
IMPACT OF TOCOMIN AND LOVASTATIN ON HEPATIC 
TRIGLYCERIDES AND TOTAL CHOLESTEROL IN DIABETIC -
HYPERLIPIDEMIC RATS AFTER 14 WEEKS OF TREATMENT 
Group Triglycerides Total cholesterol 
N-C 0.70±0.010* 2.70±0.04 
D-C L13±0.013" 3.40±0.08 
(+61.4 %) ' (+25.9 %)" 
D-TT 0.92±0.012^ 2.90±0.05 
(-18.6 %f (-14.1 %)" 
D-LT 0.95±0.018^ 2.90+0.06 
(-15.9 %)" (-14.7 %f 
Values are mean (mg/100 mg protein) ± SD from pooled liver homogenate of 
7 rats in N-C. 
Values are mean (mg/100 mg protein) ± SD from pooled liver homogenate of 
4 rats in D- C. 
Values are mean (mg/100 mg protein) ± SD from pooled liver homogenate of 
5 rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/day 
and D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at '•p<0.001. 
Significantly different from D-C at *p<0.001. 
TABLE 8 
IN VIVO MODULATION OF HEPATIC HMG-CoA REDUCATSE ACTIVITY 
IN DIABETIC-HYPERLIPIDEMIC RATS TREATED WITH TOCOMIN OR 
LOVASTATIN FOR 14 WEEKS 
Group HMG-CoA reductase activityf 
N-C 4.58±0.44* 
D-C 7.2110.68** 
(-57.4 %)" 
D-TT 5.0510.23^ 
(+30.0 %)" 
D-LT 4.66±0.25^ 
(+35.4 %)" 
t Expressed as ratio of HMG-CoA to Mevelonate; lower the ratio higher the 
enzyme activity. 
Values are mean ± SD from pooled liver homogenate of 7 rats in N-C. 
Values are mean ± SD from pooled liver homogenate of 4 rats in D-C. 
^ Values are mean ± SD from pooled liver homogenate of 5 rats each in D-TT and 
D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/day 
and D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at ''p<0.001. 
Significantly different from D-C at ''p<0.001. 
3.4.7 Impact on plasma total antioxidants and lipidperoxiadtion products 
The data summarized in Table 9 demonstrate the antioxidant impact of Tocomin 
or Lovastatin on plasma concentrations of total antioxidants, conjugated dienes, lipid 
hydroperoxides and TBARS in diabetic-hyperlipidemic rats. Fourteen weeks after 
induction of diabetes in rats, total plasma antioxidant levels was reduced from a control 
value of 50 to 37 (27 %) [xmole/dl. Treatment of diabetic-hyperlipidemic rats with 
Tocomin or Lovastatin for 14 weeks resulted in an increase of total antioxidant levels 
by 95 % and 59 %, which is significantly higher than values in N-C. The oxidative 
stress induced by diabetes significantly enhanced plasma lipid peroxidation products, 
such as conjugated dienes, hydoperoxides and malondialdehydes (TBARS). Formation 
of conjugated dienes, hydroperoxides and TBARS in plasma was increased from 9.44, 
1.18 and 1.44 in N-C to 13.72 (45 %), 1.99 (68 %) and 2.90 (100 %) ^mole/dl, 
respectively, in D-C. A significant decrease of 19 %, 25 % and 25 % was seen in the 
formation of conjugated dienes, hydroperoxides and TBARS, respectively, in D-TT, 
when compared to D-C rats. Similarly in D-LT, conjugated dienes, hydroperoxides and 
TBARS in plasma were also markedly decreased by 16 %, 17 % and 33 %, 
respectively, in D-LT, when compared to D-C rats. These results demonstrate that both 
Tocomin and Lovastatin act as a potent antioxidant in diabetic-hyperlipidemic rats. In 
addition, the results also show that the feeding of Tocomin or Lovastatin to diabetic 
rats, has contributed a substantial and significant increase in plasma total antioxidant 
levels, which is higher than N-C values. 
3.4.8 Effect on membrane lipid peroxidation in erythrocytes 
Since diabetic erythrocytes exhibit membrane lipid peroxidative damage in vivo, 
we have examined the cause of this membrane damage by quantifying an end product 
of fatty acid peroxidation, namely, malondialdehyde. As depicted in Table 10, 
erythrocytes from D-C group showed a greater susceptibility to hydrogen peroxide-
induced lipid peroxidation than those from N-C group. A significant increase of 117 % 
in the release of MDA in D-C was observed, when compared to N-C value. Fonnation 
of MDA was markedly decreased by 64 % and 48 % after the administration of 
Tocomin or Lovastatin for 14 weeks, when compared to the value in D-C. Similarly, 
malondialdehyde content of erythrocytes hemolysate was increased from 6.88 in N-C to 
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TABLE 9 
IMPACT OF TOCOMIN AND LOVASTATIN ON PLASMA TOTAL 
ANTIOXIDANTS, CONJUGATED DIENES, LIPID HYDROPEROXIDES AND 
THIOBARBITURIC ACID REACTIVE SUBSTANCES IN DIABETIC-
HYPERLIPIDEMIC RATS AFTER 14 WEEKS OF TREATMENT 
Group Total antioxidants Conjugated dienes Lipid hydroperoxides TBARS 
N-C 50.35±L30 9.44±0.55 L184±0.052 1.447±0.102 
DC 
D-TT 
D-LT 
37.031L04 
(-26.5 %)* 
72.17±2.48^ 
(+94.9 %f 
58.74±1.24^ 
(+58.6 %)" 
13.72±0.81 
(+45.3 %)" 
11.07±0.42 
(-19.3 %)* 
11.60±0.68 
(-15.5 %)" 
1.994±0.099 
(+68.4 %)" 
1.497±0.027 
(-24.9 %)" 
1.648±0.041 
(-17.4 %)" 
2.900±0.075 
(+100.4 %) ' 
2.173±0.090 
(-25.1 %)* 
1.943±0.075 
(-33.0 %)• 
Values are mean (^moIe/dl) ± SD from pooled plasma of 7 rats in N-C. 
Values are mean (^mole/dl) ± SD from pooled plasma of 4 individual rats in D-C. 
^Values are mean (^mole/dl) + SD from pooled plasma of 5 rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/day and D-LT, 
given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at *p<0.001. 
Significantly different from D-C at 'p<0.001 and ''p<0.05. 
TABLE 10 
IMPACT OF TOCOMIN AND LOVASTATIN ON IN VITRO 
ERYTHROCYTES MDA RELEASE AND THIOBARBITURIC ACID 
REACTIVE SUBSTANCES IN DIABETIC-HYPERLIPIDEMIC RATS 
AFTER 14 WEEKS OF TREATMENT 
Group Erythrocytes MDA release 
(percent) 
TEARS 
(nmole/g Hb) 
N-C 25.42±0.99 6.88±0.43 
D-C 
D-TT 
D-LT 
55.06±2.07 
(+116.6 %f 
19.81±0.63^ 
(-64.0 %)" 
28.51±0.79^ 
(-48.2 %)" 
14.08±0.20 
(+104.6 %)" 
6.62±0.43 
(-53 %)" 
5.5010.27 
(-60.9 %)" 
Values are mean ± SD from pooled packed erythrocytes of 7 rats in N-C. 
Values are mean ± SD from pooled packed erythrocytes of 4 rats in D-C. 
^ Values are mean ± SD from pooled packed erythrocytes of 5 rats each in D-TT 
and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/ day 
and D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at ''p<0.001. 
Significantly different from D-C at ''p<0.001 and ''p<0.05. 
14.08 (105 %) in D-C. A highly significant decrease of 53 % and 61 % in MDA content 
was seen in diabetic rats treated with 6 mg Tocomin or 0.50 mg Lovastatin, 
respectively, for 14 weeks, when compared to D-C rats. These results demonstrate that 
the induction of diabetes in rats is associated with a significant increase in erythrocytes 
membrane lipid peroxiadtion, which is significantly prevented by the administration of 
Tocomin or Lovastatin. 
3.4.9 Regulation of erythrocytes membrane bound total and Na'^, K^-dependent 
A TPase activities 
Since it is known that in diabetics erythrocytes membrane bound total and Na^, 
K^-ATPase activities are significantly altered, we have investigated the regulatory 
effect of Tocomin and Lovastatin on these enzymes in diabetic-hyperlipidemic rats. As 
shown in Table 11, total and Na*, K^-ATPase activities were significantly declined by 
37 % and 78 %, respectively, in D-C, when compared to activities in N-C. Following 
treatment of diabetic rats with Tocomin or Lovastatin, total and Na^, K'^ -ATPase 
activities were substantially and significantly increased by 39 % and 164 %, 
respectively, in D-TT, whereas, in D-LT, the enzyme activities were increased by 31 % 
and 169 %, respectively, in comparison to values in D-C. These results suggest that 
changes in the erythrocytes membrane bound ATPase activities may be involved in the 
pathophysiology of diabetes. In addition, treatment with potent antioxidants resulted in 
a significant improvement in the above enzymes. 
3.4.10 Impact on liver and kidney lipid peroxiadtion products 
As depicted in Table 12, formation of conjugated dienes in liver and kidney was 
increased from 5.69 and 1.32 units/mg in N-C to 7.09 (25 %) and 1.95 (48 %) units/mg, 
respectively, in D-C. These values in liver were reduced by 14 % and 0.84 %, 
respectively, in D-TT and D-LT, whereas, formation of conjugated dienes in kidney 
was reduced by 19 % and 26 %, respectively, in D-TT and D-LT, when compared to the 
corresponding values in D-C rats. Similarly, in D-C, formation of hydroperoxides and 
TBARS in liver were increased by 48 % and 24 %, respectively, whereas, kidney 
hydroperoxides and TBARS were increased by 97 % and 45 %, respecfively, in 
comparison to N-C values. After treatment of diabetic rats with Tocomin or Lovastatin, 
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TABLE 11 
REGULATORY EFFECT OF TOCOMIN AND LOVASTATIN ON 
ERYTHROCYTES MEMBRANE BOUND TOTAL AND Na^, K" -DEPENDENT 
ATPase ACTIVITIES IN DIABETIC-HYPERLIPIDEMIC RATS AFTER 14 
WEEKS OF TREATMENT 
Group Total ATPase Na% iC-ATPase 
N-C 0.927±0.027 0.641±0.040 
D C 
D-TT 
D-LT 
0,586±0.11 
(-36.8 %)" 
0.812±0.022^ 
(+38.6 %)" 
0.766±0.023^ 
(+30.7 %)" 
0.141±0.024 
(-78.0 % ) ' 
0.372±0.022 
(+163.8 %)" 
0.379+0.033 
(+168.8 %)* 
Values are mean (ftmole Pi/hr/mg protein) ± SD from pooled erythrocytes 
membrane fraction of 7 rats in N-C. 
Values are mean (^mole Pi/hr/mg protein) ± SD from pooled erythrocytes 
membrane fraction of 4 rats in D-C. 
Values are mean (^mole Pi/hr/mg protein) ± SD from pooled erythrocytes 
membrane fraction of 5 rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/ day and 
D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at ''p<0.001. 
Significantly different from D-C at ''p<0.001. 
TABLE 12 
IMPACT OF TOCOMIN AND LOVASTATIN ON LIVER AND KIDNEY 
CONJUGATED DIENES, LIPID HYDROPEROXIODES AND THIOBARBITURIC 
ACID REACTIVE SUBSTANCES IN DIABETIC-HYPERLIPIDEMIC RATS AFTER 
14 WEEKS OF TREATMENT 
Group 
Conjugated dienes Lipid hydroperoxides 
Liver Kidney Liver Kidney 
TBARS 
Liver Kidney 
N-C 5.69±0.10 1.32±0.06 0.9110.12 0.283±0.015 2.25±0.18 3.22±0.02 
D-C 
D-TT 
D-LT 
7.09±0.08 
(+24.6 %)" 
6.08±0.06^ 
(-14.2 %)" 
7.15±0.07^ 
(+0.84 VoY (-25.6 %) 
1.95±0.07 
(+47.7 %)" 
1.58±0.06 
(-18.9 %)*• 
1.45±0.11 
0 / \a 
1.35±0.15 
(+48.4%)" 
1.10+0.15 
(-18.2%)" 
1.23±0.03 
(-8.9%)" 
0.55610.024 2.7810.20 4.6710.03 
(+96.5 %)" 
0.35010.029 
(-37.1%)" 
0.40010.021 
(-28.1 %)" 
(+23.6 %)" (+45.0 %)" 
2.3210.13 3.7510.12 
(-16.5 % ) ' 
2.2510.09 
(-19.7 %)" 
3.8410.12 
(-19.1%)" (-17.8%) o/ \^ 
Values are mean (nmole/mg protein) 1 SD from pooled liver or pooled kidney homogenate o 
7 rats in N-C. 
Values are mean (nmole/mg protein) 1 SD from pooled liver or pooled kidney homogenate o 
4 rats in D-C. 
^Values are mean (nmole/mg protein) 1 SD from pooled liver or pooled kidney homogenate 
of 5 rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/ day and D-LT, 
given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at "p<0.001 and VO.Ol. 
Significantly different from D-C at "p<0.001 and "^ not significant. 
formation of hepatic hydroperoxides and TEARS was significantly decreased by 19 %, 
17 %, 9 % and 19 %, respectively, in D-TT and D-LT. Whereas, hydroperoxides and 
TBARS in kidney were reduced by 37 % and 20 % in D-TT and 28 % and 18 % in D-
LT, when compared to the corresponding values in D-C. These results demonstrate that 
the induction of diabetic hyperlipidemia in rats is associated with a significant increase 
in the formation of lipid peroxidation products in liver as well as kidney, which is 
significantly prevented by the administration of Tocomin or Lovastatin. 
3.5 Impact of Tocomin and Lovastatin on Ex Vivo and Copper-Mediated In Vitro 
Oxidation of LDL, Sd-LDL and Lb-LDL in Absence or in Presence of 
Glucose in Diabetic-Hyperlipideraic Rats After 14 Weeks of Treatment 
3.5.1 Antioxidant impact on base line levels of diene conjugation and lag phase in 
LDL, sd-LDL and Ib-LDL 
As seen in Table 13, the ex vivo base line diene conjugation (BDC) levels of 
LDL, sd-LDL and Ib-LDL of diabetic-hyperlipidemic rats was increased by 57 %, 65 % 
and 43 %, respectively, in comparison to the corresponding N-C values. Feeding of 
Tocomin or Lovastatin blocked the in vivo oxidation of LDL and Ib-LDL and 
significantly reduced the BDC levels in D-TT and D-LT rats. However, in comparison 
to BDC levels of LDL and Ib-LDL in both the treated groups, the decline mediated by 
Tocomin or Lovastatin in BDC levels of sd-LDL was more pronounced. The ex vivo 
BDC value of 408 units in D-C, was reduced to 323 and 301 units, respectively, in D-
TT and D-LT. As expected, the lag phase time of LDL oxidation was reduced from N-C 
value of 98 to 50 min in D-C, whereas, for Ib-LDL oxidation it was reduced from 50 
min in N-C to 40 min in D-C. Treatment of diabetic-hyperlipidemic rats with Tocomin 
or Lovastatin restored the lag phase time of LDL oxidation to 62 min and 75 min, 
respectively, in comparison to a normal control value of 98 min, whereas, lag phase 
time of Ib-LDL oxidation in both the treated groups was restored to 50 min and 52 min, 
respectively, which is identical to lag phase values in N-C. In comparison to lag phase 
time of LDL or Ib-LDL oxidation in N-C, sd-LDL oxidation resulted in a strikingly 
lower lag phase time of 17.0 min, which was significantly reduced to 8.5 min in D-C. 
Following treatment with Tocomin or Lovastatin, the lag phase time of sd-LDL 
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oxidation was increased to 12.5 min, which represents an increase of 47 % in 
comparison to the lag phase time in D-C. 
3.5.2 Impact on ex vivo and in vitro oxidative modification ofLDL, sd-LDL and Ib-
LDL in presence of glucose, expressed as the lag time required for conjugated 
diene formation 
It has been reported earlier that glucose may act either as LDL antioxidant or 
prooxiadnt, depending on the LDL vitamin E content in a manner similar to vitamin C, 
dehydroascorbic acid and flavonoids. Based on these findings, we have determined 
whether addition of glucose mediated a different effect on the LDL, sd-LDL and Ib-
LDL oxidation depending on their vitamin E (a-tocopherol and tocotrienols) and 
Lovastatin concentrations. Data presented in Table 14 demonstrate that the addition of 
2.5 mg/ml of glucose during copper-mediated oxidation of LDL, sd-LDL and Ib-LDL 
from N-C rats, decreased the lag phase to 62 min (37 %), 10.0 min (41 %) and 40 min 
(20 %), respectively, when compared to the corresponding lag phase values of 98, 17.0 
and 50 minutes, respectively, for LDL, sd-LDL and Ib-LDL, when oxidized in absence 
of glucose (Table 13). In diabetic-hyperlipidemic rats, having high plasma glucose and 
low antioxidant concentrations the lag phase value of 50 min, 6.5 min and 40 min, 
respectively, for LDL, sd-LDL and Ib-LDL was obtained. When compared to lag phase 
values of LDL, sd-LDL and Ib-LDL of D-C rats, shown in Tablel3, only the lag phase 
value of sd-LDL was decreased from 8.5 to 6.5 min (24 %). Since Treatment of D-C 
rats with Tocomin or Lovastatin for 14 weeks was associated with a normal plasma 
glucose level and significantly higher plasma total antioxidant levels, glucose failed to 
mediate any substantial change in the oxidative susceptibility of LDL, sd-LDL and Ib-
LDL, which is expressed as the lag phase values of 58 min, 12.5 min and 43 min, for 
LDL, sd-LDL and Ib-LDL, respectively, in D-TT and 66 min, 12.5 min and 45 min, 
respectively, in D-LT were obtained, when compared to the corresponding lag phase 
values of LDL, sd-LDL and Ib-LDL oxidation in absence of glucose in D-TT and D-LT 
rats (Table 13). 
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3.5.3 Determination of the effect of glucose on oxidative susceptibility of LDL, sd-
LDL and Ib-LDL, isolated from normal rat plasma pretreated with Tocomin, a-
tocopherol or Lovastatin 
As seen in Table 15, incubation of LDL with glucose decreased the lag phase to 
75 min from a glucose untreated control value of 107 min. In plasma samples incubated 
with Tocomin, a-tocopherol or Lovastatin, prior to isolation of LDL, the lag time 
required for conjugated diene formation in presence of glucose was increased by 40 % 
(105 min), 48 % (111 min) and 60 % (120 min), respectively, when compared to control 
value of 75 min. These values are similar to a lag phase value of 107 min obtained in 
glucose untreated control, indicating that the prooxidant effect of glucose was 
minimized when LDL was enriched with Tocomin, a-tocopherol or Lovastatin. On the 
other hand, the incubation of LDL in absence of glucose was associated with an 
increase in lag phase from a control value of 107 min to 185 min (73 %), 165 (54 %) 
and 192 (79 %), respectively in Tocomin, a-tocopherol or Lovastatin enriched-LDL. 
The time course of sd-LDL oxidation in absence or presence of glucose was 
characterized by accumulation of conjugated dienes in a manner similar to LDL 
oxidation, except its susceptibility to oxidative modification was markedly enhanced. 
The data in Table 16 show that the incubation of sd-LDL without glucose increased the 
lag phase to 20.5 min, 18.0 min and 20.5 min, respectively, in Tocomin, a-tocopherol or 
Lovastatin pretreated samples, in comparison to an untreated control value of 18.5 min. 
Addition of glucose, during oxidative modification of untreated control sd-LDL, 
mediated a decline to 11.0 min, which is considerably lower (41 %) than a lag phase 
value of 18.5 min in glucose untreated control, indicating a prooxidant effect of 
glucose. On the other hand, oxidation of sd-LDL isolated from Tocomin, a-tocopherol 
or Lovastatin pretreated plasma samples produced a lag phase of 18.0 min (64 %), 16.0 
min (46 %) and 16.5 min (50 %), respectively, when compared to an unfreated control 
value of 11.0 min. These results indicate that the prooxidant effect of glucose was 
considerably neutralized by the antioxidant effect of Tocomin, a-tocopherol or 
Lovastatin associated with sd-LDL, which is responsible for the restoration of lag phase 
time close to the corresponding values obtained from sd-LDL oxidation carried out in 
absence of glucose. 
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Data presented in Table 17 show the variations in the oxidative susceptibiHty of 
Ib-LDL fractionated from Tocomin, a-tocopherol or Lovastatin-enriched LDL, 
incubated with and without glucose. Consistent with the oxidation pattern of LDL and 
sd-LDL, lag phase of Ib-LDL was increased from an untreated control value of 63 min 
to 75 min (19 %), 75 min (19%) and 90 min (43 %), respectively, in Tocomin, a-
tocopherol or Lovastatin-enriched samples. Oxidation of untreated control Ib-LDL in 
presence of glucose caused a decline in lag phase to 52 min, when compared to a lag 
phase value of 63 min obtained in absence of glucose. However, the prooxidant effect 
of glucose in the oxidation of Ib-LDL of untreated control was lower (18 %) than sd-
LDL (41 %, Table 16) and LDL (30 %, Table 15). Consistent with the results of sd-
LDL, in case of Ib-LDL the prooxidant effect of glucose was considerably blocked by 
increasing the lag phase from an untreated control value of 52 to 63 min (21 %), 75 min 
(44 %) and 75 min (44 %), respectively, in Tocomin, a-tocopherol or Lovastatin-
enriched samples. The combined results demonstrate a markedly enhanced 
susceptibility to oxidative modification of small dense LDL, which may contribute to 
the increased risk associated with atherogenesis. 
3.6 Regulatory Effect of Tocomin and Lovastatin on Plasma Arylesterase 
Activity and LDL-C: Arylesterase Activity Ratio in Diabetic-Hyperlipidemic 
Rats after 14 Weeks of Treatment 
It is known that arylesterase (paraoxonase) activity is associated with plasma 
HDL, which is involved in the protection of LDL and HDL from oxidative 
modification. Arylesterase activity is known to be reduced in hypercholesterolemia, 
diabetes, vascular cardiac diseases and in smokers. The arylesterase activity was shown 
to be regulated both genetically and by diet, indicating that adequate dietary intake of 
antioxidants such as vitamin E is essential. Therefore, we have also investigated the 
impact of Tocomin and Lovastatin on plasma arylesterase activity in diabetic-
hyperlipidemic rats. As shown in Table 18, arylesterase activity in diabetic-
hyperiipidemic rats was significantly reduced by 19 %, when compared to N-C value. 
Treatment of diabetic-hyperlipidemic rats with antioxidants, Tocomin or Lovastatin 
significantly blocked the decrease in arylesterase activity by 18 % and 51 %, 
respectively. It is interesting to note that in D-LT rats, Lovastatin was able to activate 
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TABLE 18 
EFFECT OF TOCOMIN AND LOVASTATIN ON PLASMA ARYLESTERASE 
ACTIVITY AND LDL-C: ARYLESTERASE ACTIVITY RATIO IN DIABETIC-
HYPERLIPIDEMIC RATS 
AFTER 14 WEEKS OF TREATMENT 
Group 
N-C 
Plasma arylesterase activity LDL-Cf: arylesterase activity 
ratio 
792.07±24.80* 1.24xl0"^±7xl0"^ 
D-C 
D-TT 
D-LT 
645.88±26.52** 
(-18.5 %)" 
764.11+16.38^ 
(+18.3 %)" 
975.18±16.92^ 
(+51.0 %)" 
2.66xl0"^±12xl0"'' 
(+114.5 %)" 
1.62xl0-^±5xl0"''' 
(-39.1 %f 
1.14xl0-^±1.8xl0-^ 
(-57.1 %)" 
t LDL-C (mg/ml) values are taken from Table 4. 
* Values are mean ± SD from pooled plasma of 7 rats in N-C. 
Values are mean ± SD from pooled plasma of 4 rats in D-C. 
^ Values are mean ± SD from pooled plasma of 5 rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/ day 
and D-LT, given 0. 50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at ''p<0.001 and ''p<0.05. 
Significantly different from D-C at ''p<0.05 and ''p<0.001. 
aryleslerase enzyme to a value of 975 units, when compared to a control value of 792 
units, indicating an increase of 23 %. On the other hand, in D-TT rats, Tocomin feeding 
was associated with an increase of 764 units of arylesterase activity, which is similar to 
a control value of 792 units. These results indicate that feeding of 0.50 mg 
Lovastatin/rat/day was more efficient in terms of HDL-associated arylesterase activity 
increase in comparison to D-TT rats, which were fed 6 mg Tocomin/rat/day. Consistent 
with above results, the ratio of LDL-C to arylesterase activity in D-C rats was 
significantly increased from 1.24xl0"'^  in N-C to 2.66x10'^ in D-C rats. This increase in 
the ratio of LDL-C to arylesterase activity in D-C rats was significantly reduced to a 
value of 1.62x10"' (39 %) in D-TT and 1.14x10"^  (57 %) in D-LT rats after 14 weeks of 
treatment, which is similar to N-C value. These results indicate that due to an increase 
in oxidative stress in diabetic rats, plasma arylesterase activity was significantly 
reduced. Treatment of diabetic rats with Tocomin and Lovastatin significantly 
prevented this decrease in arylesterase activity. 
3.7 Effect of Tocomin and Lovastatin on Plasma and Hepatic Xanthine Oxidase 
Activity in Diabetic-Hyperlipidemic Rats after 14 Weeks of Treatment 
Xanthine oxidase is known to be an important biological source of fi"ee radicals. 
There is overwhelming evidence to suggest that serum xanthine oxidase activity is 
significantly increased in various pathological disorders, like hepatitis, inflammatory 
diseases, hypercholesterolemia, atherosclerosis, ischemia-reperfusion, carcinogenesis, 
aging and diabetes and that free radicals generated in the enzymatic processes are 
involved in oxidative damage. Thus, it may be possible that the inhibition of this 
enzymatic pathway by the compounds that have both antiradical and xanthine oxidase 
inhibitory properties may have additional therapeutic importance in the treatment of the 
above diseases. Therefore, we have investigated the possible inhibitory effect of 
Tocomin and Lovastatin on plasma and hepatic xanthine oxidase activity in diabetic-
hyperlipidemic rats. As seen in Table 19, plasma xanthine oxidase activity was 
significantly increased from 2.98 units in N-C to 5.74 units/ml in D-C, whereas, in liver 
it was increased from 22.74 units in N-C to 32.86 units/ lOOmg in D-C rats. Tocomin 
had a significant effect in preventing this increase in both plasma and hepatic xanthine 
oxidase activity and was decreased by 29 % and 23 %, respectively, when compared to 
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TABLE 19 
REGULATORY EFFECT OF TOCOMIN AND LOVASTATIN ON PLASMA 
AND HEPATIC XANTHINE OXIDASE ACTIVITY IN DIABETIC-
HYPERLIPIDEMIC RATS AFTER 14 WEEKS OF TREATMENT 
Group Plasma Xanthine oxidasef Hepatic Xanthine oxidase^ 
(U/ml) (U/mg protein) 
N^C 2.98±0.12* 22.74±1.30 
D-C 5.74±0.09** 32.86±0.80 
(+92.6 %)" (+44.5 %)" 
D-TT 4.10±0.08^ 25.42±1.20 
(-28.6 %)" (-22.6 %)" 
D-LT 4.78±0.02^ 24.85±1.00 
(-16.7 %)" (-24.4 %)" 
t One unit of enzyme activity is defined as nmole of uric acid formed/min/ml. 
I One unit of enzyme activity is defined as nmole of uric acid formed/min/mg 
protein. 
* Values are mean ± SD from pooled plasma or pooled liver homogenate of 7 
rats in N-C. 
Values are mean ± SD from pooled plasma or pooled liver homogenate of 4 
rats in D-C. 
^ Values are mean ± SD from pooled plasma or pooled liver homogenate of 5 
rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/ day 
and D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at ''p<0.001. 
Significantly different from D-C at ''p<0.001. 
the corresponding values in D-C. Similarly, treatment of diabetic-hyperlipidemic rats 
with Lovastatin was associated with a significant decline of 17 % in plasma and 24 % in 
liver xanthine oxidase activity. These results demonstrate that both Tocomin and 
Lovastatin in addition to their potent antioxidant activity, also significantly inhibit the 
elevated levels of xanthine oxidase in plasma as well as liver of diabetic-hyperlipidemic 
rats, indicating a dual therapeutic benefit in the treatment of above disorders. 
3.8 Regulatory Effect of Tocomin and Lovastatin on Antioxidant Defense System 
in Diabetic-Hyperlipidemic Rats after 14 Weeks of Treatment 
Oxidant stress may be increased in diabetes owing to a higher production of 
reactive oxygen species (ROS), such as superoxide radical, hydroxyl radical, hydrogen 
peroxide and/or deficiency in the antioxidant defense systems. The increased production 
of ROS has been attributed to protein glycation and/or glucose autooxidation due to 
hyperglycemic environment. An impaired radical scavenger function has been linked to 
the decreased activity of enzymatic and nonenzymatic scavengers of fi-ee radicals. 
Therefore, the status of antioxidant enzymes, such as catalase, superoxide dismutase 
(SOD), glutathione peroxidase (Gpx), glutathione-S-transferase (GST) and glutathione 
reductase (Gred) including reduced glutathione (GSH) concentrations in erythrocytes 
and liver of experimental diabetic-hyperlipidemic rats are highly important. 
3.8.1 Impact on erythrocytes catalase and superoxide dismutase activities 
As seen in Table 20, the erythrocytes catalase activity in diabetic-hyperlipidemic 
rats was significantly decreased by 33 %, in comparison to N-C value. Feeding of 
Tocomin or Lovastatin significantly prevented this decrease in the activity by 30 % and 
17 %, respectively, when compared to the catalase activity of D-C rats. On the other 
hand, in D-C rats, the decline in the enzymatic activity of SOD was 7 % (p<O.Ol) in 
comparison to normal control value. The increase in SOD activity mediated by 
Tocomin or Lovastatin was less than 1 %, which was insignificant. 
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TABLE 20 
EFFECT OF TOCOMIN AND LOVASTATIN ON ERYTHROCYTES 
CATALASE AND SUPEROXIDE DISMUTASE ACTIVITIES IN 
DIABETIC-HYPERLIPIDEMIC RATS AFTER 14 WEEKS OF 
TREATMENT 
Group Catalase Superoxide dismutase 
(U/gHb)t (KU/gHb)J 
N-C 334±4.7* 2.19±0.12 
D-C 223±3.1 2.04±0.12 
(-33.2 %)" (-6.9 %)" 
D-TT 289±4.4^ 2.06±0.08 
(+29.6 %f (+0.98 %f 
D-LT 260±3.2^ 2.05±0.06 
(+16.6 %)" (+0.50%)' 
t One unit of enzyme activity is defined as the ^moles of H2O2 
decomposed/min/g Hb. 
% One unit of enzyme activity is defined as the amount of enzyme required to 
inhibit O. D. at 560 nm of chromogen production by 50 % in one minute. 
Values are mean ± SD from pooled erythrocytes hemolysate of 7 rats in N- C. 
Values are mean ± SD from pooled erythrocytes hemolysate of 4 rats in D-C. 
^ Values are mean ± SD from pooled erythrocytes hemolysate of 5 rats each in 
D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/ day 
and D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at ''p<0.001 and ''p<0.01. 
Significantly different from D-C at *p<0.001 and 'not significant. 
3.8.2 Effect on erythrocytes glutathione peroxidase, glutathione reductase activities 
and reduced glutathione content 
The data summarized in Table 21 showed a significant increase of 21 % in the 
activity of Gpx from 0.883 units in N-C to 1.069 units in D-C. Administration of 
Tocomin or Lovastatin to diabetic rats resulted in a significant decline in Gpx activity 
by 10-11 % in D-TT and D-LT, when compared to D-C value. On the other hand, Gred 
activity was significantly decreased (17 %) from 50.65 units in N-C to 42.23 units in D-
C. However, feeding of Tocomin or Lovastatin to diabetic rats for 14 weeks 
significantly prevented the decrease by 25 % and 7 % in D-TT and D-LT, respectively, 
when compared to Gred value in D-C rats. Analysis of GSH content in erythrocytes 
revealed a significant decline of 65 % in diabetic-hyperlipidemic rats, in comparison to 
control value in N-C. As expected, treatment of diabetic rats with Tocomin or 
Lovastatin significantly prevented this decrease of erythrocytes GSH by 44 % in D-TT 
and 73 % in D-LT, when compared to GSH value in D-C group. These results indicate 
that the decrease in erythrocytes catalase, SOD and Gred activities including GSH 
content was significantly reduced, whereas, Gpx activity was significantly increased in 
diabetic-hyperlipidemic rats. This decrease or increase in enzyme activities as well as 
GSH levels was prevented by Tocomin or Lovastatin, demonstrating their potent 
antioxidant property. 
3.8.3 Impact on the regulation of hepatic catalase, superoxide dismutase, 
glutathione peroxidase, glutathione reductase and glutathione-S-transferase 
activities 
Consistent with the decline in erythrocyte catalase activity in diabetic rats, 
hepatic catalase activity is also decreased by 39 % in comparison to control catalase 
activity in N-C (Table 22). In a similar fashion, an increase of 25 % in D-TT and 36 % 
in D-LT was observed in the activity of catalase in liver of diabetic rats treated with 
Tocomin or Lovastatin. However, in comparison to normal control value, the decline in 
hepatic SOD activity in diabetic rats was 27 %. Administration of Tocomin or 
Lovastatin to diabetic rats resulted in a significant increase in hepatic SOD activity by 
28 % both in D-TT and D-LT, when compared to D-C value. Table 23, summarizes the 
results of Gpx, Gred and GST activities in liver of diabetic rats after 14 weeks of 
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TABLE 21 
REGULATORY EFFECT OF TOCOMIN AND LOVASTATIN ON 
ERYTHROCYTES GLUTATHIONE PEROXIDASE, GLUTATHIONE 
REDUCTASE ACTIVITIES AND REDUCED GLUTATHIONE IN DIABETIC-
HYPERLIPIDEMIC RATS AFTER 14 WEEKS OF TREATMENT 
Group Glutathione peroxidase Glutathione reductase 
(U/g Hb)t (U/g Hb)$ 
Glutathione 
(^mole/g Hb) 
N-C 0.883±0.014 50.65+5.16 1.099±0.066 
D C 
D-TT 
D-LT 
1.069±0.048 
(+21.1 %)" 
0.958+0.019^ 
(-10.4 %)" 
0.950±0.021* 
(-11.1 %)" 
42.2311.78 
(-16.8 %)" 
52.85±2.52 
(+25.1 %)" 
45.1912.99 
(+7.1 %)" 
0.38410.025 
(-65.1 %)" 
0.55110.042 
(+43.5 %)" 
0.66310.028 
(+72.7 %)* 
t One unit of enzyme activity is defined as the jumoles of oxidized glutathione 
formed/min/g Hb. 
X One unit of enzyme activity is defined as the jumoles of NADPH oxidized/min/g 
Hb. 
Values are mean 1SD from pooled erythrocytes hemolysate of 7 rats in N-C. 
Values are mean 1 SD from pooled erythrocytes hemolysate of 4 rats in D-C. 
^ Values are mean 1 SD from pooled erythrocytes hemolysate of 5 rats each in D-TT 
and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/ day and 
D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at "p^^-OOl. 
Significantly different from D-C at *p<0.001 and ''p<0.01. 
TABLE 22 
EFFECT OF TOCOMIN AND LOVASTATIN ON THE REGULATION OF 
HEPATIC CATALASE AND SUPEROXIDE DISMUTASE ACTIVITIES IN 
DIABETIC-HYPERLIPIDEMIC RATS AFTER 14 WEEICS OF 
TREATMENT 
Group Catalase 
(U/mg protein)t 
Superoxide dismutase 
(U/mg protein)^: 
N-C 4.60±0.08 0.729±0.010 
D-C 
D-TT 
D-LT 
2.80±0.I6 
(-39.1 %)" 
3.50±0.20^ 
(+25.0 %)" 
3.80±0.05^ 
(+35.7 %)" 
0.529±0.014 
(-27.4 %)* 
0.677±0.070 
(+28.3 %)* 
0.678±0.036 
(+28.3 % ) " 
t One unit of enzyme activity is defined as the fimoles of H2O2 
decomposed/min/mg protein. 
I One unit of enzyme activity is defined as tfie amount of enzyme required to 
inliibit O. D. at 560 nm of chromogen production by 50 % in one minute. 
Values are mean ± SD from pooled liver PMS fraction of 7 rats in N-C. 
Values are mean ± SD from pooled liver PMS fraction of 4 rats in D-C. 
^ Values are mean + SD from pooled liver PMS fraction of 5 rats each in D-TT 
and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/ day 
and D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at ''p<0.001. 
Significantly different from D-C at ''p<0.001 and ''p<0.01. 
^«».«»- -
TABLE 23 
REGULATORY EFFECT OF TOCOMIN AND LOVASTATIN ON HEPATIC 
GLUTATHIONE PEROXIDASE, GLUTATHIONE REDUCTASE AND 
GLUTATHIONES-TRANSFERASE ACTIVITIES IN DIABETIC-
HYPERLIPIDEMIC RATS AFTER 14 WEEKS OF TREATMENT 
Group Glutathione 
peroxidase 
(U/mg protein)t 
Glutathione reductase Glutathione-S-transferase 
(U/mg protein){ (U/mg protein)# 
N-C 45.30±2.03 7.90+0.14 135.7010.60 
D C 
D-TT 
D-LT 
21.50±1.60 
(-52.5 %)" 
37.50±4.00^ 
(+74.4 %)" 
31.10+1.60^ 
(+44.7 %)" 
4.40±0.20 
(-44.3 %)* 
6.90±0.10 
(+56.8 %)" 
5.70±0.20 
(+29.5 %)" 
75.3010.63 
(-44.5 %)" 
120.4010.43 
(+59.9 %)" 
111.4011.50 
(+47.9 %)" 
t One unit of enzyme activity is defined as nmole oxidized glutathione formed/min/mg 
homogenate protein. 
t One unit of enzyme activity is defined as nmole NADPH oxidized/min/mg PMS 
protein. 
# One unit of enzyme activity is defined as the nmole of l-chloro 2,4-dinitrobenzene 
(CDNB) conjugate formed/min/mg PMS protein. 
* Values are mean 1SD from pooled liver homogenate and pooled liver PMS fraction 
of 7 rats in N-C. 
Values are mean 1 SD from pooled liver homogenate and pooled liver PMS fraction 
of 4 rats in D-C. 
^ Values are mean 1 SD from pooled liver homogenate and pooled liver PMS fraction 
of 5 rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/day and 
D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at ''p<0-001. 
Significantly different from D-C at ''p<0.001 and V^-Ol . 
Tocomin or Lovastatin treatment. In diabetic rats, the enzymatic activities of Gpx, Gred 
and GST were significantly decreased by 53 %, 44 % and 45 %, respectively, in 
comparison to normal control values. As evident, after 14 weeks of treatment with 
Tocomin resulted in a significant increase of 74 %, 57 % and 60 % in Gpx, Gred and 
GST activities, respectively, when compared to the corresponding activities in D-C rats. 
Similarly, in D-LT rats, the increase in Gpx, Gred and GST activities was 45 %, 30 % 
and 48 %, respectively, in comparison to the corresponding values in D-C. In summary, 
hepatic catalase, SOD, Gpx, Gred and GST enzymes, which constitute a mutually 
supportive team of defense against ROS, are significantly decreased in diabetic-
hyperlipidemic rats. However, feeding of Tocomin or Lovastatin substantially quenches 
these free radicals (ROS), thus positively normalizing the above enzyme levels close to 
normal values. 
3.8.4 Impact on hepatic total, free and protein-bound -sulfliydryl contents of 
glutathione 
Reduced glutathione, a major non-protein thiol plays a crucial role in 
coordinating the body's antioxidant defense processes. Perturbation of GSH status of a 
biological system can lead to serious consequences. As evident from Table 24, 
induction of diabetes significantly reduced the total, free and protein-bound -SH 
contents of glutathione by 59 %, 29 % and 64 %, respectively, when compared to the 
corresponding values in N-C. Feeding of Tocomin to diabetic-hyperlipidemic rats 
significantly prevented this decrease of hepatic total, free and protein-bound -SH levels 
of glutathione by 48 %, 23 % and 17 %, respectively, in comparison to the 
corresponding values in D-C. Similarly, in D-LT rats, administrafion of Lovastatin was 
also associated with a significant increase of 19 %, 44 % and 40 %, respecfively, for 
total, free and protein-bound -SH levels of glutathione. These results indicate that the 
decline in liver GSH content of diabetic-hyperlipidemic rats, and the subsequent 
reversal to near normal level in D-TT and D-LT rats underline a strong anti-Iipid 
peroxidative effect of Tocomin and Lovastatin. 
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TABLE 24 
IMPACT OF TOCOMIN AND LOVASTATIN ON HEPATIC TOTAL, FREE AND 
PROTEIN-BOUND -SULFHYDRYL CONTENTS OF GLUTATHIONE IN 
DIABETIC-HYPERLIPIDEMIC RATS AFTER 14 WEEKS OF TREATMENT 
Group Total-SH Free-SH Protein-bound-SH 
N-C 68.60±0.50 10.50+0.20 58.10±0.50 
^•^ 28.40±0.50" 7.50±0.20 21.00±0.60 
(-58.6 %)" (-28.6 %)" (-63.9 %)« 
D TT 
42.10±2.10^ 9.20±0.10 24.50±0.60 
(+48.2 %)* (+22.7 %)" (+16.7 %)" 
n T T 
33.90±0.97^ 10.80±0.20 29.40±0.50 
(+19.4 %)" (+44.0 %)" (+40.0 %)" 
Values are mean (nmole SH group/mg protein)± SD from pooled liver homogenate 
of 7 rats in N-C. 
Values are mean (nmole SH group/mg protein)± SD from pooled liver homogenate 
of 4 rats in D-C. 
^ Values are mean (nmole SH group/mg protein)± SD from pooled liver homogenate 
of 5 rats each in D-TT and D-LT. 
N-C, normal control; D-C, diabetic control; D-TT, fed 6 mg Tocomin/rat/day and 
D-LT, given 0.50 mg Lovastatin/rat/day for 14 weeks. 
Significantly different from N-C at ''p<0.001. 
Significantly different from D-C at ''p<0.001and Vo.Ol. 
3.9 Histological Studies in Kidney and Eyeball of STZ-Induced Diabetic Rats 
without and with 14 Weeks of Tocomin or Lovastatin Treatment 
3.9.1 Histological studies of kidney 
As depicted in Figure 3.2, Panel A and B, photomicrographs of kidney from 
normal control rats showing normal glomerular lobules with no thickening of basement 
membrane. As seen in Figure 3.3, Panel A and B, photomicrographs of kidney from 
diabetic rats showing progression of diffused nodular glomerulosclerosis and capillaries 
with thick basement membrane. In addition, an increase in the number of mesengial 
cells and enlarged Bowman space was also seen, when compared to the kidney from N-
C (Fig. 3.2, Panel A and B). After 14 weeks of Tocomin treatment, diabetic kidney 
showed a significant regression in glomerulosclerosis and normalization of basement 
membrane (Fig. 3.4, Panel A and B). The overall appearance is similar to normal 
kidney. As shown in Figure 3.5, Panel A and B, feeding of Lovastatin to diabetic rats, 
caused a substantial reduction in basement membrane thickening and 
glomerulosclerosis. However, unlike Tocomin, Lovastatin therapy has induced 
interstitial inflammation of lymphocytes. 
3.9.2 Histological studies of eyeball 
As seen in photomicrographs of Figure 3.6, Panel A and B, normal control 
retina showed intact retinal membrane with no sign of retinal detachment. In contrast, 
photomicrographs (Fig. 3.7 Panel A and B) of retina from diabetic rats showed 
proliferative retinopathy characterized by complete retinal detachment. Feeding of 
Tocomin to diabetic rats prevented these changes (Fig 3.8, Panel A and B). Tocomin 
therapy almost fully restored retinal detachment similar to retinal membrane from N-C 
rats. As depicted in Figure 3.9, Panel A and B, like Tocomin, Lovastatin freatment to 
diabetic rats significantly prevented the retinal detachment and restored close to normal 
control retinal membrane. However, Lovastatin feeding was associated with a 
substantial separation of retinal membrane, which resulted in an open space between 
retina and lens (Fig. 3.10). The combined results indicate that STZ-induced diabetes in 
rats was responsible for the onset of proliferative nephropathy as well as retinopathy. 
These untoward changes are significantly prevented by the administration of Tocomin 
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Fig. 3.2. Panel A. Photomicrograph of kidney from normal control rats, showing 
normal glomerular lobule with no basement membrane 
thickening (x 100). 
Panel B. Photomicrograph of kidney from normal control rats, showing 
normal glomerular lobule with no basement membrane 
thickening (x 400). 
Panel A 
Panel B 
Fig. 3.3. Panel A. Photomicrograph of kidney from diabetic rats after 14 weeks of 
STZ treatment, showing progression of diffused nodular 
glomerulosclerosis with thick basement membrane (x 100). 
Panel B. Photomicrograph of kidney from diabetic rats after 14 weeks of 
STZ treatment, showing progression of diffused nodular 
glomerulosclerosis with thick basement membrane (x 400). 
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Panel B 
Fig.3.4. Panel A. Photomicrograph of kidney from diabetic rats after 14 weeks of 
Tocomin treatment, showing significant regression in 
glomerulosclerosis and thickness of basement membrane. The 
overall appearance is similar to normal kidney (x 100). 
Panel B. Photomicrograph of kidney from diabetic rats after 14 weeks of 
Tocomin treatment, showing significant regression in 
glomerulosclerosis and thickness of basement membrane. The 
overall appearance is similar to normal kidney (x 400). 
Panel A 
Panel B 
Fig. 3.5. Panel A. Photomicrograph of kidney from diabetic rats after 14 weeks of 
Lovastatin treatment, showing significant regression in 
glomerulosclerosis and thickness of basement membrane. 
However, Lovastatin therapy to diabetic rats has induced 
interstitial inflammation of lymphocytes (x 100). 
Panel B. Photomicrograph of kidney from diabetic rats after 14 weeks of 
Lovastatin treatment, showing significant regression in 
glomerulosclerosis and thickness of basement membrane. 
However, Lovastatin therapy to diabetic rats has induced 
interstitial inflammation of lymphocytes (x 400). 
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Fig. 3.6. Panel A. Photomicrograph of retina from normal control rats, showing 
normal retinal membrane with no sign of detachment (x 100). 
Panel B. Photomicrograph of retina from normal control rats, showing 
normal retinal membrane with no sign of detachment (x 400). 
Panel A 
Panel B 
Fig. 3.7. Panel A. Photomicrograph of retina from diabetic rats after 14 weeks of STZ 
treatment, showing proHferative retinopathy, characterized by 
complete retinal detachment (x 100). 
Panel B. Photomicrograph of retina from diabetic rats after 14 weeks of STZ 
treatment, showing proliferative retinopathy, characterized by 
complete retinal detachment (x 400). 
Panel A 
Panel B 
iP^'^-CigN^ 
ff 
Fig. 3.8. Panel A. Photomicrograph of retina from diabetic rats after 14 weeks of 
Tocomin treatment. Tocomin treatment has significantly restored 
retinal detachment close to normal control retinal membrane 
(x 100). 
Panel B. Photomicrograph of retina from diabetic rats after 14 weeks of 
Tocomin treatment. Tocomin treatment has significantly restored 
retinal detachment close to normal control retinal membrane 
(x 400). 
Panel A 
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Fig. 3.9. Panel A. Photomicrograph of retina from diabetic rats after 14 weeks of 
Lovastatin treatment. Lovastatin treatment has significantly 
restored the retinal detachment close to normal control retinal 
membrane (x 100). 
Panel B. Photomicrograph of retina from diabetic rats after 14 weeks of 
Lovastatin treatment. Lovastatin treatment has significantly 
restored the retinal detachment close to normal control retinal 
membrane (x 400). 
Panel A 
Panel B 
Fig. 3.10. Photomicrograph of retina from diabetic rats after 14 weeks of 
Lovastatin treatment, unlike Tocomin, Lovastatin has mediated 
separation of retinal membrane resulting in an open space 
between retina and lens (x 400). 

or Lovastatin, for 14 weeks. However, treatment of diabetic-hyperlipidemic rats with 
Lovastatin, which is known to exert a host of side effects, induced interstitial 
inflammation of lymphocytes in kidney. In addition, therapy with Lovastatin has also 
mediated separation of retinal membrane from the lens, thus resulting in an open space. 
In contrast, dietary Tocotrienols (Tocomin) are vitamin E and have no toxicity, 
therefore did not exhibit any side effect. 
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(Discussion 
The present study explores the effect of long-term experimental diabetes on 
different parameters like hyperglycemia including HbAi, nephropathy and 
retinopathy, plasma and lipoprotein lipids including sd-LDL and Ib-LDL, plasma and 
liver lipid peroxidation including ex vivo and in vitro oxidation of LDL, sd-LDL and 
Ib-LDL, both in the presence and absence of glucose, erythrocytes MDA release and 
membrane bound Na^, K^-ATPase and erythrocytes as well as liver antioxidant 
enzymes including glutathione. In addition, therapeutic roles of tocotrienols 
(Tocomin) or Lovastatin in terms of their efficacy to normalize the alterations 
occurred during 14 weeks of diabetes have been delineated. 
Although, previous studies have labeled a-tocopherol (a-T) as the most 
efficient chain breaking antioxidant, tocotrienols (T3S) are known to be more potent 
than tocopherols (Suama et ah, 1993; Kamat and Devasagayan, 1995; Kamat et al, 
1997). Tocotrienols have been shown to exhibit greater free radical scavenging 
properties as cell membrane constituents than tocopherols (Yamaoka and Carrillo. 
1990; Serbinova et al., 1991). They quench free radicals in cell membranes and 
protect them against lipid peroxidation. The higher antioxidant potency of a-Ts as 
compared to a-T is attributed to the combined effects of three properties: its higher 
recycling efficiency from chromanoxyl radical, its more uniform distribution in 
membrane bilayer, and its stronger disordering of membrane lipids which makes 
interaction of chromanols with lipid radicals more efficient. Since Tocomin is a 
mixture of a-Ts, y-Ts, 5-T3 and a-T, we have examined efficiency of individual T3S, 
a-T and Tocomin as a scavenger of peroxyl radical. By using DPPH, the order of 
antiradical activity or hydrogen donating ability, expressed in terms of half quenching 
concentration (IC50) was 5-T3> a-T3> y-T3> Tocomin> a-T. Our results are in 
agreement with earlier reports (Qureshi et al., 2000) indicating that in intact 
membranes, including LDL particles, tocotrienols may have a significantly greater 
antioxidant effect than a-T and they may provide greater protection against CAD. The 
possible mechanism for this superior efficacy of tocotrienols compared to a-T has 
been reported elsewhere (Packer, 1995). The reduction in the free radical quenching 
efficiency of Tocomin (50 |iM) in comparison to 5-T3, a-T3, Y-T3 is due to the 
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presence of 23 % a-T, which has a lowest peroxyl radical scavenging efficiency of 71 
^M. These results are consistent with a previous report indicating the presence of 
higher percentage of a-T in TRF, reduces the antioxidant activity (Qureshi et al, 
2000). Previous reports in hyperlipidemic-diabetic hamsters (El-Swefy et al, 2000), 
atherosclerotic rabbits (Chen et al, 1997; Singh et al., 1997), in vitro as well as in 
vivo studies in patients with hypercholesterolemia (Aviram et al, 1992) and the 
results presented in the thesis have demonstrated antioxidative properties of 
Lovastatin. However, under our experimental conditions used for Tocomin, T3S and 
a-T, 10 min incubation of 5-100 ^M of Lovastatin did not exhibit any DPPH radical 
scavenging activity. Similarly, Rikitake et al. (2001) have also reported a weak 
radical scavenging activity for Lovastatin after it's incubation with DPPH up to 30 h. 
These results indicate that the in vivo and in vitro mechanism(s) of antioxidant effects 
of Lovastatin, described in the present study, may be different than tocotrienols 
(Tocomin) including a-tocopherol and needs further investigation. 
In animal model, STZ is known to induce diabetes along with 
hyperlipidemia/atherosclerosis, diabetic nephropathy, retinopathy, and neuropathy. 
Although the exact mechanism of STZ mediated toxicity is not known, one proposed 
site of action of STZ is at nuclear DNA. During the decomposition of STZ, highly 
reactive carbonium ions are formed, which cause alkylation of DNA bases (Doux et 
al., 1986) and also STZ may damage pancreatic P-cell membrane and break the DNA 
strand which leads to the activation of poly (ADP-ribose) synthetase and NAD 
depletion, which ultimately leads to cell death (Portha et al., 1989; Okamato, 1981). It 
has been previously reported that rats administered large dosages of STZ become 
substantially hyperglycemic as well as hyperlipidemic, but at the same time a marked 
weight loss, ketosis, and a high rate of mortality is produced (Bar-On, et al., 1976). 
Our study demonstrated that 12 days after a single injection of 60 mg/kg STZ was 
associated with an average fasting blood glucose level of 257 mg/dl when compared 
to a level of 99 mg/dl in normal control rats. However, in diabetic rats there was a 
decline in body weight from 248 g in N-C to 193 g. After 14 weeks of diabetes 
induction, average blood glucose levels in diabetic control rats were further increased 
to 329 mg/dl, whereas, there was no further decrease in body weight (205 g). 
Treatment of diabetic rats with 6 mg Tocomin or 0.50 mg Lovastatin/rat/day for 14 
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weeks lowered the elevated blood glucose levels, from 329 mg/dl to near normal level 
(83 mg/dl). The weight loss and mortality rate of STZ-induced diabetic rats seen in 
the present study is consistent with earlier findings (Bar-On, et al., 1976). The extent 
of hemoglobin glycation is currently used as a cumulative index of glycemia over the 
previous few weeks in the clinical management of diabetes (Kennedy and Baynes, 
1984). Our results demonstrate a substantial decrease in hemoglobin and a significant 
increase in HbAi levels in diabetic rats. After 14 weeks of Tocomin or Lovastatin 
treatment, both Hb and HbAi levels were restored close to normal control values. 
Nazaimoon and Khalid (2002) have initially reported that feeding of TRF-rich diet (1 
g/kg) to STZ-induced diabetic rats for 12 weeks was associated with a reduction of 
blood glucose level from 556 to 376 mg/dl. Similarly, the TRF-rich diet also mediated 
a decrease in HbA] level from 13.1 to 10.0 mg/dl. Although, in principle our results 
are in agreement with their findings but the hypoglycemic effect of TRF was minimal 
and both the glucose and HbA| levels after TRF treatment were still within diabetic 
range (Nazaimoon and Khalid, 2002). In another report (El-Swefy et al., 2000), where 
hyperlipidemia was amplified by feeding a cholesterol-saturated fat-rich diet to STZ-
induced diabetic Syrian hamsters for 12.5 weeks; 10-week feeding of vitamin E (d-1-
a-tocopheryl acetate), probucol or Lovastatin supplemented with the above diet, 
failed to reduce significantly elevated fasting blood glucose. Our results showing a 
strong hypoglycemic effect of Lovastatin in diabetic-hyperlipidemic rats is in 
complete disagreement with the findings in hyperlipidemic-diabetic hamsters (El-
Swefy et al., 2000). In addition, efficacy of other statins (simvastatin, pravasatin and 
atorvastatin) in terms of their beneficial effects on glucose metabolism also remains 
controversial (Pyorolla et al., 1997; Freeman et al., 2001; KPSCG, 2002; Sever et al., 
2003; Sabatine et al., 2004). Among statins, only pravastatin has been shovra to 
exhibit beneficial effects on glucose metabolism especially in the postprandial state in 
CAD patients with IGT (Sugiyama et al., 2006). 
Our results demonstrate that treatment of STZ-induced diabetic rats with 
Tocomin or Lovastatin, for 14 weeks, mediated a reduction in the elevated fasting 
blood glucose levels, ranging from 257 to 329 mg/dl, to near normal range. STZ 
selectively destroys pancreatic insulin secreting P-cells (Doux et al, 1986; Portha et 
al., 1989; Okamato, 1981) causing diabetes close to type 2 in humans. The elevated 
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blood glucose levels in the diabetic rats used in this study were in the range of 236 to 
329 mg/dl, which resembles type 2 diabetes (150 to about 250 mg/dl) with partially 
functional pancreas as well as type 1 (above 300 mg/dl) with considerable amount of 
damaged pancreas. This shows that both Tocomin and Lovastatin may be useful in the 
treatment of both type 2 and type 1 diabetes, irrespective of whether the pancreas is 
partially functional or almost totally dysfunctional. In contrast, sulphonylurea drugs 
act only when there is a fiinctional pancreas (Sharma et ah, 1997; Ivora, 1988). 
Chronic hyperglycemia is a major determinant of the development of secondary 
complications of diabetes such as nephropathy and retinopathy. At present the most 
important factor influencing the occurrence of diabetic nephropathy and retinopathy is 
the duration of disease. In addition, there is a positive correlation between the 
presence of diabetic nephropathy and retinopathy. Our results demonstrate that after 
14 weeks of STZ-induced diabetes, histology of kidney resulted in the progression of 
difftjsed nodular glomerulosclerosis along with thickening of basement membrane in 
capillaries. Furthermore, an increase in the number of mesangial cells and enlarged 
Bowman space was also seen. After 14 weeks of Tocomin treatment, kidney from 
chronic diabetic rats showed a significant regression in glomerulosclerosis and 
normalization of basement membrane. In addition, histologically, the overall 
appearance was similar to normal kidney. Similarly, feeding of Lovastatin to diabetic 
rats was associated with a substantial reduction in basement membrane thickening and 
glomerulosclerosis. However, unlike Tocomin, Lovastatin therapy induced interstitial 
inflammation of lymphocytes. After 14 weeks of sustained hyperglycemia and 
increased oxidative stress, retina from diabetic rats exhibited poliferative retinopathy, 
characterized by complete retinal detachment. Tocomin or Lovastatin therapy 
prevented these changes and almost ftilly restored retinal detachment, similar to 
retinal membrane from normal control rats. Since Lovastatin is knovra to have host of 
side effects, it's feeding to diabetic rats was associated with a substantial separation of 
retinal membrane, which resulted in an open space between retina and lens. In 
conclusion, both Tocomin and Lovastatin mediated a significant decline in blood 
glucose and HbAi levels and restored the glycemic state similar to normal control 
rats. In addition, histologically, all the untoward features of nephropathy and 
retinopathy were significantly regressed and normalized by the administration of 
Tocomin or Lovastatin. However, treatment of chronic diabetic rats with Lovastatin 
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induced interstitial inflammation of kidney lymphocytes as well as separation of 
retinal membrane from the lens, resulting in an open space. In contrast, dietary 
tocotrienols (Tocomin), are vitamin E and have no toxicity, therefore, did not exhibit 
any side effect (Fig. 3.2-3.10). Our results are consistent with previous reports 
indicating that improved glycemic control is strongly associated with decreased 
development or regression of diabetic complications in both type 1 and type 2 
diabetes (UKPDS, 1998; Cusick et ah, 2002). Furthermore, recently it has been 
reported that a combined therapy of chronic diabetic rats with a hypoglycemic agent, 
Ocimum sanctum Linn and an antioxidant, a-tocopherol, for 16 weeks completely 
reversed the retionpathic changes (Eshrat and Mukhopadhyay, 2006). Similar to these 
findings, our results demonstrate a potent hypoglycemic property of both Tocomin 
and Lovastatin, which in conjunction with their strong antioxidant activity, as 
described in the present study, may have contributed to the prevention of diabetic 
nephropathy and retinopathy. The effectiveness of vitamin E (a-T) supplementation 
in preventing or reducing diabetic complications has been demonstrated in several 
studies. D-a-tocopherol was shown to act directly on the diacylglycerol-protein 
kinase-C pathway (Fig. 1.4), preventing glomerular dysfunctions (Koya et al., 1997) 
and normalizing the abnormal retinal blood flow (Kunisaki et al, 1998) in diabetic 
rats. Vitamin E could also exert its protective effects indirectly by improving insulin 
action (Paolisso et al., 1993b), and as an antioxidant in many pathological disorders 
associated with oxidative stress (Jialal et al., 1995; Rimm et al., 1993; Watson and 
Leonard, 1986). In the present investigation we have shown that the treatment of 
chronic diabetic rats with Tocomin or Lovastatin mediated a decline in blood glucose 
and HbAi levels close to normal values, as well as offered a significant protection 
against nephropathy and retinopathy. These results imply that there is a significant 
association between improved glycemic control and Tocomin or Lovastatin. Although 
a detailed investigation is needed to elucidate the possible mechanism(s) involved, it 
is intriguing to postulate that both Tocomin and Lovastafin being potent antioxidants 
may have effectively protected the P-cells from total damage by STZ and/or 
glucotoxicity. In the presence of residual ftinctional islet cells, the blood glucose and 
HbA] levels of diabetic rats treated with Tocomin or Lovastatin were significantly 
lower. Our results appear to be in agreement with an earlier study, which showed that 
by pretreating rats with a-tocopherol before STZ administration, the severity of 
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pancreatic damage could be significantly reduced (Slonim et al., 1983). Similar 
effects were also reported for soybean diet, postulated to be due to the presence of 
soybean trypsin inhibitor that promotes the binding capacity of insulin receptor and 
arginine, a potent insulinotrophic agent (Lee and Park, 2000). Our data also suggest 
that the amount of total antioxidants present in the circulation or perhaps in the tissues 
during the chemical insult was an important factor. In diabetic rats, plasma total 
antioxidants level was reduced to 37 famole/dl from a normal value of 50 i^mole/dl. 
Treatment of diabetic rats with Tocomin or Lovastatin significantly increased the total 
antioxidant levels to a value of 72 and 59 ^mole/dl, respecfively (Table 9). This 
increase in plasma total antioxidant levels in Tocomin or Lovastatin treated rats, along 
with their novel and potent hypoglycemic activity, seems to be adequate for the 
normalization of glycemic state. 
Diabetic mellitus confers an increased propensity to accelerated atherogenesis. 
Abnormalities in lipid profile are one of the major contributing causes of vascular 
complications in diabetic patients (Ono et al, 1998; Giugliano et al, 1996). It has 
been well documented that diabetic patients have increased glycation and increased 
lipoprotein oxidation and a reduced anfioxidant status (Bellomo et al, 1995; Maxwell 
et al, 1997). Thus, oxidative modificafion of lipoproteins, particularly LDL, could be 
one of the mechanisms for an early development of atherosclerosis in diabetes. An 
enhanced susceptibility to oxidative modification could contribute to the greater 
athergenecity of sd-LDL (De Graff et al, 1991; Tribble et al, 1992; Chait et al, 
1993). The report of the Diabetes Control and Complicafions Trial (DCCT, 1996) 
clearly showed the benefit of antioxidants in the prevention of diabetic microvascular 
disease. However, to date, the treatment of diabetic macrovascular disease is far fi-om 
optimal. We have investigated the role of Tocomin and Lovastatin in the prevention 
of hyperlipidemia, which is known to be associated with a long-term STZ-induced 
diabetes in rats. As expected, our data showed a striking increase in TG, TC, and non-
HLD-C in diabetic-hyperlipidemic rats. Treatment of these rats with Tocomin or 
Lovastatin mediated a significant reduction in the above lipid parameters, which were 
close to their respective normal values. It is important to note that Lovastatin, in 
comparison to Tocomin, was more effective in selectively reducing the atherogenic 
lipoprotein particles (non-HLDL-C). Similarly, VLDL-C, LDL-C, HDL-C and its 
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subfractions, HDL2-C and HLD3-C levels were significantly increased in diabetic rats, 
which were significantly reduced after treatment with either Tocomin or Lovastatin. 
Plasma HDL-C and it's subfractions, HDL2-C and HDL3-C levels, were substantially 
increased after 14 weeks of STZ-induced diabetes. These results are consistent with 
other reports, where a significant increase in HDL-C level in diabetic rats has been 
reported (Ebara et al., 1994; Kobayshi et al., 2000). Since these diabetic rats are 
considered as essentially models of type 1 diabetes (Halliwell, 2002), an increased 
plasma HDL-C level has been reported in type 1 diabetic patients (Drexel et al., 1992; 
Guerin et al., 2000). In contrast, type 2 diabetics, as well as hyperlipidemic-diabetic 
hamsters (El-Swefy et al, 2000) exhibited a decrease in plasma HDL-C. Tocomin 
treatment to diabetic rats (D-TT) significantly suppressed (41 %) the increase in 
HDL-C levels; however, this decreased HDL-C value was higher than N-C value by 
14 %. On the other hand, feeding of Lovastatin mediated a decrease of 32 % in HDL-
C level, which was higher than N-C value by 31 %. A similar increase of 29 % in 
HDL-C of Lovastatin treated hyperlipidemic-diabetic hamsters has been reported (El-
Swefy et al., 2000). The cholesterol content of large, light, cholesteryl ester-rich 
HDL2, which is considered to be a strong predictor of presence and extent of CAD 
(Drexel et al., 1992), was significantly and equally reduced (37 %) in both Tocomin 
and Lovastatin treated groups. Small, dense, lipid-poor HDL3, which exerts potent 
protection of atherogenic LDL against oxidative stress, was significantly reduced (45 
%) in D-TT and to a less extent (31 %) in D-LT. Similar to HDL-C, the reduced 
levels of HDL3-C in D-TT and D-LT were still higher by 10 % and 21 %, 
respectively, when compared to HDL3-C value in N-C, indicafing a two-fold higher 
increase in HDL-C and HDL3-C levels in Lovastatin treated diabetic rats. These data 
are in agreement with published evidence indicating that Lovastatin treatment of 
hyperlipidemia was associated with a significant increase in antiatherogenic HDL-C 
concentrations (Helve and Tikkanen, 1988; El-Swefy et al., 2000). The above results 
indicate that both Tocomin and Lovastatin mediated a significant decline of plasma 
and lipoprotein lipids in a long-term experiment in diabetic rats. In general, both 
Tocomin and Lovastatin were equally effective in terms of their lipid lowering 
efficacy. These results are in agreement with our previous finding in type 2 diabedc-
hyperlipidemic patients (Baliarsingh et al., 2005), where after 60 days of TRF 
treatment, subjects showed a significant decline in serum total lipids, TC and LDL-C 
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with no significant effect on TG and HDL-C levels. However, in another study, 
feeding of TRF to type 2 diabetic patients for 60 days caused no significant change in 
TG, TC, LDL-C and HDL-C levels (Nazaimoon et al, 1996). The results of present 
study are also consistent with our previous findings and reports fi^om other 
laboratories indicating strong hypolipidemic effects of TRF or purified tocotrienols 
(Tocomin) in normolipidemic and hyperlipidemic rats (Beg et al., 1996b; Minhajuddin 
et al, 1999; Minhajuddin et al, 2005; Sharma and Rukmini, 1986 and 1987; 
Seetharamaiah and Chandrasekhara, 1989; Watkins et al, 1993); normolipidemic and 
genetically hyperlipidemic swines and chickens (Qureshi et al, 1991c; Qureshi and 
Qureshi, 1993; Qureshi et al, 2000); hyperlipidemic rabbits (Teoh et al, 1994); 
cholesterol/oxidized cholesterol-induced hyperlipidemic/atherosclerotic rabbits 
(Zainuddin, 2004; Beg and Zainuddin, 2003); normolipidemic and hyperlipidemic 
humans (Beg et al, 1995; Beg et al, 1996b, Beg et al, 1997; Minhajuddin et al, 
1999; Tan et al, 1991; Qureshi et al, 1991a, Qureshi et al, 1997; Qureshi et al, 
2001b; Qureshi et al, 2002) and hyperlipidemic hamsters (Raederstorff e/ al, 2002). 
Similarly, our results showing lipid lowering effects of Lovastatin are consistent with 
previous findings indicating strong hypolipidemic effects of Lovasatin and other 
statins. Statins have been used to reduce plasma cholesterol levels in many animal 
species (Alberts et al, 1980; Kovanen et al, 1981; Tobert et al, 1982). In another 
study, feeding of Lovastatin to hyperlipidemic-diabefic hamsters mediated a 
significant reduction in TG, TC, non-HDL-C and phospholipids, with an increase in 
HDL C levels (El-Swefy et al, 2000). In clinical studies, Lovastatin and compactin 
effectively reduced plasma LDL-C in normal (Tobert et al, 1982) as well as subjects 
with heterozygous familial hypercholesterolemia (Bilheimer et al, 1983). 
LDL particles are heterogeneous with respect to their size, density and lipid 
composition. Compared with Ib-LDL, sd-LDL is thought to be more atherogenic as a 
result of their better penetration into the arterial wall, lower binding affinity for the 
LDL-receptor, prolonged plasma half life, and lower resistance to oxidative stress 
(Chapman et al, 1998; Bjomheded et al, 1996). Several studies have reported a 2- to 
3-fold increase in CHD risk among patients with a predominance of sd-LDL particles 
(Austin et al, 1988; Austin et al, 1990; Ausfin et al, 1994). Hirano et al (2004) have 
shown that not only the prevalence of sd-LDL but also its concentration was 
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substantially increased in patients with diabetes, CHD or diabetes with CHD. 
Similarly, Quebec cardiovascular study has confirmed that a predominance of sd-LDL 
is a strong and independent predictor of CHD in the first seven years of follow-up (St-
Pierre et ai, 2005). Recently, Koba et al. (2006) have reported that the progression of 
CHD was closely linked not to the LDL particle size, but to the concentration of sd-
LDL. Therefore, sd-LDL has been highlighted as a new powerful and useful marker 
for the lisk of CHD or type 2 diabetes with and without CHD (Austin et al., 1995; 
Hirano et al, 2004; Koba et al, 2006). The results presented in Table 5 demonstrate 
that sd-LDL-C and its percent share of total LDL-C, as well as sd-LDL-apoB and its 
percent share of total LDL-apoB have always increased or decreased in tandem, 
indicating a very strong correlation between sd-LDL-C and sd-LDL-apoB values. 
Furthermore, these data suggest that the measurement of cholesterol content may be 
sufficient to evaluate the sd-LDL mass and that apoB measurement is not essential. It 
is likely that both the cholesterol and apoB content of each particle is homogeneous in 
the sd-LDL fraction. These results are fiilly consistent with earlier reports (Hirano et 
al, 2003; Hirano et al, 2004), where only sd-LDL-C was measured and Ib-LDL-C 
was estimated as difference between LDL-C and sd-LDL-C. In the present study, 
mean sd-LDL-C level in normal rats was 32 mg/dl, which was 32 % of total LDL-C. 
Similarly, sd-LDL-apoB level in N-C rats was 36 mg/dl, which was 27 % of total 
LDL-apoB. As expected, in diabetic-hyperlipidemic rats, sd-LDL-C was markedly 
increased (245 %) and the majority (63 %) of LDL-C was recovered in the sd-LDL 
fraction. Similarly, sd-LDL-apoB level was significantly increased by 154 %, which 
was 62 % of total LDL-apoB. Our results indicating a substantial increase in the 
levels of sd-LDL-C, sd-LDL-apoB and their percent share of total LDL-C or LDL-
apoB in diabetic-hyperlipidemic rats are similar to the data reported in patients with 
diabetes, CHD alone, diabetes with CHD, hypertriglyceridemia and combined 
hyperlipidemia (Hirano et al, 2004). However, in these patients, sd-LDL-apoB levels 
were not reported. 
Treatment of diabetic-hyperlipidemic rats with Tocomin or Lovastatin was 
associated with a significant reduction in sd-LDL-C levels by 53 % in D-TT and 56 % 
in D-LT. Whereas, in both the treated groups, sd-LDL-C as a percent of total LDL-C 
was reduced to a level of 42-43 %, which is close to normal control value of 32 %. 
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Similar to sd-LDL-C, sd-LDL-apoB content and its percent share of total LDL-apoB 
was significantly reduced after 14 weeks of Tocomin or Lovastatin treatment. As 
expected, the mean Ib-LDL-C and its apoB content in normolipidemic rats were 65 
and 91 mg/dl, respectively, which was 66 % of total LDL-C and 69 % of total LDL-
apoB. These results represent a significant increase in comparison to sd-LDL-C and 
sd-LDL-apoB values in N-C. Due to substantial increase in sd-LDL-C level in 
diabetic-hyperlipidemic rats, no increase in Ib-LDL-C was seen in comparison to N-C 
value. In addition, the levels of Ib-LDL-C in D-TT and D-LT rats remained 
unchanged and were similar to values in D-C or N-C. In contrast to sd-LDL-apoB, Ib-
LDL-apoB content as well as its percent share of total LDL-apoB in diabetic rats was 
significantly reduced (40-47 %), when compared to corresponding Ib-LDL-apoB 
values of normal rats. Treatment of diabetic-hyperlipidemic rats with Tocomin or 
Lovastatin mediated a significant increase in Ib-LDL-apoB levels close to normal 
value. It is interesting to mention that sd-LDL is known to be generated fi-om large 
triglyceride-rich VLDL particle, production of which is enhanced by insulin 
resistance during diabetes, thus resulting in an increased prevalence of sd-LDL 
(Packard and Shephered, 1997; Tribble et al, 2001; Bemeis and Krauss, 2002). Our 
results are consistent with these findings, showing a significant increase in the level of 
plasma VLDL-C (76 %), TG (76 %) and sd-LDL-C (244 %) in chronic diabetic rats. 
Therefore, based on our results, the greater atherogenic potential of sd-LDL in 
comparison to Ib-LDL may explain the higher incidence of CHD in diabetic patients 
than in isolated hypercholesterolemia (Hirano et al, 1998; Hirano et al., 2004). In 
addition, because of greater preponderance of sd-LDL, a moderately high LDL-C 
(between 130 and 160 mg/dl) in a type 2 diabetic patient is equivalent to a much 
higher LDL-C in terms of CHD risk for a nondiabetic subject (Grundy et al., 1999; 
Haffner et al., 1998; NCEP Expert Panel, 1993). Therefore, the primary target of 
therapy in type 2 diabetic patients is lowering LDL-C to a level < 100 mg/dl as 
suggested by NCEP Expert Panel for patients with preexisting CHD (NCEP Expert 
Panel, 1993). Similarly, the substantial increase in more atherogenic sd-LDL in our 
study as well as in diabetic patients with and without CHD requires an immediate 
attention. However, no therapeutic interventions to reduce the elevated levels of sd-
LDL-C in diabetic-hyperlipidemic patients or animals have been reported (Hirano et 
al. 2004; Hirano et al, 2005; Koba et al, 2006). In the present study, which 
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represents an initial demonstration, administration of dietary tocotrienols (Tocomin) 
or Lovastatin to diabetic rats was associated with a concomitant and significant 
decline in the levels of both LDL-C and more atherogenic sd-LDL-C. In D-TT rats, 
LDL-C was reduced from 172 to 124 mg/dl, whereas, in D-LT it was reduced to 111 
mg/dl. The decline registered in sd-LDL-C from an elevated level of 109 mg/dl in D-
C to a value of 52 mg/dl in D-TT and 48 mg/dl in D-LT rats represent a very potent 
cholesterol lowering therapeutic impacts of Tocomin and Lovastatin. It has been 
established that LDL-C/HDL-C and HDL-C/TC ratios are good predictors for the 
presence and severity of CAD (Drexel et al, 1992). In addition to LDL-C/HDL-C and 
HDL-C/TC ratios, we have also presented the ratios of sd-LDL-C/HDL-C and HDL-
C/sd-LDL-C (Table 6), which were increased (80 %) or decreased (44 %) in D-C rats, 
respectively, in comparison to the corresponding ratios in N-C. Tocomin or Lovastain 
treatment of diabetic rats for 14 weeks resulted in a significant improvement in these 
ratios, indicating normalization of above lipid and lipoprotein lipid parameters. Our 
results also demonstrate that similar to plasma TG and TC, liver TG and TC levels 
were significantly increased in diabetic-hyperlipidemic rats. Feeding of Tocomin or 
Lovastatin to diabetic rats resulted in a significant decline of both TG and TC to 
nearly normal values. The combined results indicate that increased levels of plasma 
and hepatic lipids as well plasma lipoprotein lipids in diabetic rats were significantly 
reduced after treatment with 6.0 mg Tocomin or 0.50 mg Lovastatin/rat/day for 14 
weeks. 
It has previously been established that diabetic rats deficient in insulin are 
known to express low levels of hepatic HMG-CoA reductase activity (Ness et al, 
1994a; Ness et al, 1994b; Ness and Gertz, 2004) and frequently exhibit elevated 
serum cholesterol levels (Eshrat and Mukhopadhyay, 2006; Chen and Cheng, 2006). 
In addition, diabetic rats given replacement doses of insulin restored high levels of 
hepatic HMG-CoA reductase (Ness and Chambers, 2000; Lakshmanan et al, 1973; 
Ness et al, 1994a; Ness et al., 1994b). Our results also show a significant decrease (57 
%) in liver HMG-CoA reductase activity and a substantial increase in plasma and 
tissue lipid levels in rats after 14 weeks of STZ-induced diabetes. This decrease in 
hepatic HMG-CoA reductase activity in diabetic rats may be due to a sustained 
insulin deficiency/hyperglycemia and hyperlipidemia. Treatment of these diabetic-
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hyperlipidemic rats with Tocomin or Lovastatin for 14 weeks was associated with a 
significant reduction in glucose and lipid levels as well as restoration of hepatic 
HMG-CoA reductase activity to a level similar to normal control value. This increase 
in hepatic HMG-CoA reductase activity in D-TT and D-LT rats close to normal levels 
may be due to an increase in insulin activity along with a concomitant 
decline/normalization of both glucose and lipid levels. Both tocotrienols (Tocomin) 
and Lovastatin are known to exert their hypolipidemic effects in hyperlipidemic 
animals by reducing HMG-CoA reductase activity (Minhajuddin et al, 1999; Beg et 
ai, 2000a; Beg et al, 2000b; Minhajuddin et al., 2005; Endo et al, 1979; Tanaka et 
al, 1982). However, our present results indicate that the mechanism(s) of their 
cholesterol lowering effects in diabetic-hyperlipidemic rats may be quiet different. 
Support for the existence of such a mechanism is obtained from a recent report (Chen 
and Cheng, 2006), where rice bran oil containing y-tocotrienol or y-oryzanol have 
been shown to exert their hypolipidemic effects in diabetic rats by increasing fecal 
neutral sterol and bile acid excretion, via upregulating cholesterol synthesis and 
catabolism. After 4 weeks of feeding RBO containing y-tocotrienol or y-oryzanol to 
STZ/nicotinamide-induced diabetic rats, there was a 50 % increase in hepatic HMG-
CoA reductase mRNA, 89 % increase in the hepatic LDL-receptor and -100 % 
increase in the mRNA of 7a-hdroxylase -the rate controlling enzj'me in the 
biosynthetic pathway of bile acids (Chen and Cheng, 2006). It is likely that the 
mechanism described for the cholesterol lowering actions of RBO containing y-
tocotrienol or y-oryzanol in diabetic rats, may also be operative for tocotrienols 
(Tocomin) and Lovastatin in diabetic-hyperlipidemic rats. 
Increased lipid peroxidation can be detected in early stages of type 2 diabetes, 
long before the development of any diabetic complications (Halliwell, 2002). Since 
most animal studies of diabetes are induced by administration of STZ or alloxan, toxic 
agents that target P-cells, they are thus essentially considered as models of type 1 
diabetes. Nevertheless, such animals show increased lipid peroxidation (Halliwell, 
2002), hyperlipidemia and other diabetic complications seen in type 2 diabetes. In 
addition, hyperglycemia directly causes cellular dysfunctions (Koya and King 1998; 
Nishikawa et al, 2000), glycation (Brownlee, 1994) and oxidative stress (Wolff, 
1993). All these factors aggravate the consequences of the diabetic dyslipidemia by 
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increasing susceptibility to lipid peroxidation. This leads to accumulation of products 
of oxidative damage to lipids (Griesmacher et al., 1995), foam cell formation and 
eventually increased atheroma plaque deposition (Ross, 1990). When the lipid 
peroxides formed and accumulate to a certain degree, they leak from the organ or 
tissue in to the blood stream and increase the lipid peroxide level in the blood. Thus, 
the increased blood lipid peroxide level obviously indicates the occurrence of some 
membrane damage in cells of some organ or tissue provoked by diabetes. 
Accordingly, the blood lipid peroxide level also indicates the severity of the disease 
(Yagi, 1987). Several studies have shown that supplementation of antioxidants, such 
as vitamin E, prevent membrane lipid peroxidation in vivo, thereby decreasing the 
extent of diabetic complications (Halliwell, 2002). In our study, the increase in 
plasma lipid peroxidation products in diabetic-hyperlipidemic rats is consistent with a 
substantial decline (27%) in plasma total antioxidant levels. Elevated plasma 
concentrations of conjugated dienes, lipid hydroperoxides and TBARS suggest that 
lipid peroxidation is significantly enhanced in diabetic-hyperlipidemic rats. Several 
other workers have also reported elevated lipid peroxidation products in blood 
samples of type 1 and type 2 diabetic patients (Karasu et al., 1997; Slonim et al., 
1983; Laight et al., 1999; Ihara et al., 2000; Tanaka et al., 1999) as well as in STZ-
induced diabetic rats (Bukan et al., 2003; Eshrat, 2002). The reduction in the levels of 
these products in both the treated groups is directly related with a significant increase 
in the plasma total antioxidant levels. This increase in the levels of plasma total 
antioxidant was above the normal value by 43 % in D-TT and 17 % in D-LT 
indicating an increased scavenging capacity against elevated lipid peroxiadtion 
process in diabetic rats. As a-tocopherol (vitamin E) is known for its antioxidative 
property (Gapor et al., 1989; Asmah et al., 1993; Bieri et al., 1983; Aoki et al., 1992; 
Vannucchi et al., 1999), the decreased levels of MDA and other intermediate products 
of lipid peroxidation in our study was apparently due to increased consumption of the 
antioxidants, tocotrienols (Tocomin) or Lovastatin. Our observation that there is a 
significant inverse association between plasma lipid peroxidation products and total 
antioxidant levels in treated diabetic rats in D-TT and D-LT, further supports the 
potent antioxidative role of tocotrienols (Tocomin) and Lovastatin. In another report 
(Nazaimoon and Khalid, 2002), no increase in serum MDA level was seen in STZ-
induced diabetic rats. In addition, feeding of TRF or vitamin C-rich diet to diabetic 
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rats for 12 weeks failed to influence serum MDA levels (Nazaimoon and Khalid, 
2002). This was rather unexpected as we in the present investigation and others have 
reported significant increase in MDA levels when rats became diabetic (Aoki et ah, 
1992) or when diabetic rats were on vitamin E (a-tocopherol) deficient diet 
(Vannucchi et al., 1999). In our opinion, no increase in serum MDA level in diabetic 
rats, as reported by Nazaimoon and Khalid (2002), was apparently due to the feeding 
of TRF or vitamin C-rich diet for 4 weeks prior to induction of diabetes. Recently, 
Zhu et al. (2005) have demonstrated an increase in the plasma MDA level in 12-week 
STZ-induced diabetic rats. This increase in MDA levels of diabetic rats was less 
pronounced after simvastatin treatment for 12 weeks. In another report, El-Swefy et 
al. (2000) have demonstrated a substantial and significant increase in plasma MDA 
concentration in hyperlipidemic-STZ-induced diabetic hamsters. Hyperlipidemic-
diabetic hamsters treated with Lovastatin or a-tocopherol had significantly lower 
plasma MDA levels. Our results are consistent with two reports (Zhu et al., 2005; El-
Swefy et al, 2000), indicating an increase in plasma MDA levels in diabetic rats and 
hyperlipidemic-diabetic hamsters, and reduction in MDA levels following treatment 
with simvastatin or Lovastatin. Our results are also in agreement with a previous 
report, where basal serum MDA levels in type 2 diabetic patients were significantly 
higher than in normal subjects. Daily intake of TRF for 60 days caused a significant 
decrease in MDA levels (Nazaimoon et al, 1996). 
It is well known that the increase of free radicals in diabetic-hyperlipidemic 
condition is further aggravated due to the increased lipid peroxidation and the damage 
of antioxidant defense systems (Wolf, 1993), which may lead to disruption of cellular 
functions and oxidative damage to membranes. Lipid peroxidation products including 
MDA reflect the oxidant/antioxidant balance in diabetes. Our results demonstrate that 
treatment of diabetic-hyperlipidemic rats with two potent antioxidants (Tocomin and 
Lovastatin) may mediate a reduction in lipid peroxidation products by scavenging 
cellular free radicals, thus improving overall oxidant/antioxidant balance as well as 
possibly protecting the oxidative damage to membranes and tissues. Several 
abnormalities have been identified in the erythrocytes of diabetic patients as reviewed 
by Jones and Peterson (1981). In particular, erythrocytes of diabetic patients have a 
reduced life span (Lehrman, 1977; Pescarmona et al., 1982), excessive aggregation 
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(Schmid-Schonbein and Volger, 1976; Satoh et al, 1984), altered membrane 
phospholipid asymmetry (Wali et al, 1988), and an increased tendency to adhere to 
endothelial cells (Wali et al., 1988; Wautier et al., 1981). Erythrocytes of diabetic 
patients are exposed to continuous oxidative stress, because oxygen radicals are 
continuously generated by the autooxidation of hemoglobin (Misra and Fridovich, 
1972). Oxygen radicals formed over and above the detoxifying capacity of 
erythrocytes can cause peroxidative breakdown of phospholipid fatty acids and 
accumulation of MDA (Halliwell and Gutteridge, 1984). In addition, erythrocytes of 
diabetics are more susceptible to lipid peroxidation when treated with hydrogen 
peroxide in vitro (Uzel et al, 1987). Our results show a greater susceptibility to 
hydrogen peroxide-induced lipid peroxidation in erythrocytes from diabetic-
hyperlipidemic rats than those from normal rats. A significant increase of 117 % in 
the percent release of MDA from erythrocytes in D-C was markedly decreased to a 
level similar to normal value following treatment with Tocomin or Lovastatin. 
Consistent with these results, MDA content of erythrocytes hemolysate was 
significantly increased (105 %) in diabetic-hyperlipidemic rats. Similarly, a highly 
significant decrease in MDA content was seen in diabetic rats treated with Tocomin 
or Lovsatatin. Our results in diabetic rats are consistent with previous reports 
indicating that erythrocytes of diabetic patients are more susceptible to lipid 
peroxidation when treated with hydrogen peroxide in vitro (Matkovics et al, 1982; 
Uzel et al, 1987). However, in these studies no antioxidant treatment of diabetics was 
included. The exact mechanism by which elevated blood glucose leads to membrane 
lipid peroxidation of erythrocytes of diabetic-hyperlipidemic subjects is not known 
(Jain et al, 1989). However, based on our results it seems plausible that oxygen 
radicals formed over and above the detoxifying capacity of erythrocytes can cause 
peroxidative breakdown of phospholipid fatty acids and accumulation of MDA and 
hence membrane damage. This free radical mediated enhanced peroxidation of 
membrane fatty acids is significantly blocked in diabetic rats treated with 
antioxidants, Tocomin or Lovastatin. 
As indicated above, alterations in lipid composition can affect the physico-
chemical properties of the erythrocytes membrane, including plasma membrane, Na^, 
K^-ATPase and Mg^^-ATPase activities (Tsakiris and Deliconstantinos, 1984). In 
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previously published reports (Raccah et al., 1996; Mimura et al., 1994; Llewelyn and 
Thomas, 1987), a decrease in Na^, K*-ATPase activity in various tissues including 
erythrocytes of diabetic animals as well as humans have been observed. Consistent 
with these reports, our results indicate a significant reduction of 37 % and 78 % in 
total, and Na^, K^-ATPase activities, respectively, in erythrocyte membranes of 
diabetic rats. Consistent with hypolipidemic, antioxidant and hypoglycemic 
properties, Tocomin and Lovastatin significantly prevented the decline in total 
ATPase activity in D-TT and D-LT and restored to a level similar to normal rats. 
Since the decline in Na\ K^-ATPase activity in D-C was more drastic, treatment with 
Tocomin or Lovastatin partially restored this activity in comparison to normal value. 
A decrease in this enzyme activity has been implicated in the pathogenesis of diabetic 
polyneuropathy via an activation of the polyol pathway (Fig. 1.3) leading to an 
accumulation of sorbitol and fructose and decrease in myoinositol concentrations in 
the peripheral nerve (Greene et al., 1987a). It has also been previously observed that 
this enzyme activity was lower in the erythrocyte membranes of male type 1 diabetic 
patients with neuropathy than those without it (Raccah et al., 1992). A decreased 
activity of this enzyme has been linked to the development of atherosclerosis in 
diabetes (Stojadinovic et al, 1996). Previous report showing a reduced erythrocytes 
Na^, K*-ATPase activity in type 2 diabetics has explained this effect on an alteration 
in membrane fluidity (Mazzanti et al., 1989), which has a strong influence on 
important membrane function such as the conformation and thus the activities of 
membrane associated enzymes. The enhanced oxidative damage of membranes in 
diabetes may also contribute to the alteration in activities of membrane bound 
enzymes (Jain and Lim, 2001). Insulin therapy to diabetic patients normalizes lipid 
composition and other abnormal changes. It stimulates Na^, K^-ATPase activity and 
translocation to plasma membrane via phosphorylation of the a-subunits by protein 
kinase-C (Al-Khalili et al., 2004). Previous studies have shown that a number of 
dietary components may influence membrane characteristics such as fluidity, stability 
and susceptibility to membrane oxidative damage (Peck, 1994; Gutteridge and 
Halliwell, 1996). Dietary modulators of membrane structure and function include 
several antioxidants such as flavonoids (Gutteridge and Halliwell, 1996), P-carotene 
(Gutteridge and Halliwell, 1996; Thumham, 1994), ascorbic acid (Gutteridge and 
Halliwell, 1996; Thumham, 1994) and vitamin E (Gutteridge and Halliwell, 1996; 
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Morrissey et al., 1994). Based on potent antioxidative and protective properties of 
Tocomin and Lovastatin described here, the mechanism of action of these 
antioxidants, in terms of effectively preventing the dysfunction of erythrocytes 
membrane bound Na ,^ K -^ATPase activity induced by diabetes, may be similar to 
other antioxidants including a-tocopherol described elsewhere (Gutteridge and 
Halliwell, 1996; Thumham, 1994; Morrissey etal., 1994). 
Similar to plasma, the conjugated dienes, lipid hydroperoxides and TBARS in 
liver and kidney were significantly increased. Treatment of diabetic rats with 
Tocomin or Lovastatin for 14 weeks mediated a significant decline in all lipid 
peroxidation products, except the hepatic conjugated diene formation in D-LT did not 
respond to Lovastatin treatment. Failure of Lovastatin to reduce the level of hepatic 
conjugated dienes in diabetic rats and a lesser (9 %) reduction in hepatic 
hydroperoxides is similar to another report (Duthie, 1991). 
An increasing number of studies have pointed out a possible role of LDL 
peroxidation in the occurrence of atherogenic lesions, which are one of the most 
frequent complications of diabetes (Deckert et al., 1978; Stout, 1979; Clowell et al, 
1981). The involvement of increased oxidative stress in diabetes is supported by 
several data such as increased concentrations of lipid peroxidation products 
(conjugated dienes, hydroperoxides and TBARS) and decreased levels of antioxidants 
in the plasma of patients (Sato et al, 1979; Karpen et al, 1984; Wolf, 1987). In 
addition, an elevated glucose concentration in plasma could promote LDL oxidation 
by leading to glycated forms of the particle, which are more sensitive to transition 
metal-dependent autooxidation (Sakurai et al, 1991). High glucose concentrations 
have been reported to enhance in vitro LDL oxidative modification induced by copper 
ions (Hunt et al, 1990; Hunt et al, 1994). The observation that elevated glucose 
concentrations in the culture medium enhances superoxide production and the 
subsequent ability of endothelial and smooth muscle cells to oxidatively modify LDL, 
brings a new insight to the pathogenesis of atherosclerotic lesions in diabetes (Mazeri 
et al, 1995). Otero et al (2002) have demonstrated that the consumption of vitamin E 
in normal human LDL subjected to Cu'^ '^ -induced oxidation was delayed by a glucose 
concentration frequently foimd in subjects with poorly controlled type 1 diabetes. 
Since vitamin E is one of the first compounds to be consumed during the LDL 
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oxidation process (Esterbauer et ah, 1991), this finding indicates that glucose delays 
the early phases of LDL oxidation. However, high glucose concentration accelerated 
the LDL oxidation once LDL associated vitamin E was consumed. This prooxidant 
effect of glucose was reflected by increased formation of conjugated dienes, TEARS 
and a decreased lag phase (Otero et al, 2002). Although lipid oxidation in the vessel 
wall is thought to occur as result of local deficiency of endogenous antioxidants or an 
excess of free metal ions, only limited data support these hypotheses (Jialal and 
Devraj, 1996; Steinberg, 1997). Research has shown that human atherosclerotic 
plaques contain massive amounts of lipid peroxidation products, despite the presence 
of large quantities of a-tocopherol and ascorbate (Suama et al., 1993). Thus, it is 
unclear whether oxidized lipoproteins originate in the arterial wall or are produced in 
the circulation and then enter the intimal space. Nevertheless, oxidative modification 
of lipoproteins would be one of the possible mechanisms for an early development of 
atherosclerosis in diabetes. This hypothesis has led to great interest in the 
development and evaluation of antioxidants as potential antiatherosclerotic agents. As 
discussed earlier (p. no. 157-160), increase in the concentration of more atherogenic 
sd-LDL has directly been linked to the progression of diabetes with and without CHD 
or CHD alone. Therefore, we sought to determine the differential ex vivo and in vitro 
oxidative susceptibility of sd-LDL and Ib-LDL as well as LDL isolated from plasma 
of normal and diabetic-hyperlipidemic rats. Considering the potent hypoglycemic, 
hypolipidemic and antioxidant properties of Tocomin and Lovastatin shovm in the 
present study, possible protective impacts of these agents on the in vivo oxidative 
modification of these lipoproteins in diabetic rats were determined. Consistent with ex 
vivo BDC levels of LDL, sd-LDL and Ib-LDL, susceptibility of these particles to 
copper-induced oxidation, as measured by their lag time, was decreased in D-C. It is 
important to mention that in comparison to a lag phase value of 98 min and 50 min for 
LDL and Ib-LDL, respectively, in N-C, the lag phase of sd-LDL was only 17.0 min, 
indicating a substantially high oxidative susceptibility to oxidation. After treatment 
with Tocomin or Lovastatin, the lag phase time of sd-LDL was increased from a value 
of 8.5 min in D-C to an identical value of 12.5 min in D-TT and D-LT. In contrast to 
sd-LDL, the lag phase of Ib-LDL was reduced to 40 min in D-C from a value of 50 
min in N-C. However, the lag phase of Ib-LDL was fully restored to 50 min in D-TT 
and 52 min in D-LT. It is worth mentioning that in comparison to N-C, the decline in 
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lag phase values of LDL and sd-LDL in D-C was significantly liigher (-50 %) than 
the decrease in the lag phase of Ib-LDL, which was only 20 %. On the other hand, the 
lag phase time of LDL was partially restored in D-TT and D-LT rats; however, the 
increase in D-LT was more pronounced. 
As expected, the ex vivo BDC levels of LDL, sd-LDL and Ib-LDL isolated 
from plasma of N-C, D-C, D-TT and D-LT rats were not affected in the presence of 
glucose. However, with glucose the lag phases of copper-induced conjugated diene 
formation in LDL, sd-LDL and Ib-LDL of N-C group were reduced, when compared 
to their corresponding lag phase values obtained in the absence of glucose. In D-C 
rats, which were deficient in antioxidants, and exhibit a high plasma glucose level, 
addition of glucose in the incubation medium further mediated a prooxidant effect 
only on sd-LDL lag phase, which was reduced to 6.5 min from a lag phase value of 
10.0 min in N-C. No prooxidant effect of glucose was seen on the lag phase values of 
LDL and Ib-LDL of D-C rats. The substantial prooxidant effect of glucose on sd-LDL 
lag phase of N-(' and D-C rats is consistent with the previous reports indicating it's 
enhanced susceptibility to oxidation (De Graaf et al. 1991; Tribble et ai, 1992; 
Dejager et al., 1993; Tribble et al. 1994; Tribble et al., 1995) and reduced content of 
antioxidants in sd-LDL, relative to Ib-LDL (De Graaf e/ al. 1991; Tribble et al., 1992; 
Dejager et al., 1993; Tribble et al. 1994; Tribble et al., 1995). In D-TT and D-LT rats, 
due to the presence of high plasma levels of antioxidants, tocotrienols 
(Tocomin)/Lovastatin, prooxidant effect of glucose was not seen and the lag phase 
values of sd-LDL were increased to a level similar to corresponding values in D-TT 
and D-LT obtained after the oxidation of sd-LDL in absence of glucose. Our results 
show that due to sustained oxidative stress in D-C, the ex vivo base line diene 
conjugation (BDC) levels of LDL, sd-LDL and Ib-LDL were significantly increased. 
However, in comparison to ex vivo BDC level of Ib-LDL, the BDC level of sd-LDL 
was higher by 3.5 fold, indicating a markedly enhanced susceptibility of sd-LDL to in 
vivo oxidation. Treatment of diabetic rats with Tocomin or Lovastatin significantly 
reduced the ex vivo BDC levels. It is interesting to mention that in both the treated 
groups, the decline mediated by Tocomin and Lovastatin in BDC levels of sd-LDL 
was more pronounced. This increase in BDC levels of lipoprotein particles in D-C and 
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subsequent decrease in treated groups is consistent with the plasma values of 
conjugated dienes, lipid hydroperoxides and TEARS (Table 9) 
Based on the ex vivo results described above, we investigated 
prooxidant/antioxidant effect of glucose on in vitro Cu^^-induced oxidative 
modification of LDL, sd-LDL and Ib-LDL isolated from normal plasma pretreated 
with no antioxidant, Tocomin, a-tocopherol or Lovastatin. These results (Tables 15-
17) show that due to markedly enhanced in vivo oxidation of sd-LDL, it's ex vivo 
BDC levels, measured before the initiation of Cu"^-induced oxidation, represented a 
3-fold increase in comparison to BDC values of Ib-LDL. Similar increase in the ex 
vivo BDC levels of sd-LDL was observed in N-C rats, when compared to BDC levels 
of Ib-LDL (Table 13 and 14). As expected, glucose mediated a maximum prooxidant 
effect by decreasing the lag phase of sd-LDL, which was isolated from untreated 
control plasma and apparently had a least amount of associated antioxidants. When 
Tocomin, a-tocopherol or Lovastatin enriched LDL, sd-LDL, and Ib-LDL were 
subjected to oxidation with copper, as expected, a marked increase in the lag phase of 
LDL was observed. However, apparently due to low retention of antioxidants in sd-
LDL and Ib-LDL particles, after their fractionation from LDL, the increase in lag 
phase values of sd-LDL and Ib-LDL was less pronounced. Under these conditions, the 
addition of glucose (250 mg/dl) to the media delayed the oxidation of antioxidant-
enriched LDL, sd-LDL and Ib-LDL, and markedly increased the lag phase values to a 
level similar to their corresponding lag phases in non antioxidant treated control 
samples obtained in absence of glucose. 
Consistent with these results, an inverse relationship between lag time of LDL 
oxidation and severity as well as progression of coronary atherosclerosis has been 
reported (De Rijke et al., 1995; van de Vijver et al., 1998). Since sd-LDL isolated 
from diabetic rats is markedly more susceptible to ex vivo oxidation, which suggests 
that diabetic sd-LDL may be more susceptible to further oxidation in the vessel wall. 
Consistent with previous findings (De Graaf e/ al. 1991; Tribble et al., 1992; Dejager 
et al., 1993; Chait et al., 1993; Tribble et al. 1994; Reaven et al., 1994; Tribble et al., 
1995; Jansen et al, 1995; Sevanian et al. 1996), our results demonstrate that sd-LDL 
particles are substantially more susceptible to both in vivo and in vitro oxidation than 
Ib-LDL or LDL. This property has been proposed to contribute to the increased 
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disease risk associated with the sd-LDL phenotype. Differences in oxidative 
susceptibility between sd-LDL and Ib-LDL have been attributed to differences in their 
physical-chemical properties. Relative to Ib-LDL, sd-LDL has a reduced content of 
antioxidants (De Graaf e/ al. 1991; Tribble et al, 1992; Dejager et al., 1993; Tribble 
et al. 1994; Tribble et a!., 1995) and free cholesterol (De Graaf e/ al. 1991; Tribble e( 
al., 1992; Tribble et al. 1994; Jansen et al., 1995), and are enriched with 
polyunsaturated fatty acids (De Graaf et al. 1991), and, possibly, hydroperoxides 
(Sevanian et al., 1996). Antioxidants concentrations and free cholesterol content have 
been shown to predict differences in the oxidative susceptibility of LDL density 
subfractions (De Graaf et al. 1991; Tribble et al, 1992; Tribble et al. 1994). The 
origins of these physical-chemical differences are unclear, but may include 
differential metabolic processing of buoyant and dense LDL and their metabolic 
precursors. Kinetic tracer studies indicate that sd-LDL particles are metabolic 
products of both intermediate density lipoproteins and large, buoyant LDL (Griffin 
and Packard, 1994; Packard and Shepherd, 1997). Hence sd-LDL particles have a 
greater residence time in plasma, and undergo more metabolic processing, than do 
IDL and Ib-LDL. Moreover, because sd-LDL particles bind less avidly to the LDL 
receptor and are degraded less efficiently (Nigon et al., 1991; Campos et al., 1996; 
Musliner et al, 1987), these subfractions may include some very long lived, 
extensively lipolysed particles. Tribble et al (2001) reported that IDL from subjects 
with sd-LDL phenotype had a greater oxidative susceptibility and lower antioxidant 
concentrations than corresponding particles from subjects with the Ib-LDL phenotype. 
Therefore, the differences in oxidative behavior of Ib-LDL and sd-LDL arise from 
differences in their metabolic precursors, suggesting that factors contributing to an 
enhanced oxidation response are amplified in subjects with sd-LDL phenotype. An 
enhanced oxidative susceptibility of IDL and their LDL end-products could be one 
important consequence of reduced lipoprotein clearance in subjects with sd-LDL 
phenotype. This hypothesis is consistent with the fact that in diabetes, due to insulin 
resistance, generation of triglyceride-rich VLDL is increased which results in 
increased prevalence and concentration of sd-LDL (Hirano et al, 2004). Our results 
also show a substantial increase in VLDL (Table 4) and sd-LDL (Table 5) mass in 
diabetic-hyperlipidemic rats and hence a markedly increased in vivo and in vitro 
susceptibility to oxidation. Among the other physical-chemical factors that could be 
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important in determining differences in lipoprotein oxidative susceptibility are fatty 
acid composition and hydroperoxide content (De Graaf et al. 1991; Tribble et al., 
1995; Sevanian et al., 1996;Thomas et al, 1994; Kontush et al, 1994; Frei and 
Gaziano, 1993). Previous reports have suggested that sd-LDL may be enriched in 
more oxidizable polyunsaturated fatty acids and preformed hydroperoxides (De Graaf 
et al 1991; Sevanian et al, 1996). Tribble et al (2001) also reported that in subjects 
with either the Ib-LDL or the sd-LDL phenotype, oxidative susceptibility increased, 
and antioxidant concentrations decreased, from IDL to Ib-LDL to sd-LDL. Moreover, 
they also showed that parinaric acid oxidation lag times were correlated with 
concentrations of ubiquinol-10 and a-tocopherol among all three lipoprotein 
subfractions. Our results are consistent with extremely low antioxidant content of sd-
LDL in diabetic rats, which apparently was responsible for the prooxidant effect of 
glucose only on sd-LDL. It has been reported by Otero et al (2002) that glucose may 
act either as LDL antioxidant or prooxidant, depending on the LDL vitamin E (a-
tocopherol) content. Consistent with these findings, our combined ex vivo and in vitro 
results demonstrate that glucose may act either as antioxidant or prooxidant during 
copper-induced oxidative modification of LDL, sd-LDL and Ib-LDL, depending on 
their antioxidant (a-tocopherol, Tocomin or Lovastatin) content. 
Based on the findings reported by Otero et al (2002), a model of LDL 
oxidation has been proposed, where the free radicals generated in the water phase by 
copper, will be taken up by the vitamin E attached to the LDL surface and also by the 
glucose of the media, thus, delaying the vitamin E consumption. As the process 
continues and the LDL associated vitamin is consumed, the copper mediated 
oxidation of fatty acids starts generating peroxides, as has been described in other 
systems containing transitional metal ions, can also oxidize glucose, generating 
glucose-derived aldehydes (Mlakar et al, 1996). Both the oxidation of glucose-
derived aldehydes will generate more free radicals, further accelerating the LDL fatty 
acids oxidation as described by Hunt et al (1990). This mechanism is very similar to 
the one proposed to explain the antioxidant and prooxidant effects of ascorbic acid 
(Halliwell, 1996b). It is worthwhile to mention the structural similarities between 
ascorbic acid and glucose and the fact that both of them when subjected to oxidation 
may generate the same aldehydes (Mlakar et al, 1996). In addition, glucose, like 
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ascorbic acid, may also reduce the oxidized copper in the presence of lipid peroxides, 
as described previously (Hunt et al., 1990; Halliwell, 1996a; Niki, 1991; Kadiiska et 
al., 1992; Thomalley and Stem, 1984). A phenomenon like this could also lead to an 
acceleration of the LDL oxidation by allowing further generation of free radicals from 
the copper oxidation (Hunt et al., 1990; Halliwell, 1996a). Therefore, glucose as other 
compounds like ascorbic acid, dehydroascorbic acid, or flavonoids (Otero et al, 
1997b) could act either as LDL antioxidant or prooxidant, depending on the presence 
of vitamin E in the LDL. 
The mechanism for enhanced lipoprotein oxidation in vivo in diabetic rats may 
be similar to the one described by Maziere et al. (1995), where preculture of 
endothelial or smooth muscle cells in glucose-enriched medium induced a dose-
dependent increase in LDL oxidative modification. This phenomenon was correlated 
to a marked stimulation of superoxide anion secretion by cells. Regardless of the 
mechanism(s) involved in the in vivo oxidation of LDL, sd-LDL and Ib-LDL, it will 
accelerate the atherosclerotic process, particularly in diabetes where mass and 
oxidative susceptibility of sd-LDL is considerably increased. Our results also indicate 
that LDL, sd-LDL and Ib-LDL associated with higher content of antioxidants, 
Tocomin, Lovastatin or a-tocopherol, will be less susceptible to the prooxidation 
effects of glucose in vivo and, therefore, less prone to the development of 
atherosclerosis. In contrast, in diabetics due to low intake of antioxidants, their 
antoxidant-defecient LDL, sd-LDL and Ib-LDL would be more susceptible to the 
oxidative effects of hyperglycemia. Indeed, some studies in type 2 diabetic patients 
have shown lower levels of vitamin E, making them more susceptible to the 
prooxidant effects of hyperglycemia (Otero et al., 1997a; Jain et al., 1991). Several 
other studies in animal model have shown that some of the complications secondary 
to diabetes can be prevented with the administration of antioxidants, including 
vitamin E, despite no improvement in hyperglycemia (Srivastava and Ansari, 1988; 
Viana et al., 1996; Cameron et al., 1993). Furthermore, based on the present results, 
there is a possibility of minimizing the effects of glucose on the oxidation of LDL, sd-
LDL, and Ib-LDL by increasing the antioxidant content of these particles. Finally, 
since the present study describes a potent hypoglycemic, hypolipidemic and 
antioxidant impacts of Tocomin and Lovastatin in diabetic-hyperlipidemic rats, intake 
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of these compounds will automatically prevent the prooxidant effect of glucose on 
lipoprotein oxidation, especially sd-LDL, by normalizing hyperglycemia as well as 
hyperlipidemia. To the best of our knowledge, the above results represent an initial 
demonstration of ex vivo and in vitro oxidative modification of sd-LDL, Ib-LDL as 
well as LDL. In addition, in response to substeintial increase in oxidative stress, 
evoked in experimental diabetes coupled with hyperlipidemia, as reflected by higher 
ex vivo BDC levels of sd-LDL, and Ib-LDL including LDL, as modified in vivo, and a 
decrease in lag phase time of their oxidation was substantially blocked by Tocomin or 
Lovastatin, also represents an initial demonstration. 
Our results indicating strong antioxidant impacts of Tocomin in diabetic-
hyperlipidemic rats are in agreement with earlier findings of our laboratory in 
normoHpidemic and hyperlipidemic rats as well as hyperlipidemic/atherosclerotic 
rabbits (Beg et al, 2000a; Beg et ah, 2000b; Beg and Zainuddin, 2003), and other 
reports indicating an inhibition in the formation of conjugated dienes and TBARS by 
TRF or individual tocotrienols and tocopherols when fed to rats along with an 
atherogenic diet. These results also indicate that y-tocotrienol exerts a significantly 
more potent impact as compared to a-tocopherol (Watkins et al., 1993). Support to 
our results is also obtained fi-om another study where feeding of a mixture of 
tocotrienols along with an atherogenic diet to rabbits was associated with a significant 
reduction in the formation of serum lipid peroxides (Teoh et al., 1994). TRF treatment 
of patients with hyperlipidemia and carotid stenosis caused a significant decrease in 
TBARS, an ex vivo indicator of maximal platelet peroxidation (Tomeo et al., 1995; 
Theriault et al., 1999b). The antioxidant activity of the a-tocoterienol (T3) homolgue 
has been shown to be more than 3-fold greater than that of a-tocopherol (T) (Packer, 
1995). Using an in vitro liposome system, antioxidant activities for several 
tocotrienols were 4-33-fold higher than that for a-T. The order of activity was d-P25-
T3 > d-P21-T3 > TRF25 > 5-T3 > y-T3 > a-T3 > a-T (Qureshi et al, 2000). These 
results indicate that in intact membranes, including LDL particles, tocotrienols may 
have a significantly greater antioxidant effect than tocopherols and they may provide 
greater protection against CAD. D-P25-T3 is the most potent homologue of all natural 
forms of unsaturated (T3) and saturated (T) vitamin E tested. These findings were 
further confirmed by determining the antioxidant activities involving coupled 
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autoxidation of (3-carotene and linoleic acid. The antioxidant activities of known a-, 
y- and 5-tocotrienols and TRF25 (prepared from stabilized and heated rice bran with 6 
% a-T) were 22 %, 27 %, 32 % and 24 % better than a-T, respectively (Qureshi et al, 
2000). The possible mechanism for this superior efficacy of tocotrienols compared to 
tocopherols has been reported elsewhere (Packer, 1995). Comparative protective 
effects of TRF (75 % tocotrienols and 25 % a-tocopherol) and a-tocopherol on 
copper-induced oxidation of plasma LDL and indices of lipid peroxidation in human 
umbilical vein endothelial cells revealed that TRF is a more (2.5-fold) potent 
antioxidant than a-tocopherol (Mutalib et al, 2003). Differences in the transport and 
tissue uptake of the saturated (T) and unsaturated (T3) tocols have been reported by 
other investigators (Kayden and Traber, 1993; Hayes et al., 1993; Pearson and 
Barnes, 1970). A hepatic binding protein with high specificity for a-T in the liver 
results in the subsequent enrichment of this tocol in the VLDL moiety and as a 
consequence, the LDL moiety. The tocotrienols on the other hand are transported non-
specifically like other lipid soluble compounds (Kayden and Traber, 1993; Pearson 
and Barnes, 1970; Suama et al., 1993). Thus, although tocotrienols was found to be 
more potent in vitro, the poor absorption of these compounds in the intestine is 
suggested to significantly affect their efficacy in vivo. It has been previously reported 
that treatment of hypercholesterolemic humans with TRF25 resulted in substantial 
increases in the levels of LDL-bound antioxidants, especially tocotrienols, which are 
known to have significantly greater antioxidant activity than tocopherols (Qureshi et 
al, 1997). Therefore, it appears that tocotrienols as TRF or Tocomin exert their 
antioxidant effect on plasma LDL oxidation while being attached to LDL particle. 
In general, our results indicating a protective effect of Lovastatin in the in vivo 
and in vitro oxidation of LDL, sd-LDL and Ib-LDL is consistent with another report, 
where Lovastatin, in addition to lowering cholesterol, also prevented the foam cell 
formation by inhibiting the oxidation of LDL in hyperlipidemic-diabetic hamsters. 
This is evidenced by data showing that Lovastatin decreased plasma lipid peroxide 
level, increased the lag time, and reduced the conjugated diene formation, during in 
vitro LDL oxidation (El-Swefy et al., 2000). The antioxidant activity of Lovastatin 
has also been reported in atherosclerotic rabbits (Chen et al, 1997; Singh et al, 1997) 
and in vitro as well as in vivo studies in patients with hypercholesterolemia (Aviram et 
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al, 1992). However, in this study, Lovastatin did not exhibit any radical scavenging 
activity. Whereas, Rikitake et al. (2001) have reported a strong radical scavenging 
activity for fluvastatin and a very weak activity for Lovastatin, simvastatin and 
pravastatin. In addition, direct antioxidative effect on LDL oxidation in vitro was 
observed at nontherapeutic concentrations of Lovastatin (Aviram et al., 1992). These 
results indicate that the mechanism(s) of antioxidant activity of Lovastatin is not 
clear. However, inhibitory effect of Lovastatin on LDL oxidation has been suggested 
to be caused mainly by increased removal of aged plasma LDL as a result of 
upregulation of LDL receptor. Hussein et al. (1997) have demonstrated that 
fluvastatin exerted its antioxidative effect as a result of binding to LDL. It is likely 
that Lovastatin may also exert its antioxidative effect after binding to LDL. 
Alternatively, the open ring of Lovastatin is probably an effective metal chelating 
agent and thus it is possible that the ester groups present in the Lovastatin molecules 
chelate the copper ions during in vitro LDL oxidation. However, antioxidative activity 
of Lovastatin was not evident in terms of inhibiting the formation of oxysterols in the 
lipoproteins of hyperlipidemic-diabetic hamsters (El-Swefy et al., 2000). Due to 
above discrepancies further investigation is needed to elucidate the exact 
mechanism(s) involved in the antioxidative actions of Lovastatin. 
A low concentration of HDL-C is a powerful and independent predictor of 
premature CHD (Miller and Miller, 1975; Gordon et al, 1989). However, type 1 
diabetes is associated with an increased incidence of CHD (Laing et al., 1999), 
despite normal or increased HDL-C concentrations (DuUaart, 1995). Our results also 
show increased levels of HDL-C in diabetic rats. This paradox may be explained by 
quantitative changes in HDL that affect its ftmctional properties, such as its 
antioxidant capacity, related to paraoxonase (PON)/arylesterase activity. PON is a 
HDL-associated enzyme that protects LDL from oxidative stress by destroying 
biologically active phopholipids (Mackness et al, 1996). Castellani et al. (1997) have 
shown that depletion of PON results in the loss of the antioxidant function of HDL, 
and addition of PON to HDL restores the protective function of HDL. Aviram et al. 
(1998) also reported that purified PON is a potent inhibitor of LDL and HDL 
oxidation in vitro. Finally, a PON knockout mice model where absence of serum PON 
is associated with greater susceptibility of lipoproteins to oxidation and more 
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extensive atheromas (Shih et al., 1998), an extrapolation of these studies suggest that 
lower serum PON activity constitutes a risk factor for atherosclerotic disease. The 
enzyme has been identified as an independent genetic risk factor for vascular disease, 
particularly in type 2 diabetics (Ruiz et al., 1995; Blatter Garin et al., 1997; Odawara 
et al., 1997; Pfohl et al., 1999). In patients with type 1 diabetes, Boemi et al. (2001) 
have reported a lower PON activity and concentration, higher LDL: PON 
concentration ratio and a reduced capacity to prevent LDL oxidation. Serum PON 
activity is also reported to be reduced in STZ-induced diabetic rats (Patel et a!., 1990). 
Antioxidant supplements may be expected to influence PON activity by altering 
oxidative stress. Inactivation of PON by oxidized LDL can be inhibited by 
antioxidants (Aviram et al., 1999). Although the effects of PON on LDL oxidation 
appear to be independent of the function of antioxidant vitamins (Watson et al., 
1995), vitamin C and E (a-tocopherolj have been shown to inhibit LDL oxidation 
(Jialal et al., 1990; Harats et al., 1990). Therefore, any reduction in oxidative stress 
related to vitamin C and E intake may preserve PON activity. Consistent with these 
findings, our results (Table 18) show a significant decline in plasma arylesterase 
activity of diabetic-hyperlipidemic rats. In addition, the ratio of LDL-C: arylesterase 
activity was significantly higher in D-C, indicating a reduced capacity to protect LDL 
from oxidation. Tocomin treatment significantly blocked the reducdon in arylesterase 
activity and increase in LDL-C: arylesterase activity ratio and restored these levels 
close to normal values, indicating an increased capacity to protect LDL from 
oxidation. In D-LT, Lovastatin not only prevented the decline in arylesterase activity 
but also significantly increased it to a level above N-C value. The mechanism of 
action of Lovastatin appears to be different than tocotrienols (Tocomin) and may be 
similar to simvastatin, which has been reported to be involved in the upregulation of 
PON at the gene level in vitro. In addition, hypercholesterolemic patients with CAD 
treated with simvastatin showed a significant increase in serum concentrations and 
activities of PON (Deakin et al., 2003). 
It has been reported that xanthine oxidase, a superoxide radical generating 
enzyme is increased in plasma and liver of diabetic rats (Desco et al., 2002). In 
diabetic animals, xanthine oxidase is released by the liver into the plasma and is 
bound to the vascular endothelial cells (Adachi et al., 1993). The role of xanthine 
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oxidase in the vascular dysfunction that occurs in atherosclerosis was reported by 
White et al. (1996). Arterial rings from diabetic rabbits produce superoxide in 
presence of xanthine. The fact that the production of such a reactive molecule as 
superoxide is increased in the vessel wall of diabetic animals may be relevant in 
explaining some of the arterial complications of diabetes and underscores the 
importance of xanthine oxidase in this process. Consistent with published reports, our 
results show a significant increase in plasma and liver xanthine oxidase activity of 
diabetic-hyperlipidemic rats. Treatment of diabetic rats with Tocomin or Lovastatin 
significantly inhibited the elevated levels of plasma and hepatic xanthine oxidase 
activity. Results described here show that both Tocomin and Lovastatin in addition to 
their potent antioxidant activity also exhibit a xanthine oxidase inhibitory property, 
indicating an additional therapeutic benefit in the treatment of diabetes with and 
without CHD. 
Increasing evidence in both experimental and clinical studies suggest that 
oxidative stress plays a major role in the pathogenesis of both type 1 and type 2 
diabetes. Free radicals are formed disproportionately in diabetes by glucose 
degradation, nonenzymatic glycation of proteins, and the subsequent oxidative 
degradation, which may play an important role in the development of complications 
in diabetic patients. The generation of free radicals may lead to enhanced lipid 
peroxidation, which may mediate cellular damage in diabetes. The hyperlipidemia 
associated with diabetes may also lead to increased lipid peroxidation (Chirico et al, 
1993; Palombo et al. 1999) perhaps because an increased lipid load allows 
lipoproteins to reside for longer periods in the circulation and in the vessel walls, 
giving them a greater exposure to free radicals (Walzem et al, 1995). 
Hyperketonemia may also promote lipid peroxidation (Jain et al, 1999). Several 
reports have demonstrated that blood MDA levels, a lipid peroxidation product and a 
marker of oxidative stress, were significantly elevated in type 1 and type 2 diabetes 
(Mahboob et al, 2005; Maritim et al, 2003; Sekeroglu et al, 2000; Sundaram et al, 
1996; Telei et al, 2000). Higher plasma and erythrocyte MDA levels were observed 
in diabetics with retinopathy relative to diabetics without retinopathy (Atamer et al, 
1998; Uzel, et al, 1987; Jennings, et al, 1991; Gallau et al, 1993; Augustin et al, 
1993; Katoh, 1992). In the present study, consistent with above findings, we have 
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seen a substantial increase in plasma (101 %, Table 9) and erythrocytes (105 %, Table 
10) MDA levels of chronic (14-week) diabetic-hyperlipidemic rats. In addition, we 
have also observed an increase of 117 % in MDA release of intact erythrocytes from 
diabetic rats. Increased erythrocyte MDA concentrations are known to cause a 
decrease in the membrane fluidity of the membrane lipid bilayer and increased 
osmotic stability of cells (Raccah et al, 1996). Consistent with these findings, we 
have observed a significant decrease in erythrocytes membrane boimd Total ATPase 
and Na ,^ K"-ATPase activities (Table 11). It seems likely that oxidation process and 
MDA accumulation can contribute directly to changes in the properties of diabetic 
erythrocytes and may cause the development of long-term complications. Therefore, 
oxidative stress is the imbalance between production and removal of ROS. Increased 
oxidative stress, which contributes substantially to the pathogenesis of diabetic 
complications, is the consequences of either enhanced ROS production or attenuated 
ROS scavenging capacity. Several tissues have an effective mechanism to neutralize 
and prevent the free radical-induced damage, which is accomplished by a set of 
endogenous enzymes such as catalase, SOD, Gpx and Gred. As the balance between 
ROS production and antioxidant defenses is lost, the resultant oxidative stress through 
a series of events deregulates the cellular functions leading to various pathological 
conditions. An antioxidant compound might contribute partial or total alleviation of 
such damage. An impaired ROS scavenging function has been linked to the decreased 
activity of enzymatic and nonenzymatic scavengers of free radicals. Reports about the 
status of antioxidants and scavengers as defense mechanism in diabetes are very 
contradictory. Increase, decrease or no change in antioxidant enzyme activities have 
been reported (Siddiqui et al, 2005; Bukan et al, 2003). These discrepancies may be 
partly explained by the variability in the diabetes models used, including the strain 
and sex of the animals, their age at the induction of diabetes, the severity of the 
resulting insulin deficiency, and the duration of diabetes (Szaleczky et al, 1999). 
Our results demonstrate a significantly lower catalase and SOD activities in 
erythrocytes hemolysate of chronic diabetic rats with retinopathy, which are 
consistent with an earlier report where plasma catalase and SOD levels were 
significantly decreased in type 2 diabetics with retinopathy (Atamer et al, 1998). 
Other reports also indicate that catalase and SOD activities were reduced in 
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uncontrolled diabetics, but unchanged in well-controlled diabetics (Cousins, 1985; 
Faure et al, 1993; Hayakawa and Kuzuya, 1990; Balashova et al., 1993). In contrast, 
our results are inconsistent with other reports (Wohaieb and Godin, 1987; Matkovics 
et al, 1982) where no change in erythrocytes catalase activity in diabetic animals was 
observed. Our results indicating a decline in erythrocytes SOD activity is consistent 
with the results reported by Loven et al. (1986) in STZ-induced diabetic rats. The 
decreased activities of catalase and SOD may be a response to increased production of 
H2O2 and O2" by the autooxidation of excess glucose and nonenzymatic glycation of 
proteins (Argano et al., 1997). Hodgson and Fridovich (1975) and Pigeolet et al. 
(1990) have reported the partial inactivation of these enzyme activities by hydroxy] 
radicals and hydrogen peroxide. The decreased activity of catalase and SOD could 
also be due to their decreased protein expression levels in the diabetic condition as 
reported in liver (Sindhu et al., 2004). As expected, treatment of the diabetic rats with 
antioxidants, Tocomin or Lovastatin restored the reduced activities of catalase and 
SOD. The restoration of enzymatic activity of catalase was partial (78-87%), whereas, 
for SOD it was similar to normal activity levels. 
Reduced glutathione is a major intracellular non-protein sufhydryl compound. 
It has many biological functions, including maintenance of membrane protein and 
lipoprotein SH groups in the reduced form, the oxidation of which can otherwise 
cause altered cellular structure and function. Glutathione cycle operates in the 
erythrocytes for the disposal of H2O2 generated in the cell supplementing the ftinction 
of catalase. GSH and H2O2 are twin substrates for glutathione peroxidase. GSH is 
formed from its oxidized form, GSSG by the enzyme glutathione reductase, which 
requires NADPH as a cofactor. Glucose oxidation through the pentose phosphate 
pathway operates in the erythrocytes precisely to supply this NADPH (Halliwell, 
2002). Normally, insulin promotes the operation of this pathway. In diabetes, due to 
inadequate function of insulin, the efficiency of this pathway is hampered, which 
results in reduced formation of NADPH (Fig. 1.3). Our observation of decreased 
levels of intracellular GSH and glutathione reductase in diabetic erythrocytes is 
corroborated by previous reports (Riemersma et al, 2001; Stojadinovic et al, 1996; 
Mukherjee et al, 1994: Murakami, 1991; Uzel et al, 1987). This decrease in GSH 
levels in diabetes may be due to combined effect of inhibited Gred and reduced 
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supply of NADPH. In our study, activity of Gpx is enhanced in diabetic rat 
erythrocytes, thus causing a further decline in GSH content. In addition, the increased 
Gpx activity represents a compensatory mechanism to degrade H2O2. This result is 
consistent with the findings of Matkovics et al. (1982), where erythrocytes Gpx 
activity was increased in diabetics. Decreased GSH content indicate a decreased 
scavenging capacity of glutathione-dependent antioxidant defensive system against 
the elevated lipid peroxidation processes in diabetic-hyperlipidemic rats. It has been 
suggested that diabetic complications may be the result of a long-term effect of small 
deficiency in intracellular GSH (Mazzanti et al, 1989). Tocomin or Lovastatin 
treatment of diabetic-hyperlipidemic rats for 14 weeks, mediated a significant reversal 
to near nonnal levels of Gpx, Gred and a partial restoration (51-61 %) of GSH 
content, indicating a strong anti-lipid peroxidative effect of these antioxidants. 
As discussed above, hyperglycemia is the most important factor in the onset 
and progress of diabetic complications mainly by producing oxidative stress, which is 
mainly based on the evidence of increased lipid peroxidation, or by indirect evidence 
of reduced antioxidant reserve (Palanivel et al., 1998). Increased production of free 
radicals may lead to disruption of cellular fimctions and oxidative damage to 
membranes (Oberley, 1988). It has also been reported that free radicals generate 
during diabetes deteriorate membrane structure and decrease membrane fluidity. 
Changes in membrane fluidity have been implicated in disease process and diabetic 
complications (Hong et al, 2004). Enhanced lipid peroxidation and oxidation of thiol 
groups have been implicated in the development of liver necrosis (EUenhom and 
Mathew, 1997). The levels of ROS are controlled by antioxidant enzymes, SOD, 
catalase, Gpx, Gred and nonenzymatic scavengers such as GSH. Earlier reports 
indicate increased or decreased SOD, catalase, Gpx and Gred activities in various 
tissues including liver (Ramanathan et al, 1999; Kinalski et al, 2000). Thus, the 
hepatic antioxidant status seems to have an important role in the etiology of diabetic 
complications. Antioxidant activity or inhibition of generation of free radicals plays a 
crucial role in providing protection against hepatic damage. Consistent with the above 
findings, our results show that chronic diabetes in rats is associated with a significant 
increase in hepatic lipid peroxidation, as evidenced by elevated levels of conjugated 
dienes, hydroperoxides and TBARS. Lipid peroxidation has been used as a measure 
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of oxidative stress, which was originally defined as the disequilibrium between 
prooxidants and antioxidants in biological systems. Once this imbalance appears, 
cellular macromolecules may be damaged by the predominant free radicals. The role 
of ROS in causing cell injury or death is increasingly recognized. Superoxide and 
hydroxyl radicals are involved in a large number of degenerative changes often 
associated with an increase in peroxidation process and linked to low antioxidant 
concentrations (Romero et al, 1998). Mammalian cells are equipped with both 
enzymatic and nonenzymatic antioxidant defense mechanisms to minimize the 
cellular damage resulting from interaction between cellular constituents and ROS 
(Irshad and Chaudhuri, 2002). The enzymatic antioxidant defense mechanism 
contains various forms of SODs, catalase and Gpx, as well as the enzymes involved in 
the recycling of GSSG such as Gred and glucose-6-phosphate dehydrogenase, the 
major enzyme in pentose phosphate pathway for generation of NADPH (Ho et al., 
1998). An unbalanced production of ROS in localized compartments has been 
reported to play a role in the pathogenesis of diabetic complications, which illustrates 
the importance of antioxidant defense system in maintaining normal cellular 
physiology. Results of the present study show decreased activities of hepatic 
antioxidant enzymes, SOD and catalase, in chronic diabetic rats, which could be due 
to harmful effects of free radicals on these enzymes. A reduced activity of SOD and 
catalase may lower its cellular efficacy to detoxify these potentially active 
oxyradicals, thus leading to an increased level of lipid peroxidation products. 
Diabetic-hyperlipidemic rats treated with Tocomin or Lovastatin exhibited near 
normal activities of SOD and catalase enzymes, which indicates an antioxidant and 
possibly hepatoprotective nature of Tocomin and Lovatatin. Our results are consistent 
with the findings of Wohaieb and Godin (1987), where in a long-term experiment, a 
decrease in liver SOD activity of STZ-induced diabetic rats was observed. They 
proposed that this reduction in SOD activity might be due to the direct damaging 
effect of free radicals on the enzyme. The activity of catalase in the liver of diabetic 
animals is generally believed to decrease (Wohaieb and Godin, 1987; Asayama et al, 
1989), although there are also reports of it's increase (Dohi et al, 1988). In another 
recent report, Eshrat and Mukhopadhyay (2006) have demonstrated a significant 
decline in hepatic SOD, and catalase activities in 16-week STZ-induced diabetic rats. 
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Treatment of these rats with vitamin E for 16 weeks showed a partial reversal of these 
antioxidant enz>'mes. 
GSH acts as a reducing agent and a vital substance in detoxification. It 
provides antioxidant protection in the aqueous phase of cellular systems (Rana et al, 
2002); its antioxidant activity is through the thiol group of its cysteine residue. Like 
ascorbic acid, another important water soluble antioxidant, GSH can directly reduce a 
number of ROS and is oxidized to GSSG in the process. Liver is viewed as a 
glutathione-generating site, which supplies the kidney and intestine with other 
constituents for glutathione resynthesis (Rana et al, 2002). Intrahepatic glutathione is 
reported to afford protection against liver dysfunction by at least two ways: (i) as a 
substrate for Gpx, GSH serves to reduce large variety of hydroperoxides before they 
attack unsaturated lipids or convert already formed lipid hydroperoxides to the 
corresponding hydroxy compounds, (ii) As a substrate of glutathione-S-transferase, it 
enables the liver to detoxify foreign compounds or other metabolites and to excrete 
the products, preferably in to bile. Decline in GSH, Gpx, Gred and GST levels in the 
liver of diabetic-hyperlipidemic rats, and their subsequent reversal to near norma' 
levels in Tocomin or Lovastatin treated rats demonstrates strong anti-lipid 
peroxidative effects of these compounds. This decrease in hepatic GSH levels in 
diabetic rats may be due to the effect of inhibited Gred activity and also apparently 
due to reduced supply of NADPH. In addition, since GSH also acts as substrate and 
cosubstrate in essential enzymatic reactions of Gpx and GST, inhibition of their 
activities may also be due to decreased levels of GSH in diabetic liver. Thus, during 
oxidative stress, depletion of GSH, which is of clinical importance in tissue injury, 
mediated a significant impact on the antioxidant poise of liver cells. Treatment of the 
chronic diabetic rats with Tocomin or Lovastatin for 14 weeks, significantly restored 
the reduced hepatic activities of SOD, catalase, Gpx, Gred and GST including GSH, 
indicating an almost total alleviation of such damage by these antioxidants. Our 
results are consistent with other reports indicating a reduction in levels of hepatic 
GSH and Gred of STZ-induced diabetic rats (Mukherjee et al, 1994). Others have 
reported reductions in mitochondrial GPx and Gred activities in liver of diabetic 
(Sukalski et al, 1993). Wohaieb and Godin (1987) found that in the liver, which 
normally contains high content of GSH and strong Gpx activity, induction of diabetes 
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caused a decrease in their levels. Our results are also in agreement with the findings of 
Eshrat and Mukhopadhyay (2006), where in a long-term experiment a decrease in 
liver GPx and GST activities of STZ-induced diabetic rats was observed. In addition, 
treatment of diabetic rats with vitamin E (a-tocopherol) fully restored the enzymatic 
activities of Gpx and GST. 
The combined results demonstrate that strong hypoglycemic, hypolipidemic 
and antidiabetic impacts of dietary tocotrienols (Tocomin) and Lovastatin coupled 
with their potent antioxidative property can provide additional benefits in the 
inhibition of oxidative stress, particularly resistance of highly atherogenic sd-LDL to 
oxidation and hence in the prevention and treatment of nephropathy, retinopathy, and 
diabetes linked hyperlipidemia with and without CHD. Although multiple therapeutic 
benefits of Tocomin and Lovastatin observed in the present study were comparable, 
but Lovastatin, which is known to exert a host of adverse effects (Haffher et ah, 1998; 
Assmann et al., 1998), induced interstitial inflammation of lymphocytes in kidney and 
also mediated separation of retinal membrane from the lens, thus creating an open 
space. In contrast, dietary tocotrienols (Tocomin) are vitamin E and have no toxicity, 
therefore, did not induce any side effect. In conclusion, based on our combined 
findings, daily intake of dietary tocotrienols (Tocomin) or Lovastatin may be useful in 
the prevention and treatment of type 1 and type 2 diabetes, including nephropathy and 
retinopathy, diabetes linked hyperlipidemia with and without CHD and 
atherosclerosis. However, in view of the several toxic effects exhibited by Lovastatin 
including the ones exhibited in the present study, use of dietary tocotrienols 
(Tocomin) as an effective hypoglycemic, hypolipidemic, antioxidant and antidiabetic 
agent should be preferred. Furthermore, daily intake of Tocomin as a dietary 
supplement will be an excellent source of vitamin E. In addition, therapy with 
tocomin will be both efficacious and cost effective. 
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Results presented in the thesis demonstrate that rats after 14 weeks of 
administration of a single dose (60 mg/Kg) of STZ became substantially hyperglycemic 
as well as hyperlipidemic. In addition, long-term diabetes was associated with fully 
developed nephropathy and retinopathy. Daily treatment of these diabetic-hyperlipidemic 
rats with 6 mg Tocomin (tocotrienols) or 0.50 mg Lovastatin for 14 weeks significantly 
lowered the elevated blood glucose levels to near normal values. Since the extent of 
hemoglobin glycation is currently used as a cumulative index of glycemia over the 
previous few weeks in the clinical management of diabetes, our results demonstrate a 
significant increase in HbAi levels in diabetic rats, which were restored close to normal 
control values after 14 weeks of Tocomin or Lovastatin treatment. After 14 weeks of 
STZ-induced diabetes, histology of kidney resulted in the progression of diffused nodular 
glomerulosclerosis along with thickening of basement membrane in capillaries. An 
increase in the number of mesangial cells and enlarged Bowman space was also seen. 
Similarly, after 14 weeks of sustained hyperglycemia and increased oxidative stress, 
retina from diabetic rats exhibited proliferative retinopathy, characterized by complete 
retinal detachment. Consistent with the Tocomin and Lovastatin mediated decline in 
blood glucose and HbAi levels, and normalization of glycemic state, histologically, all 
the untoward features of nephropathy and retinopathy were regressed and normalized in 
Tocomin or Lovastatin treated diabetic rats. However, treatment of chronic diabetic rats 
with Lovastatin, which is known to have host of side effects, induced interstitial 
inflammation of kidney lymphocytes as well as separation of retinal membrane from the 
lens, resulting in an open space. In contrast, dietary tocotrienols (Tocomin), are vitamin E 
and have no toxicity, therefore, did not exhibit any side effect. These results represent an 
initial demonstration of strong hypoglycemic and antidiabetic action of Tocomin and 
Lovastatin in rats induced with chronic diabetes coupled with hyperlipidemia. 
Since long-term STZ-induced diabetes in rats is associated with a substantial 
hyperlipidemia, feeding of Tocomin or Lovastatin significantly prevented the increase in 
plasma TG, TC, atherogenic non-HDL-C, VLD-C, LDL-C, HDL-C and its subfractions, 
HDLi-C and HDLj-C levels. The cholesterol content of HDL2, which is considered to be 
a strong predictor of presence and extent of CAD, was significantly and equally reduced 
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in both Tocomin and Lovastatin treated diabetic rats. However, Lovastatin, in comparison 
to Tocomin, was more effective in selectively reducing the atherogenic non-HDL-C, 
whereas, levels of plasma antiatherogenic HDL-C and HDL3-C in Lovastatin treated 
diabetic rats were significantly higher than Tocomin treated group. 
Consistent with published reports that relative to Ib-LDL, the concentration of 
more atherogenic sd-LDL was substantially increased in patients with diabetes, CHD 
alone or diabetes with CHD, sd-LDL-C and sd-LDL-apoB levels of diabetic-
hyperlipidemic rats were increased by 245 % and 154 %, respectively, in comparison to 
corresponding values in N-C. Thus, > 60 % of total LDL-C and LDL-apo B were 
recognized in sd-LDL fraction, isolated from LDL of diabetic rats. Treatment of diabetic 
rats with Tocomin or Lovastatin significantly reduced both the cholesterol and apoB 
content of sd-LDL, as well as their percent share of total LDL, close to normal control 
values. In addition, sd-LDL-C/HDL-C ratio was increased (80 %), HDL-C/sd-LDL-C 
ratio was reduced (44 %) in diabetic-hyperlipidemic rats. Treatment with Tocomin or 
Lovastatin during diabetes resulted in significant improvement in these ratios, indicating 
normalization of sd-LDL levels and strong antiatherogenic property of Tocomin and 
Lovastatin. The therapeutic intervention of dietary tocotrienols (Tocomin) and Lovastatin 
in diabetic-hyperlipidemic rats, indicating a significant decline in the levels of sd-LDL-C, 
represents an initial demonstration. 
Both tocotrienols (Tocomin) and Lovastatin are known to exert their 
hypolipidemic effects in hyperlipidemic animals by reducing hepatic HMG-CoA 
reductase activity. However, results in the present study show a decrease of 57 % in liver 
HMG-CoA reductase activity along with a substantial increase in plasma and tissue lipid 
levels after 14 weeks of chronic diabetes. This decrease in hepatic HMG-CoA reducatse 
activity in diabetic animals may be due to a sustained insulin deficiency/hyperglycemia 
and hyperlipidemia. Treatment of these rats with Tocomin or Lovastatin for 14 weeks 
was associated with a significant reduction in glucose and lipid levels as well as 
restoration of HMG-CoA reducatse activity to near normal levels. This increase in 
enzyme activity in treated diabetic rats may be due to an increase in insulin activity as a 
result of normalization of both glucose and lipid levels. Recently, it has been shown that 
RBO containing y-T3 or y-oryzanol exert their hypolipidemic effects in diabetic rats by 
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increasing fecal neutral sterol and bile acid excretion, via up regulating cholesterol 
synthesis and catabolism. In the present study involving dlabetic-hyperllpidemic rats, 
dietary tocotrienols and Lovastatin may exert their hypolipidemic effects in a similar 
fashion. 
In response to oxidative stress, evoked in experimental diabetes/hyperlipidemia, 
as reflected by increased formation of plasma and liver lipid peroxidation products, 
conjugated dienes, lipid hydroperoxides and TBARS, and increased release of MDA 
from intact erythrocytes subjected to hydrogen peroxide-induced lipid peroxidation was 
substantially and significantly blocked by Tocomin and Lovastatin. In addition, the 
enhanced oxidative damage of membranes during long-term diabetes is also associated 
with a decrease in membrane bound Na"*^ , K"^ -ATPase activity, which is implicated in the 
pathogenesis of several diabetic complications. Consistent with these reports, our results 
show a significant reduction in total and Na"*", K"^ -ATPase activities in erythrocyte 
membranes of diabetic rats. Consistent with hypoglycemic, hypolipidemic and 
antioxidant properties, Tocomin or Lovastatin feeding during diabetes prevented the 
decline in total and Na ,^ K^-ATPase activities and restored to a level close to normal 
values, apparently by blocking and protecting the ROS-mediated membrane damage. 
Similarly, due to enhanced oxidative stress and increased consumption of antioxidants in 
chronic diabetic rats, total antioxidant concentrations in plasma was significantly 
reduced, which was substantially increased to a level higher than normal control value in 
both the treated groups. 
Our results show that due to substantial oxidative stress in diabetic-
hyhyperlipidemic rats, the ex vivo base line diene cojugation (BDC) levels of sd-LDL and 
Ib-LDL including LDL were increased. However, in comparison to Ib-LDL BDC level, 
sd-LDL BDC value was higher by more than 3-fold indicating a markedly enhanced 
susceptibility of sd-LDL to in vivo oxidation. Similarly, treatment of diabetic rats with 
Tocomin or Lovastatin reduced the ex vivo BDC levels of sd-LDL, Ib-LDL and LDL, 
with a maximum effect on sd-LDL. Consistent with ex vivo BDC levels of LDL, sd-LDL, 
and Ib-LDL, susceptibility of these particles to Cu"^-induced oxidation, as measured by 
their lag time, was decreased in diabetic rats. It is important to mention that in 
comparison to a lag phase value of 98 min and 50 min for LDL and Ib-LDL, respectively. 
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in N-C, the lag phase of sd-LDL was only 17.0 min, indicating a substantially increased 
in vitro oxidative susceptibility to oxidation. In treated groups, both Tocomin and 
Lovastatin increased the resistance of sd-LDL to oxidative modification, as shown by an 
increase in lag time from a value of 8.5 min in D-C to 12.5 min. In contrast to sd-LDL, 
the lag time of Ib-LDL was reduced from 50 min in N-C to 40 min in D-C, which was 
fully restored to 50 min in Tocomin or Lovastatin treated groups. Consistent with known 
property of glucose that it may act either as LDL antioxidant or prooxidant depending on 
the vitamin E/antioxidant content of LDL, presence of glucose during Cu^-induced 
oxidation of LDL, sd-LDL and Ib-LDL from normal rats, further reduced their lag 
phases. However, in diabetic rats, which were deficient in antioxidants, and had a high 
plasma glucose level, addition of glucose in the incubation medium further mediated a 
prooxidant effect on sd-LDL lag phase with no effect on Ib-LDL and LDL. The 
substantial prooxidant effect of glucose on lag phase of sd-LDL from normal and diabetic 
rats is consistent with its enhanced susceptibility to oxidation and reduced content of 
antioxidants, relative to Ib-LDL. In Tocomin or Lovastatin treated rats due to the 
presence of high plasma concentrations of antioxidants, tocotrienols 
(Tocomin)/Lovastatin, prooxidant effect of glucose was blocked and lag phase value of 
sd-LDL was increased. 
Based on the ex vivo results, proooxidant/antioxidant effect of glucose was 
investigated on Cu"^-induced oxidative modification of LDL, sd-LDL and Ib-LDL, 
isolated from normal rat plasma pretreated with no antioxidant, Tocomin, a-tocopherol or 
Lovastatin. Similar to ex vivo studies, BDC level of untreated sd-LDL represented a 3-
fold increase in comparison to BDC value of Ib-LDL. As expected, glucose mediated a 
maximum prooxidant effect by decreasing the lag pahse of sd-LDL, which was isolated 
from untreated control plasma and apparently had a least amount of associated 
antioxidants. When Tocomin, a-tocopherol or Lovastatin enriched LDL, sd-LDL and Ib-
LDL were subjected to oxidation with copper, a marked increase in the lag phase of LDL 
was observed. However, apparently due to low retention of antioxidants in sd-LDL and 
Ib-LDL particles, after their fractionation from LDL, the increase in lag phase values of 
sd-LDL and Ib-LDL was less pronounced. Addition of glucose to the media delayed the 
oxidation of antioxidant-enriched LDL, sd-LDL and Ib-LDL, and markedly increased the 
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lag phase values similar to their corresponding values in untreated control samples 
obtained in the absence of glucose. These results represent an initial demonstration of ex 
vivo and in vitro oxidative modification of sd-LDL and Ib-LDL, isolated from LDL. In 
addition, in response to substantial increase in oxidative stress, evoked in experimental 
diabetes coupled with hyperlipidemia as reflected by higher ex vivo BDC levels of sd-
LDL and Ib-LDL including LDL, as modified in vivo, and a decrease in lag phase time of 
their oxidation, was substantially and effectively blocked by Tocomin or Lovastatin, also 
represents an initial investigation. 
Xanthine oxidase is known to be an important biological source of superoxide 
radical generating enzyme. In diabetic animals, xanthine oxidase is released by the 
vascular endothelial cells. Serum xanthine oxidase activity is known to be increased in 
various pathological disorders, such as carcinogenesis, hepatitis, inflammatory diseases, 
aging, hyperlipidemia and diabetes and that free radicals generated in the enzymatic 
processes are involved in the oxidative damage. Thus, it is possible that the inhibition of 
this enzymatic pathway by compounds, such as tocotrienols (Tocomin) and Lovastatin, 
that have both antiradical and xanthine oxidase inhibitory properties may have additional 
therapeutic importance in the treatment of diabetes with hyperlipidemia and other 
pathological disorders. Consistent with this hypothesis, our results show a significant 
increase in plasma and liver xanthine oxidase activity of diabetic-hyperlipidemic rats. 
Feeding of Tocomin or Lovastatin to diabetic rats was associated with a significant 
inhibition of the elevated levels of plasma and hepatic xanthine oxidase activity. These 
results show that both Tocomin and Lovastatin, in addition to their potent antioxidant 
activity, also exhibit xanthine oxidase inhibitory property, indicating an additional 
therapeutic benefit in the treatment of diabetes with and with out CHD. 
It is well known that diabetes may enhance oxidative stress not only through the 
increased production of ROS but also through weakening the antioxidant defense system. 
In this context the antioxidant role of serum HDL-complexed paraoxonase 
(PON)/arylesterase enzyme in the protection of LDL as well as HDL from oxidative 
modification is important. In diabetics, a lower PON/arylesterase activity and 
concentration, higher LDL: PON concentration ratio and a reduced capacity to prevent 
LDL oxidation have been reported. In addition, antioxidant supplementation may be 
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expected to influence PON/arylesterase activity by altering oxidative stress. Consistent 
with these reports, our results shov^ ^ a significant decrease in plasma arylesterase activity 
and increase in the LDL-C: arylesterase activity ratio in diabetic-hyperlipidemic rats, 
indicating a reduced capacity to protect LDL from oxidation. Both Tocomin and 
Lovastatin treatment significantly blocked the reduction in arylesterase activity and 
increase in LDLC: arylesterase activity ratio, indicating an increased capacity to protect 
LDL from oxidation. However, Lovastatin not only prevented the decline in arylesterase 
activity but significantly increased its level above normal control value. Similarly, in D-
LT, LDL-C: arylesterase activity ratio was reduced to a level lower than N-C value. 
As indicated above, increased oxidative stress, which contributes substantially to 
the pathogenesis of long-term diabetic complications, is the consequences of either 
enhanced ROS production or attenuated ROS scavenging capacity. Several tissues, 
including erythrocytes and liver, have an effective mechanism to neufralize and prevent 
the free radical induced damage, which is accomplished by a set of endogenous enzymes 
such as cataiase, SOD, Gpx and Gred, as well as nonenzymatic antioxidant, GSH. As the 
balance between ROS production and combined antioxidant defenses is lost, the resultant 
oxidative stress through a series of events deregulates the cellular fimctions leading to 
various pathological conditions. An antioxidant compound might contribute partial or 
total alleviation of such damage. Our results demonstrate that feeding of 6 mg Tocomin 
or 0.50 mg Lovastatin/rat/day for 14 weeks were found to be therapeutically quiet 
effective in restoring/normalizing the altered enzymatic and nonenzymatic antioxidant 
defense system in erythrocytes and liver. 
Based on the above combined results, dietary tocotrienols (Tocomin) or 
Lovastatin can be used in the prevention and treatment of both type 1 and type 2 diabetes, 
including long-term complications, such as nephropathy and retinopathy, diabetes 
associated hyperlipidemia with and without CHD and atherosclerosis. However, 
considering the host of side effects exhibited by Lovastatin, use of dietary Tocomin as a 
multitherapeutic agent should be preferred. In addition, daily use of Tocomin as a dietary 
supplement will be highly cost effective as well as a good source of vitamin E. 
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